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The purpose of the study was to assess medication adherence, medication 
persistence, suicide ideation/attempts, health care utilization and costs, and medication 
adverse events in Texas Medicaid patients with psychotic depression who utilized 
antidepressant monotherapy (AD cohort) or antidepressant plus second-generation 
antipsychotic therapy (AD/SGA cohort). Using prescription and medical records from 
September 2007 to December 2012, beneficiaries were included if they were aged 18-63 
years, had no confounding psychiatric disorders, had a 6-month pre-index period with no 
antidepressants plus a 12-month post-index period, and had a diagnosis for unipolar 
major depressive disorder with psychotic features (ICD-9-CM 296.24 or 296.34). The 
index date was the first claim date for an antidepressant. All participants had at least two 
antidepressant claims, and those in the AD/SGA cohort also had at least two SGA claims. 
Study covariates included: age, race/ethnicity, gender, residence, Charlson Comorbidity 
Index score, tobacco use and/or dependence, and antidepressant persistence.  
A total of 926 participants met study criteria (AD cohort n=510; AD/SGA 
n=416). Overall, the mean age (±SD), Charlson Comorbidity Index score, and 
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antidepressant persistence rate was 40.5 (±13.2) years, 0.6 (±1.3), and 172.3 (±130.4) 
days, respectively. The final sample included 66.8% females, 25.2% Caucasians, 34.9% 
African Americans, 36.7% Hispanics, 79.5% urban dwellers, and 19.7% with known 
tobacco use/dependence. The AD/SGA cohort had a 53% significantly higher likelihood 
of being adherent to antidepressant therapy, compared to the AD cohort (p=0.006). 
Similarly, the AD/SGA cohort had a 23% significantly lower hazard of antidepressant 
nonpersistence (based on persistence with a 45-day gap) (p=0.001). Alternatively, the AD 
cohort had a significantly lower rate of psychotic depression-related 
outpatient/emergency department visits (p<0.001), as well as significantly lower 
psychotic depression-related costs (medication, medical, and total) and all-cause 
medication costs (p<0.001). There were no differences in suicide ideation/attempts or 
rates of incident dyslipidemia or diabetes mellitus between cohorts. Evidence of incident 
extrapyramidal symptoms were rare (n=12).  
In conclusion, the AD/SGA cohort had better outcomes associated with 
antidepressant adherence and persistence, and the AD cohort had lower rates of health 
care utilization and costs. These real-world estimates should help increase the 
understanding of appropriate treatment for psychotic depression. 
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Chapter 1:  Introduction and Literature Review 
INTRODUCTION 
I. Importance of Major Depression with Psychotic Features to Society 
Major depression with psychotic features (MD-Psy), or psychotic depression, is a severe 
subtype of major depressive disorder characterized as depression with delusions or 
hallucinations.
1
  MD-Psy is an important public health problem, where the prevalence rate of 
MD-psy among patients with a diagnosis of major depressive disorder is estimated to be as low 
as 15% (based on a large community sample) to as high as 45% (based on a sample of inpatient 
geriatric patients).
2
  The incidence rate of first-episode MD-Psy is approximately 44% higher 
than the incidence rate of first-episode schizophrenia.
3
 
MD-Psy is associated with significant morbidity and mortality and a worse clinical 
course compared to major depressive disorder without psychotic features.
4
  Patients with MD-
Psy experience longer persisting and more severe depressive episodes, higher rates of relapse, 
increased hospitalization, more comorbidities, and higher financial dependency compared to 
patients with nonpsychotic depression.
5
  The risk of suicide ideation, suicide attempts, and 
completed suicide is also high in patients with MD-Psy, with a likelihood of committing suicide 
five times greater in patients with MD-Psy compared to depressed patients without delusions.
4,6-8
 
Treatment guidelines and algorithms have been developed for MD-Psy.
7,9-11
  However, 
the lack of evidence and expert consensus presents no clear treatment strategy for this disorder, 
and the risk of suffering and relapse is very high.
2
  In order to help alleviate and further prevent 







II. Epidemiology of Major Depression with Psychotic Features 
Several epidemiological studies have estimated the rates of MD-Psy among patients in 
the general population and in psychiatric populations;
3,5,12-15
 however, lower prevalence rates are 
commonly reported in overall populations.
5,15
  For example, the National Institute of Mental 
Health Epidemiologic Catchment Area study estimated the lifetime prevalence rates of MD-psy 
and major depression without psychotic features to be very low at 0.6% and 3.8%, respectively. 
In other words, approximately 14.7% of all patients with major depressive disorder also had 
psychotic features.
5
  A large epidemiological study conducted in five Western European 
countries utilized telephone interviewing to investigate psychiatric disorders and found that the 
prevalence of MD-Psy in the overall population was only 0.4% compared to 2.0% for major 
depression without psychotic features. Essentially, about 18.5% of patients who met the criteria 
for major depressive episode also reported having psychotic features.
15
   
Studies utilizing psychiatric populations generally report higher rates of MD-Psy 
compare to overall population studies.
3,5,12-15
  In a sample of community patients seeking 
outpatient psychiatric treatment, approximately 4.5% of patients with current diagnoses of major 
depression also had psychotic features, and 2.4% of the sample had a lifetime history of 
psychotic depression.
14
  Coryell and associates
12
 estimated that, over a two-year period, 25.3% of 
admitted patients diagnosed with major depression also presented with delusions or 
hallucinations.  And a study utilizing a five-year period chart review of psychiatric hospital 
admissions estimated that 44.7% of geriatric patients diagnosed with unipolar major depression 
were also delusional, indicating much higher rates of MD-Psy later in life.
13
  Finally, Crebbin 
and associates
3
 conducted an epidemiological study from 1998 to 2005 assessing the incidence 






MD-Psy. Out of 540 cases of first-episode psychotic illness, there were 105 new cases of MD-
Psy (19.4%) compared to 73 new cases of schizophrenia (13.5%).  Specifically, patients with 
first-episode psychosis were significantly more likely to present with MD-Psy than with 
schizophrenia (RR=1.44, 95% CI=1.09-1.89, p<0.05). 
III.  Classification of Major Depressive Disorder with Psychotic Features 
MD-Psy represents a severe subtype of major depressive disorder, further classified under 
“depressive disorders” (also known as “unipolar depression”) in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR).
1
  The clinical course 
of major depressive disorder is based on the occurrence of one or more major depressive 
episodes.  A major depressive episode is indicated by symptoms that last at least two weeks, 
where either a depressed mood or the loss of pleasure or interest in all activities is present.  A 
major depressive episode also requires four additional symptoms of any of the following: 
significant change in weight (5% gain or loss of body weight in one month) or appetite, 
hypersomnia or insomnia, observable psychomotor agitation or retardation, loss of energy or 
fatigue, feelings of worthlessness or excessive guilt, decreased ability to concentrate or think, or 
recurrent thoughts of death or suicide.  The majority of these symptoms must be experienced 
nearly every day.  Other symptom criteria for a major depressive episode include: not meeting 
the criteria for Mixed Episode; significant impairment in areas of functioning (e.g., social and 
occupational); not due to other medication, drug abuse, or to a general medical condition; and 
not due to the bereavement of a loved one that persists for two months or less.  
Specifically, MD-Psy refers to the classification of “Major Depressive Disorder, Severe 






with the presence either delusions or hallucinations.  Delusions are defined as false beliefs held 
with sustained conviction despite apparent or indisputable evidence to the contrary.  These 
beliefs are not generally accepted by others in relation to culture, subculture, or religious faith.  
Hallucinations are defined as sensory perceptions that occur in the absence of external stimuli 
but have the sense of real perception.
1
 
Delusions and hallucinations can be further classified as either mood-congruent 
(consistent with depressed mood) or mood-incongruent (not consistent with depressed mood).  
Examples of mood-congruent psychotic features include: delusions of guilt, punishment, or 
poverty; nihilistic or somatic delusions; auditory hallucinations about inadequacies or sins.  
Mood-incongruent psychotic features involve delusions or hallucinations that do not typically fit 
the consistent themes of depression, such as persecutory delusions, delusions of thought insertion 
or thought broadcasting, or delusions of control.
1,16
 
Because previous studies on MD-Psy used various methodologies (e.g., different 
definitions of MD-Psy or the inclusion of patients with bipolar disorder), discrepancies between 
the types and frequencies of delusions and hallucinations exist among studies.  Gaudiano and 
associates
14
 reported that the majority of their MD-psy patients presented with hallucinations 
compared to delusions (80% versus 32%, respectively), while other studies reported current 
hallucinations in 7.7% to 29.0% of MD-psy patients.
17,18
 Current delusions were reported in 
various studies assessing MD-Psy, where somatic delusions (3.6% to 28.4%), nihilistic delusions 
(17.8% to 53.8%), and delusions of guilt (7.7% to 57.1%) were the most commonly occurring 
types.
14,17-19






IV. Biological and Clinical Factors of Major Depression with Psychotic Features  
Irregular biological processes are associated with MD-Psy relating to increased 
hypothalamic pituitary adrenal (HPA) axis activity, enlarged ventricle-to-brain ratios (VBRs), 
and decreased dopamine beta-hydroxylase activity.
20-23
  Increased activation of the HPA axis in 
MD-Psy has been established through the use of dexamethasone suppression tests (DST), 24-
hour urinary cortisol levels, and cortisol blood levels.  A meta-analysis of 14 studies comparing 
DST results among depressed patients with and without psychotic features reported that patients 
with MD-Psy were significantly more likely to have higher rates of nonsuppression on the DST 
(OR=3.0, 95% CI=2.2-4.1, p<0.001).  The overall rate of nonsuppression was higher for patients 
with MD-Psy compared to nonpsychotic depressed patients (64% and 41%, respectively).
24
  A 
study assessing cortisol blood levels also reported increased HPA axis activity in patients with 
MD-Psy.  Specifically, evening cortisol levels (6pm – 1am) were significantly higher in patients 




A study that found significantly higher post-dexamethasone cortisol levels in patients 
with unipolar psychotic depression compared to unipolar nonpsychotic patients (p<0.05) also 
reported larger VBRs and more brain atrophy in patients with unipolar psychotic depression.  
Psychotic depressed patients had significantly larger anterior pole and cella media VBRs (both 
p<0.05) and were significantly more likely to have cella media VBRs greater than 0.061 
(p=0.03), compared to nonpsychotic depressed patients.  Significantly more atrophy was 
observed in the left and right parietal lobes of the brain in patients with unipolar MD-psy, 








Studies have hypothesized that dopamine, glucocorticosteroid, and serotonin pathways 
have an association with delusions and MD-Psy.
27-31
  Meyers and associates
27
 found that elderly 
patients with delusional depression had significantly lower dopamine beta-hydroxylase activity 
compared to patients with nondelusional depression (p=0.04) and elderly controls (p=0.02).  
Belanoff and associates
28
 hypothesized that the metabolism of dopamine and delusion 
development was related to excessive glucocorticosteroid activations.  Short-term medication 
trials of four or seven days with mifepristone (also known as RU486), a glucocorticosteroid 
antagonist, reported favorable responses and improved Hamilton Rating Scale for Depression 
scores (HRSD) and Brief Psychiatric Rating Scale (BPRS) scores in patients with psychotic 
major depression.
28,29
  Finally, two Italian studies assessing selective serotonin reuptake inhibitor 
(SSRI) monotherapy advocated the importance of serotonergic pathways in patients with 
delusional depression.  Both studies reported high response rates to SSRI monotherapy with 72% 
and 84% responding to sertraline and fluvoxamine therapy, respectively.
30,31
 
The effect of biological factors on clinical features has been studied by Keller and 
associates,
25
 where an interaction of depression and psychotic symptoms was significantly 
associated with a higher cortisol nadir (p<0.02).  Rothschild and associates
26
 found that 
neuropsychological functioning was much worse in patients with unipolar psychotic depression 
compared to nonpsychotic depressed patients in relation to brain atrophy and VBRs.  
Specifically, patients with MD-Psy performed significantly worse on the “m and n’s” subtest for 
both the left and right hands (p=0.022 and p=0.017, respectively), indicating frontal lobe 
dysfunction.  They also had significantly lower drawing quality test scores (p=0.037), which are 
associated with the function of both frontal and temporal lobes.  Overall, patients with larger 






anterior pole VBRs were associated with significantly worse scores on immediate visual memory 
(p<0.01), immediate recall (p<0.01), delayed drawing quality (p<0.05), animal naming (p<0.01), 
blocked design (p<0.05), and digit span (p<0.05).  Atrophy of the inferior parietal lobe of the 
brain also correlated with worse scores on immediate drawing quality recall, delayed drawing 
quality recall, finger tapping, the “m and n’s” test, digit span, and digit symbol (all p<0.05). 
The neuropsychological functioning of patients with MD-Psy has been reported in two 
other studies.
32,33
  Fleming and associates
32
 conducted a meta-analysis of five studies to assess 
the correlation between five domains of neuropsychological functioning (i.e., visual-spatial 
skills, psychomotor speed and dexterity, attention, memory, and executive functioning) and 
psychotic major depression.  The authors noted that analyses of the psychomotor speed, verbal 
memory, and executive functioning cognitive domains had the largest standardized differences 
and more precise standard errors.  Hill and associates
33
 reported similar but less severe profiles 
of neuropsychological functioning in patients with psychotic depression when compared to 
patients with schizophrenia. Interestingly, patients with nonpsychotic depression had 
neuropsychological profile patterns similar to healthy individuals.   
Other clinical factors linked with MD-Psy include: psychosocial impairment, a family 
history of mental disease, low depression scores, and poor outcomes related to depression.
4,6,14,20-
23,34
  Psychosocial impairment related to work, relationships, recreation, overall satisfaction, and 
social functioning was higher in patients with psychotic depression compared to those with 
nonpsychotic depression at follow-up.  Social functioning was significantly worse in patients 
with psychotic depression at five years follow-up (p<0.002), and relationships with friends, 
recreational activities, and social functioning were significantly more impaired in these patients 
at 10 years follow-up (p<0.01, p=0.03, p=0.006, respectively).
35






patients with psychotic depression had significantly higher social impairment, compared to 
patients with nonpsychotic depression (p<0.001).
34
  Oppositely, significantly higher Global 
Assessment of Functioning (GAF) scores were reported in patients with psychotic depression, 
compared to patients with nonpsychotic depression.
14
 
Family history of mental disease has been discussed in a few review papers on psychotic 
depression.  The reviews find that the general lack of information and the lack of agreement 





 determined that 53.5% of first-admission patients with major depressive 
disorder with psychotic features had a family history of mood disorder.  A study conducted by 
Coryell and associates
12
 found that more patients with psychotic depression had a first-degree 
relative that was diagnosed with schizophrenia, compared to nonpsychotic depressed patients 
(p=0.016).  And a significantly larger proportion of patients with delusional depression had a 
family history of depression compared to non-delusional depressed patients (84.6% and 25.0%, 
respectively; p<0.01).
18
  However, Gaudiano and associates
34
 found that patients with psychotic 
depression did not have an increased likelihood of having a first-degree relative with major 
depression, bipolar disorder, anxiety disorder, psychotic disorder, or substance abuse disorder, 
compared to patients with nonpsychotic depression. 
Depression scales, such as the Clinical Global Impression Scale (CGI), the Beck 
Depression Inventory (BDI), the Montgomery-Ashberg Depression Rating Scale (MADRS), the 
Brief Psychiatric Rating Scale (BPRS), and the Hamilton Depression Rating Scale (HAM-D)—
also known as the Hamilton Depression Rating Scale (HDRS), the Hamilton Depression Scale 
(HDS), the Hamilton Rating Scale (HRS17 and HRS15), and the Modified Hamilton Rating Scale 






more severe depression was generally associated with MD-Psy.
12,14,18,36-39
  Compared to patients 
with nonpsychotic depression, patients with psychotic depression had significantly more severe 
depression based on the CGI (p<0.001).
14
  At baseline, patients with psychotic major depression 
had more severe depression based on MADRS, HRSD, HRS17, and HRS15, compared to 
patients with nonpsychotic depression (p=0.02, p=0.03, p=0.024, p=0.042, and p<0.001, 
respectively),
12,37,38
 while only one study found no difference in depression severity based on the 
BDI.
12
  A study on delusional depression showed that pre-treatment and post-treatment HDS 
scores were significantly worse for patients with delusional depression versus patients with non-
delusional depression (both p<0.01).
18
 
Depression-related outcomes in MD-Psy are poor, where over a four-year period the rates 
of partial remission and non-remission were 23.0% and 8.0%, respectively, and relapse into 
depression occurred in 43.3% of patients who remitted.
36
  Psychotic depressed patients were 
significantly more likely to be younger at onset, experience episodes of longer duration, and have 
a higher number of past episodes of psychotic depression (p<0.001, p<0.001, and p=0.024, 
respectively).
40
  Compared to nonpsychotic depressed patients, psychotic depressed patients 
experienced significantly more chronic depression (p=0.002), recurrent depression (p=0.03), 
previous episodes of depression (p<0.001), and previous treatment with ECT (p=0.03).
34,38
  
Patients with psychotic depression also had significantly higher suicidality (i.e., past suicide 
attempts, suicide ideation, thoughts of death, thoughts of suicide, or a suicide plan) (all p<0.05 or 
less) and more past hospitalizations (p<0.001) versus those with nonpsychotic depression.
14,34
  
Psychomotor agitation, indecisiveness, and insomnia were significantly higher in patients with 
psychotic depression compared to those with nonpsychotic depression (all p<0.05).
14
  Also, these 










), loss of insight (p=0.005), depersonalization p=0.02), 
paranoia (p=0.002), and obsessive compulsive symptoms (p=0.002).
12,37,41
  Correspondingly, the 
likelihood of being diagnosed with obsessive-compulsive disorder (p=0.002), posttraumatic 
stress disorder (p<0.001), somatoform disorders (p=0.002), and cluster A personality disorder 
(p=0.008) psychiatric comorbidities during their lifetime was significantly higher in patients with 





I. Past and Present Diagnoses 
Hamoda and Osser,
7
 of the Harvard South Shore group, cite the difficulty in developing 
treatment algorithms for MD-Psy.  The diagnosis of MD-Psy is complex, and the diagnostic 
criteria for this mental disorder have changed and varied over time – making it difficult to 
compare MD-Psy treatment outcomes associated with different diagnostic criteria.
7,21
   
The American Psychiatric Association’s first and second editions of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-I and DSM-II) did not provide explicit criteria for 
the diagnosis of psychiatric illnesses.
42
  In 1972, the Feighner Criteria,
43
 a publication on 14 
different psychiatric illnesses, did not include a subcategory of psychotic depression under their 
criteria for “Depression.”  In 1978, Spitzer and associates
42
 published the “Research Diagnostic 
Criteria” (RDC), which further elaborated on the work of the Feighner group and established 25 
major diagnostic categories.  Of these categories, “Psychotic, Incapacitating, and Endogenous 
Major Depressive Disorder” was characterized as major depression with delusions, 






During the 1980s, key fundamental studies on patients with major depressive disorder 
who presented with delusions utilized the term “delusional depression.”  Some of these studies 
may have also included patients with bipolar I or II disorder experiencing psychotic symptoms 
(bipolar MD-Psy), making interpretation with these studies more difficult.
7,13,44,45
  The 
Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) was published 
in 1980 and utilized the term “Major Depression with Psychotic Features,” and included the 
same psychotic symptoms as the RDC (i.e., hallucinations, delusions, stupor).  In the 1987 DSM-
III-R (revised edition), stupor was no longer a part of the diagnostic criteria for “Major 
Depression with Psychotic Features.”  The term “severe” was added in the fourth edition of the 
DSM (DSM-IV) in 1994, and the term “Major Depressive Disorder, Severe with Psychotic 
Features” continues to be used in the 2000 text revision also known as the DSM-IV-TR.
1,7
  
 Although the term “severe” is currently utilized in the DSM-IV to characterize psychotic 
depression, researchers warn against the sole use of the term in diagnosing patients with 
psychotic depression, as patients without psychotic depression (no hallucinations or delusions 
present) may experience more severe or worse episodes of depression compared to those with 
psychotic depression.
46
  Also, Kamara and associates
19
 support that the presence of certain 
delusional subtypes (i.e., somatic delusions) cannot predict a distinct subgroup of patients with 
MD-Psy.  In 2000, Carpenter and Price
47
 acknowledged the need for a valid, reliable, and 
widely-used instrument to help enable the proper diagnosis of psychotic depression.  In 2006, 
Meyers and associates
48
 published the Delusional Assessment Scale (DAS), a valid, reliable, and 
useful five-domain instrument for the identification and characterization of delusions.  This scale 
was used in the Study of Pharmacotherapy of Psychotic Depression (STOP-PD), a randomized 










II.  Issues with Diagnosing Major Depression with Psychotic Features 
The difficulty in correctly diagnosing patients with MD-Psy is associated with several 
issues, such as the lack of a distinct diagnostic syndrome for psychotic depression, the low 
research priority for MD-Psy, the difficulty in executing MD-Psy research, and the missed 
diagnosis and misdiagnosis of patients by clinicians.
6,23
  In 1982, Brown and associates
51
 
suggested the need for a distinct subtype rather than “a severe variant of major depression” for 
psychotic depression.  Roose and associates
8
 also felt that, theoretically, delusional depression 
should be characterized as a distinct syndrome versus a severe variant based on evidence 
provided by studies on delusional depression.  In 1992, the need for psychotic depression as a 
distinct syndrome in the DSM-IV was advocated by Schatzberg and Rothschild,
4
 who published 
a review article focusing on the clinical and biological differences between patients with 
psychotic depression and those with nonpsychotic depression. 
The low priority given to research in the treatment of MD-Psy is compounded by the fact 
that many obstacles stand in the way of conducting scientific research for this psychiatric illness.  
The inability of obtaining informed consent due to patients’ incompetence and decreased 
decision-making skills, as well as complications in obtaining legal informed consent, are 
important problems associated with research in MD-Psy.  Also, study protocols and 
methodologies (e.g., a medication-free period before randomization) can complicate patients’ 
clinical situations to where doctors, nurses, and family members may observe the suffering of 






also lead to higher study drop-out rates.  Finally, licensing of treatments for only a major 
depressive disorder subcategory rather than a distinct syndrome is also suspected to cause a 
hindrance in obtaining funding for research in MD-Psy.
9
 
There are many reasons for missed diagnoses in MD-Psy.  Clinicians often fail to 
adequately diagnose psychotic depression because patients and family members may not 
recognize the symptoms of psychotic illnesses.
52
  Sometimes, during early episodes of psychotic 
depression, adequate patient history is unavailable.
22
  Affected patients may also choose to 
conceal their symptoms for fear of being stigmatized as “crazy” or become so guarded and 
concrete that clinicians must be very particular in the way they ask about the symptoms in order 
to obtain accurate patient histories.  Psychotic symptoms can also occur while patients are in a 
dissociated state, further complicating diagnosis.
52
  Also, one study attributed clinicians’ general 
failure to recognize psychotic features in major depression as a reason for the low utilization of 
antipsychotics in psychotic depression.
53
 
Misdiagnosis in MD-Psy occurs because differentiation among other psychiatric illnesses 
(e.g., schizophrenia, schizoaffective disorder, bipolar disorder, posttraumatic stress disorder, 
obsessive-compulsive disorder, and body dysmorphic mood disorder) can be very challenging 
due to clinical similarities and symptom overlap.
6,20,22
  For example, one study reported that 
56.3% of patients who should have been diagnosed with MD-Psy received clinical diagnoses of 
psychosis not otherwise specified (36.7%), schizophrenia (24.4%), other psychosis (8.1%), 
bipolar disorder with psychotic features (6.1%), and nonpsychotic major depression (3.5%) 
instead.   
Furthermore, the diagnosis status of patients has been shown to change over time. Two 










).  At one-
year follow-up, 3.3% of psychotic depressed patients met the diagnostic criteria for either bipolar 
I disorder or bipolar II disorder.
5
  In patients who were followed for two or more years, 
diagnoses for 28.6% and 12.2% of psychotic depressed patients were changed to bipolar I 
disorder and schizoaffective disorder, respectively, and 40.8% of all study patients had a clinical 





I.  Current Treatment Recommendations 
The American Psychiatric Association’s 2010 Practice Guideline for the Treatment of 
Patients with Major Depressive Disorder, third edition,
11
 recommended electroconvulsive 
therapy (ECT) or combination pharmacological therapy with an antidepressant and antipsychotic 
as first-line therapy for patients with MD-psy.  Monotherapy with either an antidepressant or 
antipsychotic agent is recommended after failure with first-line therapy, and lithium 
augmentation with combination therapy may be appropriate after partial response to treatment in 
patients with bipolar psychotic depression.  The guidelines further support the need for 
maintenance treatment in major depressive disorder with psychotic features due to the high risk 
of recurrence. 
In 1999, the Texas Medication Algorithm Project Report on the treatment of major 
depressive disorder with psychotic features was published.  The development of the algorithm 
was based on clinical experience and existing research on major depressive disorder, consisting 
of four acute treatment stages for MD-psy.  Treatment recommendations for stage 1 included 






SSRI, or venlafaxine) or amoxapine monotherapy.  If therapy failed, treatment progressed to 
stage 2 (switch antidepressants in combination therapy or switch to combination therapy from 
amoxapine monotherapy), then stage 3 (ECT), and finally stage 4 (lithium augmentation to 
combination therapy).  Treatment response was defined as a 50% to 75% global improvement in 
symptoms, where response to therapy could be achieved at any of the four stages.  Once patients 
responded to therapy but were not yet in remission (≥75% global improvement in symptoms), 
they moved out of the acute phase and into the continuation phase of treatment, where tapering 
of medications (especially the antipsychotic agent) would begin.  Treatment beyond the 
continuation phase proceeded into the maintenance phase, where maintenance treatment was 
“very strongly recommended” in patients with three or more major depressive episodes.
10
 
A psychopharmacology algorithm for psychotic depression was more recently published 
in 2008 by the Harvard South Shore Program.
7
  ECT was recommended as first-line therapy for 
severely ill patients based on its effectiveness.  If ECT failed or was not recommended, 
combination treatment with an antipsychotic and antidepressant (TCA or SSRI) should be 
utilized first.  If failure occurred, the algorithm suggested switching the antidepressant in the 
combination therapy, or augmenting therapy with lithium.  If lithium augmentation was still not 
successful, ECT should be reconsidered or a trial of clozapine may be administered.  Finally, if 
patients were not eligible for antipsychotic therapy (e.g., risk of tardive dyskinesia), TCA or 
SSRI monotherapy may be utilized. 
A 2007 review of eight different guidelines for unipolar psychotic depression found that 
the British NICE guideline, the Dutch multidisciplinary guideline, and the American Psychiatric 
Association guideline had the highest scores in quality according to the Appraisal of Guidelines 
for Research & Evaluation instrument.
9






important role in clinical practice, it is important for clinicians to remember that guidelines have 
varying degrees of evidence-based recommendations and that guidelines should not necessarily 
be used as a substitute for clinical judgment.
9,10
 
II.  Electroconvulsive Therapy 
The use of ECT is recommended by the American Psychiatric Association guideline, the 
Harvard South Shore Program, and the Texas Medication Algorithm Project.
7,10,11
  Since the 
1930s, ECT has been used in the treatment of psychiatric illness.  ECT involves the inducement 
of seizures through electric charges measured in millicoulombs while patients are under general 
anesthesia.  Common placements of the electrodes include the right unilateral, bilateral, and 
bifrontal positions of the head. During ECT, an electroencephalogram is used to monitor seizure 
activity and seizure duration.  Depending on the severity of illness, treatment in the US typically 
involves a total of 6-12 treatments, where ECT is administered three times a week. Generally, 
maintenance pharmacotherapy is initiated after remission with ECT.
55
  
Petrides and associates found the remission rate with ECT in MD-Psy to be significantly 
higher at 95%, compared to the 83% rate in nonpsychotic depressed patients (p<0.01).  Also, 
time to remission is significantly faster in psychotic depressed patients, compared to depressed 
patients without psychosis (p<0.024).
41
  A literature review conducted by Khan and associates
56
 
also estimated that the ECT response rate in patients with psychotic depression was much higher, 
compared to nonpsychotic depressed patients (79.6% versus 52.7%, respectively).  In a small 
study, retrospective chart review found that 81.8% and 100% of patients with psychotic major 
depressive disorder had a “good” response to ECT only (n=9 of 11) and to ECT and 






“partial” response to ECT, and no patients were reported to have a “poor” response or a non-
response to treatment.
57
 A similar study conducted prospectively observed that 66.6% and 75.0% 
of psychotic depressed patients who utilized therapy had a “good” response to ECT only (n=2 of 
3) and to ECT and antipsychotic agents (n=3 of 4), respectively.  Only one patient (33.3%) had a 
“partial” response to ECT only, and one patient (25.5%) had no response to ECT and 
antipsychotic therapy.
58
  Finally, psychotic depressed patients treated with ECT had a lower 
likelihood of relapse at 12 months following treatment, compared to patients with nonpsychotic 
depression (adjusted OR=0.18, 95% CI=0.03-0.92, p=0.04).
59
 
Compared to pharmacotherapy, ECT is shown to be superior in relation to response rates 
and speed of response.  Significantly higher response rates in psychotic depression were found 
with ECT compared to TCA monotherapy (p<0.01) in a retrospective study conducted by Brown 
and associates.
51
  Two studies assessed TCA and antipsychotic agent combination therapy versus 
ECT and found that ECT had significantly higher rates of response at 86% versus 42% (p<0.005) 
and 88% versus 25% (p=0.004).
60,61
  Patients also responded significantly better to ECT in 
relation to depressive symptoms (100% versus 50%, p<0.008) and speed of resolution (1.6±0.5 
weeks versus 3.4±1.5 weeks, p<0.05) compared to TCA and antipsychotic combination 
therapy.
60
  Finally, compared to combination treatment with perphenazine and nortriptyline, 
patients who underwent ECT took approximately three weeks less time to respond to treatment 
(4 weeks versus 7 weeks, p=0.001).
61
 
Conversely, Mulsant and associates
62
 suggested that high rates of ECT referral may be 
due to inadequate treatment trials with pharmacotherapy in general and with the low use or no 
use of antipsychotic agents.  The use of ECT has been associated with high (but non-significantly 






depressed patients (45.1 days) (p>0.05).
63
  While increased costs associated with treatment 
represent one drawback to using ECT, other disadvantages include lack of access and 
reimbursement, as well as adverse events associated with cognitive impairment, anterograde 
amnesia, retrograde amnesia, and autobiographical memory loss.
7,55
  
III.  Antidepressant and Antipsychotic Combination Therapy  
Combination therapy is considered to be the first-line pharmacotherapy treatment in MD-
Psy according to the American Psychiatric Association guidelines and to US treatment 
algorithms.
7,10,11
  In a systematic review and meta-analysis of 10 randomized controlled trials, 
Farahani and Correll
64
 provided support for the current guidelines.  They found that combination 
treatment with an antidepressant and antipsychotic agent had significantly less study-defined 
inefficacy (p=0.03) and lower CGI scores (p=0.03), compared to antidepressant monotherapy, 
where CGI scores ranged from 1 (normal) to 7 (extremely ill).  In addition they found that 
combination therapy had significantly lower study-defined inefficacy and CGI depression ratings 
(p<0.0001 and p=0.0002, respectively), compared to antipsychotic therapy.  A Cochrane review 
also supports that combination therapy with an antidepressant and antipsychotic was 
significantly more effective than antipsychotic monotherapy (RR=1.92, 95% CI=1.32-2.80, 
p=0.0007).
65
  Finally, two small studies conducted by Minter and Mandel
57,58
 reported “good” 
responses with combination therapy antidepressants and antipsychotic agents in 100% (n=2 of 2) 
and 93.8% (n=15 of 16) of patients with psychotic depression based on CGI and HDRS ratings, 






First-Generation Antipsychotics and Antidepressants 
The use of combination therapy with haloperidol and perphenazine (first-generation 
antipsychotic agents) was investigated prior to the studies mentioned above.
40,44,66,67
  In one 
study, haloperidol and amitriptyline combination therapy was compared to risperidone 
monotherapy for the treatment of depressive syndrome.  In patients with psychotic features, 
those who utilized combination therapy showed significant improvement in both BPRS and 
BRMES (Bech-Rafaelson Melancholia Scale) total scores, compared to antipsychotic 
monotherapy users (p=0.016 and p=0.002, respectively).
66
  Spiker and associates
44
 found that 
patients on amitriptyline and perphenzine combination treatment had better outcomes, as shown 
by significantly lower final HRDS, BPRS, anxiety and agitation, and global scores compared to 
patients on monotherapy (perhenazine alone or amitriptyline alone) (all p<0.05).  A 78% 
response rate was seen in unipolar psychotic patients utilizing fluoxetine and perphenazine 
combination therapy, and after tapering off perphenazine therapy following four months of 
combination treatment, 73% of patients remained in remission over the next 11 months.
40,67
 
Second-Generation Antipsychotics and Antidepressants 
STOP-PD, a double-blind randomized controlled trial, was conducted from 2002 to 2007 
to assess the efficacy of olanzapine (a second-generation antipsychotic) as monotherapy or in 
combination with sertraline (an SSRI).  The STOP-PD group observed a significantly higher 
likelihood of remission (OR=1.28, 95% CI=1.12-1.47, p<0.001) and significantly higher rates of 
remission (41.9% versus 23.9%, p=0.002) with combination therapy compared to olanzapine 
monotherapy (olanzapine plus placebo).  Another double-blind randomized controlled trial 






combination therapy versus both olanzapine monotherapy and placebo in psychotic depression 
(overall p=0.014).  Additionally, compared to olanzapine monotherapy, combination therapy was 
associated with significantly more improved BPRS positive scores (p=0.038).
68
  An open-label 
study of olanzapine and fluoxetine combination therapy in patients with psychotic major 
depressive disorder reported treatment effectiveness based on the observed response rates for 
depression, psychosis, and psychotic depression (66.7%, 59.3%, and 55.6%, respectively).  The 




Studies of antidepressant and antipsychotic combination treatment using other second-
generation antipsychotic agents have been published.
70-73
  A randomized double-blind trial of 
patients with unipolar psychotic depression reported that patients on combination therapy with 
venlafaxine and quetiapine had significantly better outcomes of response (risk difference=32.5, 
95% CI=11.8-53.2), compared to patients on venlafaxine monotherapy.  In the same study, 
patients on combination therapy had better remission (risk difference=20.0, 95% CI=0.5-39.6), 
compared to patients on imipramine therapy alone.
70
  Quetiapine has also been assessed in 
combination therapy with citalopram (an SSRI). In an open-label study, patients diagnosed with 
unipolar psychotic depression had a high response rate of 71%.  Also, significant improvements 
were observed in BPRS total scores (p<0.001) and in 12 BPRS subscale scores including: 
suspiciousness, emotional withdrawal, feelings of guilt, depressive mood, anxiety, motor 
retardation, unusual thought content, tension, somatic concern, conceptual disorganization, 
blunted affect, and excitement (all p<0.05 or less).
71
  In another open-label study on psychotic 
major depression, the effectiveness of aripiprazole and escitalopram (an SSRI) combination 






62.5% and 50.0%, respectively.
72
  A case series study (n=11) analyzing combination therapy 
with amisulpride plus an antidepressant (citalopram or mirtazapine) reported resolution of 
psychotic symptoms in 100% of patients and full remission of depression in 45.5% of patients.
73
 
IV.  Antidepressant Monotherapy 
Antidepressant monotherapy is generally not recommended as first-line therapy; 
however, it can be useful in the treatment of MD-Psy.
7,11
  Interestingly, the same Cochrane 
review that found that combination therapy with an antidepressant and antipsychotic was 
significantly more effective than antipsychotic monotherapy (RR=1.92, 95% CI=1.32-2.80, 
p=0.0007) also found that combination treatment with an antidepressant and antipsychotic was 
not significantly more effective than antidepressant monotherapy (RR=1.44, 95% CI=0.86-
2.41).
65
  An open-label follow-up study found that maintaining treatment effectiveness was not 
significantly different between treatment groups at follow-up 22 weeks later (88% on imipramine 
monotherapy, 92% on venlafaxine monotherapy, and 83% on venlafaxine and quetiapine 
combination therapy, p=0.88).
74
  No significant differences in outcomes on HAM-D, BPRS, and 
BPRS psychoticism scores were observed between nortriptyline (a TCA) monotherapy and 
combination treatment with nortriptyline and perphenazine.
75
  Another study reported no 
significant difference in treatment response based on HRSD and BPRS scores between unipolar 
psychotic depressed patients taking amoxapine monotherapy or combination therapy with 
amitriptyline and perphenazine (p<0.10).
76
  Meyers and associates
77
 reported a non-significant 
difference in relapse rates in patients with delusional depression who were using antidepressant 
monotherapy (nortriptyline or sertraline) and combination therapy (either antidepressant plus 






Antidepressant monotherapy has been shown to be efficacious in one US study and in 
three Italian studies.
17,30,31,40
  In the US study, Rothschild and Duval
40
 assessed psychotic 
depression at one year follow-up and found that 26 of 27 patients maintained remission on 
monotherapy with fluoxetine.  The three Italian studies assessed patients with delusional 
depression, where patients with bipolar disorder with psychotic features were also included.  The 
first study (n=59) published in March 1996, reported an 84.2% recovery rate in patients utilizing 
fluvoxamine monotherapy, as well as significant decreases in episodic duration, final HDRS 
scores, and final delusion scores (all p<0.001).  The second study was published in December 
1996 and found an intent-to-treat response rate in unipolar patients taking paroxetine and 
sertraline at 21% (3 out of 14) and 72% (13 out of 18), respectively.  In the third study published 
in 2000, a non-significant difference in response rates were observed for patients taking 




There is evidence that antidepressant monotherapy is not superior to combination therapy 
with an antidepressant and antipsychotic,
44,64,70
 and other studies have cited poor outcomes 
associated with antidepressant monotherapy.  Specifically, two studies by Minter and Mandel
57,58
 
reported high rates of poor response (73% to 100% of no response) with TCA monotherapy in 
the treatment of psychotic depression, and significantly higher rates of poor response to TCA 
therapy occurred in patients with psychotic depression versus those with nonpsychotic 
depression (56% versus 19%, p=0.003).
78
  Another study cited a significant difference in 
response rates in psychotic and nonpsychotic depressed patients taking TCA monotherapy, 
where better outcomes favored depressed patients without psychosis (p<0.01).
51
  A literature 






versus nonpsychotic patients on TCA therapy (35% versus 60%).
56
  And a significantly lower 
proportion of patients with delusional depression reached full recovery with TCA treatment, 
compared to the proportion of non-delusional depressed patients (15.4% versus 58.3%, 
p<0.05).
18
  Oppositely, Bruijn and associates
37
 assessed the effectiveness of imipramine therapy 
and observed that more patients with psychotic depression reached remission compared to those 
with nonpsychotic depression (61.5% versus 28.1%, p=0.048). However, this study specifically 
included patients diagnosed with mood-congruent psychotic features. 
V.  Antipsychotic Monotherapy 
The use of antipsychotic monotherapy is deemed inappropriate in the treatment of MD-
Psy, and results in the literature are generally not positive.
65
  Several studies provide evidence of 
worse outcomes associated with antipsychotic monotherapy compared to combination 
therapy.
44,49,64,66,68
  The STOP-PD study group found olanzapine monotherapy to be a significant 
predictor of treatment non-completion (p=0.003).
79
 Also, not utilizing antipsychotic medication 
during the six-month to 12-month follow-up period was significantly associated with achieving 
full remission (OR=0.70, 95% CI=0.07-0.65, p<0.01).
80
  However, a pooled study on two 
double-blind randomized trials found that olanzapine monotherapy was superior to placebo 
therapy in patients with major depression with psychotic features based on CGI scores for 
depression, psychosis and overall illness (p=0.044, p=0.025, and p=0.043, respectively) in the 
first trial. Oppositely, in the second trial, no significant differences between cohorts on any 
measures were reported in the pooled study.
68
 
































based on RDC, 
DSM-III, DSM-IV 
Efficacy as measured 
as a reduction of at 
least 50% on the 
HRSD, MADRS, CGI 
 
Secondary: remission, 
quality of life, harm 
No significant difference in efficacy 
between AD+AP and AD alone 
(2 RCTs; RR=1.44, 95% CI=0.86-2.41) 
 
AD+AP more effective than AP alone 
(3 RCTs; RR=1.92, 95% CI=1.32-2.80) 
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AD+AP less inefficacy than AD alone 
(6 RCTs; RR=0.76, 95% CI=0.59-0.98) 
 
AD+AP less inefficacy than AP alone 
(4 RCTs; RR=0.73, 95% CI=0.63-0.84) 
Randomized Controlled Trials 




RCT, 5-year 122 patients (mean 
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Venlafaxine + quetiapine > venlafaxine 
(risk diff=32.5, 95% CI=11.8-53.2) 
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venlafaxine + quetiapine vs. 
imipramine; 
imipramine vs. venlafaxine 
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score of ≤10 
Olanzapine + sertraline had a higher 
remission rate than olanzapine alone 
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No significant difference in relapse 
between nortriptyline + perphenazine 
and perphenazine alone 
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Matthews et al. 
(2009) 
SGA+AD Open-label,  
7-week 
16 patients (mean 
41.8±12.9 yrs) with 
major depression 
with psychotic 









Remission rate=50.0% while on 
aripiprazole + escitalopram treatment 





45 patients (65-87 









Full remission of depression = 45.4%; 
Resolution of psychotic symptoms = 
100% of patients while on amisulpride 
+ citalopram or mirtazapine 













87 patients (15 to 
≥30 yrs) with major 
depressive disorder 
with psychotic 
features based on 
on DSM-III 
Medication use at 
discharge, 6 months, 
24 months 
 
Percent time of use at 
discharge-6 months, 6-
24 months 
Medication use at 24 months: 
AD+AP = 19 (21.8%) 
AD therapy = 10 (11.5%) 
AP therapy = 5 (5.8%) 
 
≥75% time of use 6-24 months: 
AD+AP = Not provided 
AD therapy = 24 (31.4%) 
AP therapy = 21 (24.4%) 






24 patients (mean 








CGI, adverse events 
Combination treatment with quetiapine 
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Prospective 20 patients (mean 
54±18 yrs) with 
major depression 
with psychotic 
features or bipolar I 





Response rate=55% after adding 
risperidone alone or with pre-existing 
AD or mood stabilizers 
 
Included patients with bipolar I disorder 
Rothschild et al. 
(2003) 
FGA+AD Prospective, 
5-week and  
3-month study 
40 patients (mean 
42.4±11.7 yrs) with 
major depression 
with psychotic 





HAM-D, presence of 
psychotic symptoms 
Response rate=30/40 study patients at 5 
weeks while on fluoxetine + 
perphenazine 
 
After perphenazine taper following 4 
months, 73% showed no signs of 
relapse over next 11 months 











features based on 
ICD-10 
 
Efficacy: HAM-D HAM-D response: 8/10 for nefazodone, 
6/10 for amitriptyline + haloperidol 
 
Included patients with bipolar diagnosis 
Matthews et al. 
(2002) 
SGA+AD Open-label,  
6-week 
27 patients (mean 
41.2±14.7 yrs) with 
major depression 
with psychotic 






Depression response rate=66.7%;  
Psychosis response rate=59.3%; 
Psychotic depression response 
rate=55.6%; Psychotic depression 
remission rate=40.7% while on 
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30 patients (mean 
37±11 yrs) with 
major depression 
with psychotic 








Response rate=78% in the 23 unipolar 
patients while on fluoxetine + 
perphenazine 
 
Included bipolar psychotic depression 











symptoms based on 
RDC 
 
Efficacy: HDRS, CGI “Good” response: 
AD+AP = 2/2 
ECT+AP = 3/4 
AD alone = 0/3 
AP alone = 2/4 
ECT alone = 2/3 
Retrospective Studies 









20 patients (47±8.2 





Efficacy: CGI CGI response: 6/10 for nefazodone 
monotherapy, 7/10 for amitriptyline + 
haloperidol 
 
Included patients with bipolar diagnosis 






30 patients (mean 
36.9±10.1 and 
35.0±8.2 yrs) with 
major depression 
with psychotic 
features or bipolar I 
disorder based on 
DSM-IV 
Favorable response 
defined as “much” or 
“very much” 
improvement 
Favorable response rate=73% (8/11) 
with olanzapine vs. 27% (3/11) with 
other AP in of unipolar patients 
(p=0.043) 
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54 patients (mean 
41.3 yrs; no SD) 
with depression 
with psychotic 




based on remission of 
all symptoms and 
return to premorbid 
functioning 
“Good” response: 
AD+AP = 15/16 
ECT+AP = 1/1 
AD alone = 2/11 
AP alone = 10/15 
ECT alone = 9/11 
AD=Antidepressant; AP=Antipsychotic; CGI=Clinical Global Impression Scale; DSM=Diagnostic and Statistical Manual of Mental Disorders; 
EPS=Extrapyramidal Symptoms; FGA=First-Generation Antipsychotic; HAM-D=Hamilton Depression Scale; HRSD=Hamilton Rating Scale for Depression; 
MADRS=Montgomery Asberg Depression Rating Scale; PANSS=Positive and Negative Syndrome Scale; RCT=Randomized Controlled Trial; RDC=Research 





VI.  Other Medication Therapy 
The American Psychiatric Association guidelines for major depressive disorder and the 
algorithm for psychotic depression by the Harvard South Shore Program recommend lithium 
augmentation after failure with combination therapy with an antidepressant and antipsychotic.
7,11
  
The Harvard algorithm also recommends the use of clozapine based on a few case reports and 
case series.
7
  Pharmacological therapy with psychotherapy is also a treatment option suggested 
by the American Psychiatric Association.
11
  Other treatment options that have been used in 
psychotic depression involve carbamazepine augmentation and short-term mifepristone therapy, 
but these are not currently recommended by treatment guidelines.
16,22
  
Lithium augmentation is a strategy used when partial response occurs during the 
treatment of MD-Psy; however there remains insufficient evidence on this augmentation 
strategy.
23
  Two studies assessing lithium augmentation in psychotic depression found that 
patients with bipolar psychotic depression improved with lithium, perphenzine, and fluoxetine 
treatment (100%, n=3) and with TCA-lithium combination therapy (100%, n=7)
67,81
  In an open-
label study, published in 2009, focusing on patients with unipolar psychotic depression in the 
Netherlands, patients were randomized 1:1:1 to treatment with imipramine, venlafaxine, or 
quetiapine plus venlafaxine.  Patients failing to respond to treatment after seven weeks received 
lithium augmentation, and after four weeks of treatment, a 60% response remission rate was 
observed, where all patients sustained remission during follow-up.
82
 





 published a case report on a 40-year-old female with a history of failed 
treatment for psychotic depression who was started on clozapine (up to 500 mg per day) and 




Similarly, Ranjan and Meltzer
84
 reported well-tolerated and effective treatment with clozapine in 
three patients with psychotic depression.   





 reported the benefits of using psychotherapy in patients with 
psychotic major depression by comparing usual care to usual care with Acceptance and 
Commitment Therapy (ACT).  Compared to patients who only received usual care, patients who 
utilized ACT had significant improvement at discharge in BPRS total scores and hallucination 
self-ratings (frequency, believability, and distress) (both p<0.05).  However, compared to 
nonpsychotic depressed patients, patients with psychotic depression had significantly poorer 
outcomes with combined pharmacotherapy and psychotherapy treatment. Psychotic depressed 
patients had significantly higher MHRSD depression scores at post-outpatient treatment and at 
follow-up six months later (both p<0.05).  Also, psychotic depressed patients were four times 
more likely to have high symptom severity and display suicide ideation after combined 





I. Medication Adherence and Continued Treatment 
Little is known about medication adherence in MD-Psy.
79
 One study measured 
medication adherence as a percentage of time used at discharge and follow-up using three cut-off 
points (0-24%, 25-74%, and 75-100%).
80
  Specifically, 31.4% and 24.4% of patients with MD-
Psy reported regular use (≥75% of the time) of their antidepressant and antipsychotic 
medications, respectively, at follow-up 6-24 months later; however, 30.2% of the study patients 




patients that regularly used antidepressants at discharge to six months follow-up had an increased 
likelihood of regular use at 6-24 months follow-up (OR=11.08, 95% CI=3.79-32.37, p<0.001).  
A follow-up study assessed adherence to medication treatment during clinical trials in the 
45.2% of subjects who failed to complete the STOP-PD trial. Inpatient status at trial entry, 
olanzapine monotherapy, and higher total scores on the cumulative medical burden significantly 
predicted overall non-completion of the STOP-PD trial. Inadequate efficacy and poor tolerability 
were also found to be significant predictors of non-completion.
79
  
There is a lack of consensus on how long to continue maintenance treatment in MD-Psy 
due to the absence of published data.
2,86
  Often the need to weigh the risks and benefits of 
treatment are taken into consideration, especially with antipsychotic agents and their potential 
adverse events (e.g., extrapyramidal symptoms).
77,86,87
  Even with only three months of life 
exposure to a first-generation antipsychotic agent, the risk of developing tardive dyskinesia can 
increase.
87
 Compounding the situation,  some studies support the need for continued 
antipsychotic use months after remission in order to decrease the rates of relapse, where 41.8% 
and 26.5% of cases of relapse occurred during medication-free periods and during tapering or 
two months after tapering off antipsychotic therapy.
38,88
   
Wijkstra and associates
74
 reported that continuation treatment with the therapy that was 
effective during acute treatment continued to be effective during a four-month follow-up period, 
whether it was monotherapy or combination therapy.  Rothschild and Duval
40
 suggested that 
treatment for psychotic depression with an antipsychotic medication was not required for more 
than four months.  A review article found that clinicians generally discontinued antipsychotic 
medication after 4-9 months while continuing antidepressant therapy.
2




Algorithm Project recommends discontinuing an acute phase antipsychotic slowly after one to 
two months of use during the continuation phase.
10
 
II.  Suicide: Ideation, Attempts, and Completion 
MD-Psy is associated with significant morbidity and mortality partly due to the high risk 
of suicide ideation, suicide attempts, and completed suicide.
4,6,7
  A large study funded by the 
National Institute of Mental Health reported that patients with MD-Psy had significantly higher 
rates of suicidality in relation to thoughts of death (p<0.001), thoughts of suicide (p<0.001), 
suicide plans (p=.01), and suicide attempts (p=.002), compared to nonpsychotic depressed 
patients.
14
  Compared to patients with nonpsychotic depression, patients with psychotic 
depression were significantly more likely to have attempted suicide during their lifetime (26.9% 
versus 39.1%, p=0.042) and have had suicidal ideation (p=0.031).
46
  Similarly, Gaudiano and 
associates
34
 reported that patients with MD-Psy were more likely to display current suicidal 
ideation (based on Schedule for Affective Disorders and Schizophrenia score of 3 or greater) and 
were over four times more likely to have a history of suicide attempts (OR=4.3, p<0.001), 
compared to patients with nonpsychotic depression.  Another study found that patients with MD-
Psy had double the risk of attempting suicide compared to nonpsychotic patients (OR=2.10, 
p<0.05).
5
  Finally, patients with psychotic depression were more likely to display high symptom 
severity levels of depression and suicidal ideation post outpatient treatment (29% versus 9%, 
p<0.05) compared to nonpsychotic depressed patients.
39
 
Older studies on delusional depression also reported a high risk of suicide and suicidal 
ideation in depressed patients with delusions.
8,18
  Compared to non-delusional patients, Hamilton 
scores for the suicide ideation subscale were significantly higher in patients with delusional 
depression (1.4±1.4 versus 2.8±1.0).
18
  Roose and associates
8




committing suicide was over five times more likely in depressed patients with delusions 
compared to non-delusional patients. 
An epidemiological study of over 18,000 individuals reported that 29.0% of the general 
population who experienced hallucinations, delusions, or both also had thoughts of suicide.
15
  A 
four-year follow-up naturalistic study of patients with major depressive disorder with psychotic 
features found, at baseline, that over one-third of their study sample had been admitted to the 
hospital after attempting suicide.
36
  Approximately 59.6% of patients with unipolar psychotic 
depression displayed current suicidal ideation or attempted suicide during their depressive 
episode.  Factors that significantly attributed to severe suicidality during depressive episodes 
included: male gender (p=0.049), Hispanic ethnicity (p=0.025), history of suicide attempt 
(p=0.006), higher depression scores (HDRS) (p=0.005), and interestingly, higher Mini Mental 
Status Examination (MMSE) cognition scores (p=0.027).  Conversely, older age was associated 
with significantly lower likelihood of a lifetime suicide attempt (p=0.048).
89
 
While the majority of the literature has focused on suicidality, one study assessed self-
harm and reported that a significantly larger proportion of patients with first-episode psychotic 
depression cause deliberate self-harm at first presentation (p<0.01) and at follow-up one year 
later (p<0.05), compared to patients with first-episode schizophrenia. The authors felt that more 
research on effective treatment for MD-Psy may help protect patients from acts of self-harm.
3
 
III.  Hospitalizations and Length of Stay 
As discussed earlier, suicidality is associated with a high rate of hospitalization in 
patients with MD-Psy.
36
  Additionally, when the worse depressive episodes were compared, 
patients with psychotic episodes were significantly more likely to require psychiatric inpatient 






  Studies reported that patients with MD-Psy are two times more likely to be 
hospitalized for psychiatric reasons (OR=2.48, 95% CI=1.46-4.20, p<0.001), have higher rates of 
medical hospitalization in the last year (23.7% versus 15.0%, p=0.02), and have higher rates of 




In one study, patients with psychotic depression endured longer lengths of hospitalization 
stay, compared to patients with major depression without psychosis (19.0±10.2 days versus 
15.9±10.6 days, p=0.02).
56
  In another study, there were no significant differences in the total 
number of hospitalizations (p=0.76) and total length of hospitalization stay in days (p=0.78) 
between patients with first-episode psychotic depression and patients with first-episode 
schizophrenia. Non-significance was found possibly due to the fact that psychosis was being 
treated in both patient groups.
3
 
IV.  Health Care Expenditure Costs 
A review by Tyrka and associates
90
 extrapolated that the costs of MD-psy treatment 
could be affected by treatment duration, treatment adherence, type of antidepressant utilized 
(newer antidepressants versus older antidepressants), use of adjunctive antipsychotic therapy 
(first-generation versus second-generation antipsychotics), hospitalization and associated length 
of stay, use of ECT, as well as short-term and long-term adverse effects of treatment. However, 
the economic and cost burden associated with MD-Psy has been examined in only a few 
studies.
3,5,14
  Compared to patients with nonpsychotic major depression, patients with psychotic 
depression had significantly worse chronic work impairment lasting greater than one year 
(34.7% versus 18.3%, p=0.004).
14
  Also, patients with psychotic depression exhibited worse 




depression were significantly more likely to receive public assistance (p<0.01) and disability 
(p<0.01).
5
  Crebbin and associates
3
 found that the high economic burden of MD-Psy to the 
National Health Service (NHS) in the UK was comparable to the costs of schizophrenia in 
relation to adult inpatient hospitalization days, where estimated costs from 1998 to 2006 were 
approximately £2.6 million and £2.8 million (or approximately $5.2 million and $5.6 million US 
dollars in 2007), respectively. 
Studies that have assessed the use of adjunctive second-generation antipsychotic therapy 
in patients with major depressive disorder (but also included patients with psychotic depression) 
reported increased costs with the use of certain antipsychotics, namely olanzapine and 
quetiapine.
91,92
 Halpern and associates
91
 found that olanzapine combination therapy was 
associated with significantly higher total medical costs (cost ratio [CR]=1.22; 95% CI=1.07-
1.39; p<0.01), mental health-related medical costs (CR=1.33; 95% CI=1.11-1.59; p<0.01), total 
all-cause hospitalization (CR=1.58; 95% CI=1.30-1.92; p<0.01), and mental health-related 
hospitalization (CR=1.81; 95% CI=1.38-2.38; p<0.01) versus aripiprazole combination therapy. 
In the same study, similar results were seen with quetiapine combination therapy when compared 
to aripiprazole combination therapy. Nadkarni and associates
92
 also found that combination 
therapy with olanzapine or quetiapine was associated with significantly higher total medical 
costs (p<0.05), compared to combination therapy with aripiprazole, and was primarily due to 
significantly higher inpatient costs (p<0.05). 
V. Safety of Antipsychotic Agents 
The safety and tolerability of both first-generation and second-generation antipsychotic 
agents are an obvious concern with the treatment of MD-Psy.
2,6,7,10,16,23,86,87,93
  The risk of 




syndromes or extrapyramidal side effects) such as acute dystonia (e.g., sustained contractions of 
the muscles of the neck, eyes, and tongue), akathisia (e.g., feelings of restlessness), parkinsonism 
(e.g., tremor or rigidity), tardive dystonia (e.g., late onset dystonia), and tardive dyskinesia (e.g., 
late onset choreiform or jerky and irregular movements) often limits the usability of first-
generation antipsychotic agents.  While extrapyramidal symptoms may develop in patients 
utilizing second-generation antipsychotic agents, the risk is much lower with these newer 
agents.
94,95
  However, the reduced risk of extrapyramidal symptoms is accompanied by the 




Studies that have assessed the treatment of psychotic depression and delusional 
depression with first-generation antipsychotic agents, such as perphenazine and haloperidol, 
reported the development of extrapyramidal symptoms in their patients.
40,66,67,75-77
  Studies on 
MD-Psy that reported on the use of perphenazine and fluoxetine combination therapy found a 
20% to 40% incidence of mild-to-moderate tremor or rigidity during treatment.
40,67
  Patients on 
combination therapy with perphenazine and an antidepressant (sertraline or nortriptyline) had 
significantly more severe peak and average extrapyramidal side effect scores (both p=0.001) and 
a significantly higher incidence of tardive dyskinesia (p=0.01), compared to patients on 
antidepressants monotherapy (sertraline alone or nortriptyline alone).
77
  On the contrary, Mulsant 
and associates
75
 reported non-significant differences in akathisia and tardive dyskinesia between 
patients taking either perphenazine and nortriptyline combination therapy or nortriptyline 
monotherapy for psychotic depression.   Combination therapy with perphenazine was also used 
in conjunction with another tricyclic antidepressant, amitriptyline, where combination therapy 






  Interestingly, a study comparing haloperidol and amitriptyline combination 
treatment and risperidone monotherapy showed significantly higher parkinsonism subscale 
scores with risperidone (p=0.028), a second-generation antipsychotic agent, with no significant 
differences in the dystonia and dyskinesia subscale scores (p=0.82 and p=0.16, respectively).
66
  
Although there is a reduced risk of developing extrapyramidal symptoms with second-
generation antipsychotic agents,
95
 questions remain regarding the safety of these agents in the 
treatment of MD-Psy.
23
  Four studies utilizing second-generation antipsychotic agents reported 
the development of extrapyramidal symptoms.
71-73,98
  Specifically, reports of tremor or rigidity 
occurred in trials where patients were taking quetiapine, olanzapine, or amisulpride,
9,71,73,98
 and 
akathisia developed in 63% of patients taking combination therapy with aripiprazole and 
escitalopram.
72
  Akathisia and tardive dyskinesia developed in patients taking olanzapine, but no 
differences were seen between combination therapy and monotherapy groups.
49
  On the other 
hand, clozapine, a second-generation antipsychotic used primarily as a last resort for refractory 
patients, may reduce or mitigate antipsychotic-induced tardive dyskinesia. However, the severe 
risk of agranulocytosis with clozapine therapy must be weighed against its benefits.
84,95
 
The metabolic risks associated with second-generation antipsychotic agents have been 
addressed by several studies.
9,49,68-71
  The STOP-PD study, a double-blind randomized controlled 
trial, assessed the metabolic safety and tolerability of combination therapy and monotherapy with 
olanzapine (a second-generation antipsychotic agent).
49,50
  Patients with psychotic depression 
were randomized to receive combination therapy (olanzapine and sertraline) or antipsychotic 
monotherapy (olanzapine alone), where significant increases in weight gain, hyperglycemia, 
triglycerides, and cholesterol were observed during the course of the 12-week trial (p<0.001, 
p=0.006, p<0.001, and p<0.001, respectively).
49




and increase in appetite were common side effects in a six-week long open-label study utilizing 
olanzapine and fluoxetine combination therapy for the treatment of MD-Psy.
69
  A study of two 
pooled randomized trials of 249 utilizers of placebo, olanzapine monotherapy, and olanzapine 
and fluoxetine combination therapy showed a significant weight gain in olanzapine monotherapy 
compared to placebo therapy (p=0.01).  Conversely, no significant differences between 
combination therapy versus placebo (p=0.447) and combination therapy versus olanzapine 
monotherapy were observed (p=0.174).
68
  Quetiapine use in MD-Psy is also associated with 
mean changes in weight gain.
71
  Wijkstra and associates
9
 conducted a randomized, double-blind 
study and assessed the safety of antidepressant monotherapy (imipramine or venlafaxine) and 
combination therapy and found that combination treatment with quetiapine and venlafaxine led 
to significantly more weight gain compared to monotherapy (p<0.01).  And an open-label 
follow-up study with the same treatment showed a significantly higher mean increase in weight 
with combination therapy, compared to monotherapy during the continuation treatment period 
(p=0.002).
74 
SIGNIFICANCE AND PURPOSE OF STUDY 
MD-Psy is a documented public health problem associated with considerable morbidity 
and mortality.
4,6
  Epidemiological studies report that 14.7% to 25.3% of patients diagnosed with 
major depression have psychotic features, and this proportion is estimated to be much higher in 
the geriatric population with major depressive disorder at 44.7%.
5,12,13
  Compared to patients 
with nonpsychotic depression, patients with MD-Psy experience more severe depression, higher 
psychosocial impairment, worse psychomotor agitation, more indecisiveness, and higher 
frequencies of insomnia.
5,14,35
  They are also more likely to have worse health outcomes related 






  The financial burden of MD-Psy is apparent, where inpatient 
hospitalization costs to society nearly equate the costs associated with schizophrenia.
3
  While this 
disorder is associated with high rates of relapse and suffering, the treatment of MD-Psy has not 
been sufficiently studied.
9
  Therefore, additional MD-Psy studies examining effective and safe 
medication treatments, medication adherence and persistence, suicide attempts, health care 
utilization (e.g., hospitalizations and lengths of stay), and health care costs are warranted. 
Currently, there is no clear consensus regarding the treatment strategy for MD-Psy.
2
  
Treatment guidelines and algorithms for psychotic depression support the use of ECT or 
combination therapy with an antipsychotic agent and antidepressant as first-line therapy;
7,10,11
 
however, there is considerable debate about which pharmacological treatment is best.
2,99
  More 
evidence on the efficacy and safety of second-generation antipsychotic agents in MD-Psy is 
needed.
2
  While the risk of developing extrapyramidal symptoms is reduced with these newer 
agents, the metabolic adverse effects associated with long-term continuation and maintenance 
treatment in MD-Psy must be further addressed.
2,95
 
There is not a strong consensus on how long patients should be maintained on their 
medications.
2
  Only one study has assessed medication adherence (estimated as medication usage 
as a percentage of time).
80
  There is a dearth of studies concerning medication adherence in MD-
Psy.  Validated adherence measures such as medication possession ratio (MPR), proportion of 
days covered (PDC), and medication persistence may help shed more light on the 
appropriateness of therapy and long-term continuation.
100-102
 
The high risk of hospitalization in MD-Psy has been established in previous studies 
comparing patients with psychotic depression to nonpsychotic depressed patients.
5,14,46
  One 




that of first-episode schizophrenia.
3
 Two studies published in 2013 found that total 
hospitalization, mental health-related hospitalization, and emergency room visits were 
significantly higher in patients on combination treatment with olanzapine plus an antidepressant 
or quetiapine plus an antidepressant, compared to combination treatment with aripiprazole and 
an antidepressant (p<0.05); however, these studies were not specific to depressed patients 
diagnosed with just MD-Psy.
91,92
  There remains a lack of studies assessing whether differences 
in medication therapy (e.g., monotherapy versus combination therapy) play a role in decreasing 
the hospitalization rates and associated lengths of stay.   
The financial burden of MD-Psy to society has been explored by only a few studies.
3,5,14
  
One study has assessed the inpatient costs of patients with MD-Psy by comparing it to the 
inpatient costs associated with schizophrenia.
3
  While worse economic functioning and chronic 
work impairment have been established, there is an absence of studies providing actual cost 
estimates related to MD-Psy.
5,14
  Although two studies reported significantly lower total medical 
costs, mental health-related costs, inpatient costs, and outpatient costs with the use of 
combination treatment with aripiprazole over combination treatment with olanzapine or 
quetiapine (p<0.05), the studies included patients with other depression diagnoses, not just MD-
Psy.
91,92
  More cost studies are needed to assess the expenditures associated with prescription 
utilization, inpatient and outpatient visits, and suicides in order to better comprehend the 
seriousness of MD-Psy.  
The primary purpose of the proposed study is to assess medication therapy for patients 
with unipolar MD-Psy in relation to medication adherence and persistence, reduced suicide 
attempts, health care utilization, health care costs, and incidence of medication-related adverse 




antidepressant monotherapy cohort (AD cohort) and an antidepressant and second-generation 
antipsychotic combination cohort (AD/SGA cohort).  The proposed study also aims to provide 
enhanced understanding of this severe subtype of major depressive disorder and to provide 
information to fill the gaps in knowledge that clinicians and decision-makers may use when 
considering treatment options for unipolar MD-Psy.  To our knowledge, this study is the first 









Specifically, the objectives of the present study were to: 
 Objective 1:  To describe and compare the baseline socio-demographic and clinical 
characteristics of Texas Medicaid patients with MD-Psy who utilize either antidepressant 
monotherapy (AD cohort) or combination therapy with an antidepressant and a second-
generation antipsychotic (AD/SGA cohort). 
 Objective 2: To describe and compare the post-index clinical characteristics of the AD 
and AD/SGA cohorts. 
 Objective 3: To determine if medication adherence rates (medication possession ratio – 
MPR and proportion of days covered – PDC) differ between patients in the AD and 
AD/SGA cohorts, while controlling for covariates.   
 Objective 4: To determine if the risk of medication nonpersistence differs between 
patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 Objective 5: To determine if rates of post-index suicide ideation and suicide attempts 
differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 Objective 6: To identify if post-index health care utilization rates (psychotic depression-
related hospitalizations, length of psychotic depression-related hospitalization stay, 
psychotic depression-related outpatient/emergency department visits, all-cause 
hospitalizations, length of all-cause hospitalization stay, all-cause outpatient/emergency 
department visits) differ between patients in the AD and AD/SGA cohorts, while 
controlling for covariates. 
 Objective 7: To determine if post-index adjusted health care costs (psychotic depression-




total, all-cause medication, all-cause medical, and all-cause total costs) differ between 
patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 Objective 8: To determine if the risks of medication therapy (incident dyslipidemia, 
incident diabetes mellitus, and incident extrapyramidal symptoms) differ between 
patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 
STUDY HYPOTHESES 
The following hypotheses were tested: 
 No hypotheses were generated for Objectives 1 and 2. 
 H03A:  The likelihood of being adherent as measured by MPR ≥ 80% to antidepressant 
therapy does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 H03B: The likelihood of being adherent as measured by PDC ≥ 80% to antidepressant 
therapy does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 H04A: The time, in days, to antidepressant medication nonpersistence (using a 45-day gap 
of no medication) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 H04B: The time, in days, to antidepressant medication nonpersistence (using a 30-day gap 
of no medication) does not differ between the AD and AD/SGA cohorts, while 




 H04C: The time, in days, to antidepressant medication nonpersistence (using a 60-day gap 
of no medication) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 H05A: The likelihood of having post-index suicide ideation does not differ between the 
AD and AD/SGA cohorts, while controlling for covariates. 
 H05B: The likelihood of having a post-index suicide attempt does not differ between the 
AD and AD/SGA cohorts, while controlling for covariates. 
 H06A: The number of post-index psychotic depression-related hospitalizations does not 
differ between the AD and AD/SGA cohorts, while controlling for covariates. 
 H06B: The number of post-index psychotic depression-related hospitalization days (sum 
of hospital stays, in days) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 H06C: The number of post-index psychotic depression-related outpatient/emergency 
department visits does not differ between the AD and AD/SGA cohorts, while controlling 
for covariates. 
 H06D: The number of post-index all-cause hospitalizations does not differ between the 
AD and AD/SGA cohorts, while controlling for covariates. 
 H06E: The number of post-index all-cause hospitalization days (sum of hospital stays, in 
days) does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 H06F: The number of post-index all-cause outpatient/emergency department visits does 




 H07A: The post-index psychotic depression-related medication costs do not differ between 
the AD and AD/SGA cohorts, while controlling for covariates. 
 H07B: The post-index psychotic depression-related medical costs do not differ between 
the AD and AD/SGA cohorts, while controlling for covariates. 
 H07C: The post-index psychotic depression-related total costs (psychotic depression-
related prescription and psychotic depression-related medical costs) do not differ between 
the AD and AD/SGA cohorts, while controlling for covariates. 
 H07D: The post-index all-cause medication costs do not differ between the AD and 
AD/SGA cohorts, while controlling for covariates. 
 H07E: The post-index all-cause medical costs do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. 
 H07F: The post-index all-cause total costs do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. 
 H08A: The progression to the first diagnosis of dyslipidemia (after a 45-day post-index 
period) does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 H08B: The progression to the first diagnosis of diabetes mellitus (after a 45-day post-
index period) does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates.  
 H08C: The progression to the first diagnosis of extrapyramidal symptoms post-index does 
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Chapter 2:  Methodology 
CHAPTER OVERVIEW 
This chapter describes the methodology that was utilized to test the present study’s 
objectives and hypotheses.  Detail is provided for the following: data source, inclusion and 
exclusion criteria, data extraction, study timeframe, study design, and independent and 
dependent variables.  Specific statistical analyses, test assumptions, and sample size calculations 
are also presented.  
 
INSTITUTIONAL REVIEW BOARD APPROVAL 
 The University of Texas at Austin Institutional Review Board (IRB) deemed that IRB 
review and oversight was not necessary or required for the present study as it did not involve 
human subject research as defined by Common Rule (45 CFR 46) or Food and Drug 
Administration Regulations (21 CFR 50 & 56). An official letter of Non Human Subject 
Research Determination (FWA# 00002030) was granted by the Office of Research Support at 
The University of Texas at Austin in lieu of IRB approval. 
 
DATA 
I.  Data Source: Texas Medicaid 
 The proposed study utilized prescription, medical, and eligibility data from The Texas 
Department of Health Medicaid Program Database. The Texas Medicaid Program is a federal 
and state cooperative venture that provides medical and prescription coverage for needy persons, 
such as low-income families, pregnant women, children, caretakers of children, and those with 




Commission (HHSC), and at the federal level, Medicaid is overseen by the Centers for Medicare 
& Medicaid Services (CMS).  Federal laws set minimum standards, while the state determines 
individual program criteria.  The Texas Medicaid Program covers program-approved treatment 
for acute health care, such as inpatient, outpatient, prescription, and physician services.  During 
the 2011 federal fiscal year, Medicaid expenditures represented 26.0 percent of the state’s total 
expenditures, and in December of 2011, approximately 3.7 million Texans (or 14.3 percent of the 




II.  Inclusion Criteria 
Patients with a diagnosis of “severe major depressive disorder with psychotic features” 
identified using International Classification of Diseases, Ninth Revision, Clinical Modifications 
(ICD-9-CM) diagnosis codes 296.24 and 296.34 between September 1, 2007 and December 31, 
2012 were selected. The following inclusion criteria was met: 1) aged 18 to 63 years; 2) have at 
least two prescription claims with different dates within the period of March 1, 2008 to 
December 31, 2012 for an antidepressant listed in Table 2.1 (antidepressant cohort or AD cohort) 
– or – have at least two claims for an antidepressant listed in Table 2.1 and have at least two 
claims for an oral or injectable second-generation antipsychotic agent, such as asenapine, 
aripiprazole, iloperidone, lurasidone, olanzapine, olanzapine and fluoxetine, paliperidone, 
risperidone, quetiapine, or ziprasidone (antidepressant and second-generation antipsychotic 
combination cohort or AD/SGA cohort); 3) have at least six months of continuous Medicaid 
coverage prior to their index date; and 4) have at least 12 months of continuous Medicaid 





Table 2.1: Antidepressant Medications 
Medication Class Medication 
Selective serotonin reuptake inhibitor 
 
 
Citalopram, Escitalopram, Fluoxetine, 
Fluvoxamine, Paroxetine, Sertraline 




Serotonin-norepinephrine reuptake inhibitor 
 
 

















        
Amitriptyline, Amoxapine, Clomipramine, 
Desipramine, Doxepine, Imipramine, 
Nortriptyline, Protriptyline, Trimipramine 
 
Monoamine oxidase inhibitor 
 






III.  Exclusion Criteria 
In order to better control for confounding associated with other disorders and disease 
states, patients were excluded if they had an ICD-9-CM diagnosis of dementia (290.xx); 
schizophrenia (295.xx); pervasive development disorder (299.xx); mental retardation (317.xx-
319.xx); other cerebral degenerations (331.xx); Parkinson’s disease (332.xx); senility without 
mention of psychosis (797.xx); or manic depression, bipolar disorder, or cyclothymic disorder 
(296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.80, 296.81, 296.89, 301.13).
2,3
  Patients were also 
excluded if they had a claim at any time during the pre-index or post-index periods for the 
following: electroconvulsive therapy (based on ICD-9-CM codes 94.26 and 94.27 or current 




IV.  Index Date 
For both cohorts, the index date was defined as the first prescription claim date for an 
antidepressant medication listed in Table 2.1.  Patients in the AD cohort had at least two post-
index prescription claims for an antidepressant on different dates with no antidepressant 
prescription claims six months prior to the index date. These patients did not have a second-
generation antipsychotic prescription claim six months prior to and twelve months after the index 
date. For the AD/SGA cohort, patients had at least two post-index prescription claims for an 
antidepressant as well as at least two prescription claims for a second-generation antipsychotic 
agent.  The first prescription claim for a second-generation antipsychotic had to occur on the 
same day as the first antidepressant claim (also known as the index date), where at least a 30-day 




ensure combined therapy utilization.
4
  Similarly, patients in the AD/SGA cohort did not have any 
prescription claims for a second-generation antipsychotic six months prior to the index date.  
V.  Data Extraction and Timeframe 
Texas Medicaid prescription claims and inpatient, outpatient, and physician visit claims 
from September 1, 2007 to December 31, 2012 were extracted for patients who had a diagnosis 
and received medication for MD-Psy.  The index identification period ranged from March 1, 
2008 to December 31, 2011 to allow for the minimum 18-month study period of 6 months of 
continuous Medicaid coverage prior to the index date and 12 months of follow-up claims after 
the index date (Figure 2.1).  For example, if the index date (i.e., the first antidepressant claim 
date) for Patient X is March 1, 2008 then Patient X’s index period would end on February 28, 
2009 to allow for one year of follow-up data.  If Patient Y’s index date is December 1, 2010, 
then Patient Y’s index period would end one year later on November 30, 2011.  However, 
patients with index dates that fall either before March 1, 2008 or after December 31, 2011 were 
excluded from the study due to the lack of patient claims data (i.e., six months of pre-index data 










The present study employed a retrospective cohort design. Patients with MD-Psy were 
classified into two different cohorts: antidepressant medications only (AD cohort) versus 
antidepressant and SGA combination therapy (AD/SGA cohort).  Comparisons between these 
two cohorts were made in relation to antidepressant adherence, antidepressant persistence, 
suicide ideation and attempts, health care utilization (i.e., psychotic depression-related and all-
cause hospitalizations, hospitalization lengths of stay, and outpatient/emergency department 
visits), health care costs (i.e., psychotic depression-related and all-cause medication, medical, 
and total costs), and medication-related adverse outcomes (i.e., development of dyslipidemia, 






I.  Dependent Variables 
The dependent variables for the proposed study included the following: 1) medication 
possession ratio, 2) proportion of days covered, 3) medication persistence, 4) suicide ideation, 5) 
suicide attempts, 6) psychotic depression-related hospitalizations, 7) length of psychotic 
depression-related hospitalization stay, 8) psychotic depression-related outpatient/emergency 
department visits, 9) all-cause hospitalizations, 10) length of all-cause hospitalization stay, 11) 
all-cause outpatient/emergency department visits, 12) psychotic depression-related medication 
costs, 13) psychotic depression-related medical costs, 14) psychotic depression-related total 
costs, 15) all-cause medication costs, 16) all-cause medical costs, 17) all-cause total costs, 18) 
incidence of dyslipidemia, 19) incidence of diabetes mellitus, and 20) incidence of 
extrapyramidal symptoms.  
Medication Possession Ratio and Proportion of Days Covered 
Medication adherence, also known as medication compliance, is defined by the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Medication 
Compliance and Persistence Work Group as “the extent to which a patient acts in accordance 
with the prescribed interval and dose of a dosing regimen.”
7
  Adherence can be measured 
directly in prospective studies, for example, through the use of direct observation, or it can be 
measured indirectly with retrospective database claims analyses when direct methods are not 
available.
7,8
  Although there are several indirect measures of medication adherence, a study by 
Karve and associates
9
 recommended using the medication possession ratio (MPR) and 





There are advantages and disadvantages to utilizing MPR and PDC measures of 
medication adherence.  For example, an advantage to using MPR is that it is commonly 
recognized and highly utilized in administrative database analyses.  However, a disadvantage of 
MPR is that it may be less accurate (i.e., overestimates adherence) in instances when duplicative 
therapy or medication switching occur.  While PDC is advantageous in providing more 
conservative estimates of adherence with switching and duplication, it cannot be used to assess 
excessive medication use (values fall between 0 and 1) and is more complicated to compute than 
MPR.
8
  Since MPR and PDC have their advantages and limitations, both were utilized as proxies 
to medication adherence. 
MPR is operationalized as the total days’ supply of medication divided by the total days 
in a given period.
8,10
  MPR was categorized into two groups – MPRs less than 80% (not 
adherent) and MPRs greater than or equal to 80% (adherent).
10,11
  MPR values greater than 1.0 
were truncated to 1.0.
8
  For the AD cohort, MPR represented adherence to any antidepressant 
therapy.  For the AD/SGA cohort, MPR also represented adherence to antidepressants only since 
there is no standard length of second-generation antipsychotic therapy used to treat MD-Psy.  
MPR was measured using prescription claims data and physician visit claims data since 
injectable second-generation antipsychotics were provided during physician office visits (Table 
2.2). 





PDC is operationalized as the proportion of days in which medication is available over 
the total number of days in a given period.
8,10
  PDC was also categorized into two groups using 
the same cut-off point of 80% to determine adherence and non-adherence.
11
  Like MPR above, 
PDC was calculated to measure adherence to any antidepressant therapy for both cohorts.  PDC 
was measured using prescription and physician visit claims data (Table 2.2). 
PDC = (total days of available medication * 100%) / 365 days of follow-up 
 
Table 2.2: Outpatient and Physician Visit Claims for Injectable Antipsychotics 
Injectable Antipsychotic J Code(s) Day Supply Estimate 
Aripiprazole 
 
















J3486 Acute dosing (every 2 to 4 hours)
f 
a
Abilify Maintena (aripiprazole) extended-release intramuscular injection package insert. 
b
Monthly as estimated as a 30 days supply. 
c
Zyprexa Relprevv (olanzapine injectable 
suspension) package insert. Due to the lack of dosing information in claims dataset, day supply 
was estimated as 28 days. 
d
Invega Sustenna (paliperidone palmitate injectable suspension) 
package insert. 
e
Risperdal Consta (risperidone long-acting injection) package insert. 
f
Geodon® 







Persistence, also known in the literature as persistency or continuous adherence, is 
defined by the ISPOR Medication Compliance and Persistence Work Group as “the duration of 
time from initiation to discontinuation of therapy.”
7
  Persistence allows for the incorporation of 
time when analyzing adherence and represents the amount of time until medication 
discontinuation occurs.  Medication discontinuation, or nonpersistence, is indicated by reaching a 
“permissible gap,” where gaps of 30 or 60 days are often utilized.
10
   
In the present study, the unit of time was measured in days, and a 45-day permissible gap 
was utilized.  Secondary analyses using 30-day and 60-day gaps were also assessed.  The cohorts 
were compared on the persistence of any antidepressant use.  For the AD/SGA cohort, 
persistence on any second-generation antipsychotic was measured separately to determine the 
average time MD-Psy patients utilized second-generation antipsychotic therapy.  Like MPR and 
PDC, medication persistence was measured using prescription and physician visit claims data. 
Suicide Ideation 
Using inpatient, outpatient, and physician visit claims data post-index, suicide ideation 
was identified using ICD-9-CM code V62.84. In addition, a variable was created that indicated 
whether a patient had either (1) no suicide ideation diagnosis or (2) at least one suicide ideation 
diagnosis during the follow-up period. 
Suicide Attempts 
Using inpatient, outpatient, and physician visit claims data post-index, suicide attempts 
were identified using ICD-9-CM codes E950.x-E959.x.
3
  In addition, a variable was created that 
indicated whether a patient had either (1) no suicide attempt diagnosis or (2) at least one suicide 




Psychotic Depression-Related Hospitalizations 
Psychotic depression-related hospitalizations were identified using ICD-9-CM codes 
296.24 and 296.34 for MD-Psy. The number of hospitalizations was identified using data from 
inpatient hospital claims post-index. 
Length of Psychotic Depression-Related Hospitalization Stay 
Once a psychotic depression-related hospitalization was identified post-index, the 
associated length of hospitalization stay (in days) was calculated for each psychotic depression-
related hospitalization.  All lengths of stay were summated to represent the total psychotic 
depression-related hospital days for each patient. 
Length of Hospitalization Stay = (Final Stay Date – Initial Stay Date) + 1. 
Psychotic Depression-Related Outpatient/Emergency Department Visits 
Psychotic depression-related outpatient/emergency department visits were identified 
using ICD-9-CM codes 296.24 and 296.34 for MD-Psy. The number of these outpatient and 
emergency department visits was counted using outpatient claims data post-index.  
Outpatient and emergency department visits were aggregated into one variable due to the 
small sample size of emergency department visits in the dataset. Although the aggregation of 
hospitalizations and emergency department visits was considered, this was deemed a less 
appropriate option since (1) emergency department visits did not necessarily lead to 
hospitalizations (especially if patients used them similarly to an outpatient visit) and (2) it would 
not allow for strict comparisons to the previous literature regarding hospitalizations and lengths 





The number of all-cause hospitalizations was identified using data from inpatient hospital 
claims post-index. 
Length of All-Cause Hospitalization Stay 
Once all hospitalizations were identified post-index, the associated lengths of 
hospitalization stay (in days) for each hospitalization was calculated.  All lengths of stay were 
summated to represent the total hospital days for each patient. 
Length of Hospitalization Stay = (Final Stay Date – Initial Stay Date) + 1.  
All-Cause Outpatient/Emergency Department Visits 
The number of all-cause outpatient/emergency department visits was identified using 
outpatient claims data post-index. 
Psychotic Depression-Related Medication Costs 
Psychotic depression-related medication costs included all post-index direct prescription 
costs to Texas Medicaid for AD or AD/SGA combination therapy.  Costs were adjusted to 2012 
US dollars and summated. Injectable medication costs associated with physician and outpatient 







Table 2.3: J Codes Associated with Injectable Antipsychotic Medications 
First-Generation Antipsychotic Injectable J Code  
Chlorpromazine J3230 
Fluphenazine J2680 
Haloperidol J1630, J1631 
Perphenazine J3310 








Psychotic Depression-Related Medical Costs 
Psychotic depression-related medical costs included all post-index direct medical costs to 
Texas Medicaid for inpatient, outpatient, and physician visits based on ICD-9-CM codes 296.24 
and 296.34 for MD-Psy. Costs were adjusted to 2012 US dollars and summated. 
Psychotic Depression-Related Total Costs 
Psychotic depression-related total costs included all post-index direct psychotic 
depression-related medication and medical costs to Texas Medicaid.  Costs were adjusted to 
2012 US dollars and summated. 
All-Cause Medication Costs 
All-cause medication costs included all post-index direct prescription costs to Texas 




All-Cause Medical Costs 
All-cause medical costs included all post-index direct medical costs to Texas Medicaid 
for inpatient, outpatient, and physician visits.  Costs were adjusted to 2012 US dollars and 
summated. 
All-Cause Total Costs  
All-cause total costs included all post-index direct prescription and medical costs to 
Texas Medicaid.  Costs were adjusted to 2012 US dollars and summated. 
Cumulative Incidence of Dyslipidemia 
The cumulative incidence of dyslipidemia was operationalized as a simple ratio of the 
number of new cases of dyslipidemia that occurred during the 1-yr follow-up period divided by 
the total number of susceptible cases without dyslipidemia at 45 days after the index date.  
Patients considered susceptible to dyslipidemia had no diagnosis of dyslipidemia during the six-
month pre-index period plus 45 days post-index.  New onset dyslipidemia was measured as 1) 
the utilization of one or more dyslipidemia medications based on drug names
12
 and AHFS codes 
(24.06.04, 24.06.05, 24.06.05, 24.06.06, 24.06.08, 24.06.92),
13,14
 or 2) as one or more diagnoses 
of dyslipidemia (based on ICD-9-CM codes 272.xx).
15,16
  Also, a Cox proportional hazards ratio 
was calculated between cohorts based on the time, in days, from 45 days after the index date to 
the first diagnosis of dyslipidemia.       
Cumulative Incidence of Diabetes Mellitus 
The cumulative incidence of diabetes mellitus was operationalized as a simple ratio of the 
number of new diagnoses of diabetes mellitus that occurred during the 1-yr follow-up period 




after the index date.  Patients considered susceptible to diabetes mellitus had no diagnosis of 
diabetes mellitus (types I or II) during the six-month pre-index period plus 45 days post-index.  
New onset diabetes mellitus was measured as: 1) the utilization of one or more anti-diabetic 
medications based on drug name
12
 or by AHFS codes (68.20.02, 68.20.03, 68.20.04, 68.20.05, 
68.20.06, 68.20.08, 68.20.16, 68.20.18, 68.20.20, 68.20.28, 68.20.92),
13,14
 or 2) one or more 
diagnoses of diabetes mellitus (based on ICD-9-CM codes 250.xx, diabetes mellitus; 357.2, 
diabetic nephropathy; 362.01-362.02, diabetic retinopathy; and 366.41, diabetic cataract).
16,17
  
Also, a Cox proportional hazards ratio was calculated between cohorts based on the time, in 
days, from 45 days after the index date to the first diagnosis of diabetes mellitus. 
Cumulative Incidence of Extrapyramidal Symptoms 
The cumulative incidence of extrapyramidal symptoms was operationalized as a simple 
ratio of the number of new diagnoses of extrapyramidal symptoms that occurred during the 1-yr 
follow-up period divided by the total number of susceptible cases not diagnosed with 
extrapyramidal symptoms at the index date.  Patients considered susceptible to extrapyramidal 
symptoms had no diagnosis of extrapyramidal symptoms during the six-month pre-index period.  
Since the onset of extrapyramidal symptoms may occur as early as a few hours to days post 
exposure to three months to a year later,
18,19
 new onset extrapyramidal symptoms were measured 
as one or more diagnoses of extrapyramidal symptoms based on ICD-9-CM codes (333.1, 333.2, 
333.3, 333.72, 333.85, 333.90, 333.92, 333.99, 781.0, and 332.1) that occurred at any time after 
the index date. Also, a Cox proportional hazards ratio was calculated between cohorts based on 
the time, in days, from the index date to the first diagnosis of an extrapyramidal symptom. 
 




Table 2.4: Operational Definition of Dependent Variables 




0=Not adherent (MPR < 80%) 
1=Adherent (MPR ≥ 80%) 
Proportion of Days Covered Dichotomous PDC 
0=Not adherent (PDC < 80%) 
1=Adherent (PDC ≥ 80%) 
Medication Persistence Continuous 
Number of days before a permissible gap 
Suicide Ideation Dichotomous 
0=No suicide ideation diagnosis 
1=One or more suicide ideation diagnoses 
Suicide Attempts Dichotomous 
0=No suicide attempt diagnosis 




Number of post-index hospitalizations with ICD-9-CM codes 
296.24 and 296.34 




Number of post-index hospitalization days associated with 






Number of post-index outpatient/emergency department visits 
with ICD-9-CM codes 296.24 and 296.34 
All-Cause Hospitalizations Count 
Number of all-cause hospitalizations post-index 
Length of All-Cause 
Hospitalization Stay 
Count 





Number of all-cause outpatient/emergency department visits post-
index 
Psychotic Depression-
Related Medication Costs 
Continuous 
Summated, post-index direct costs to Texas Medicaid for 
antidepressant, antipsychotic, and other psychotic depression-
related prescriptions adjusted to 2012 US dollars 
Psychotic Depression-
Related Medical Costs 
Continuous 
Summated, post-index direct costs to Texas Medicaid for 
inpatient, outpatient, and physician visits with ICD-9-CM codes 
296.24 and 296.34 adjusted to 2012 US dollars 
Psychotic Depression-
Related Total Costs 
Continuous 
Summated, post-index psychotic depression-related medication 





Table 2.4: Operational Definition of Dependent Variables (continued) 
Variable Operational Definition 
All-Cause Medication Costs Continuous 
Summated, post-index direct costs to Texas Medicaid for all 
prescriptions adjusted to 2012 US dollars 
All-Cause Medical Costs Continuous 
Summated, post-index direct costs to Texas Medicaid for 
inpatient, outpatient, and physician visits adjusted to 2012 US 
dollars 
All-Cause Total Costs Continuous 
All post-index direct costs to Texas Medicaid adjusted to 2012 
US dollars and summated 
Cumulative Incidence of 
Dyslipidemia 
Continuous 
Cumulative Incidence: total new cases of dyslipidemia divided by 
total susceptible at index date based on ICD-9-CM codes (272.xx) 
and AHFS codes (24.06.04, 24.06.05, 24.06.05, 24.06.06, 
24.06.08, 24.06.92) 
Continuous 
Survival time, in days, until onset of dyslipidemia 
Cumulative Incidence of 
Diabetes Mellitus 
Continuous 
Cumulative Incidence: total new cases of diabetes mellitus 
divided by total susceptible at index date based on ICD-9-CM 
codes (250.xx) and AHFS codes (68.20.02, 68.20.03, 68.20.04, 
68.20.05, 68.20.06, 68.20.08, 68.20.16, 68.20.18, 68.20.20, 
68.20.28, 68.20.92) 
Continuous 
Survival time, in days, until onset of diabetes mellitus 
Cumulative Incidence of 
Extrapyramidal Symptoms 
Continuous 
Cumulative Incidence: total new cases of extrapyramidal 
symptoms divided by total susceptible at index date ICD-9-CM 
codes 333.1, 333.2, 333.3, 333.72, 333.85, 333.90, 333.92, 
333.99, 781.0, and 332.1 
Continuous 





II.  Independent Variables 
The primary independent variable was the patient cohort (AD cohort versus AD/SGA 
cohort).  Demographic and clinical variables included: age, race/ethnicity, gender, urban 
residence, Charlson Comorbidity Index (CCI) score, tobacco use and/or dependence, and 
antidepressant persistence using a 45-day permissible gap (for Objectives 5 through 8 only).  
Table 2.5 provides a listing of the independent variables. 
 
Table 2.5: Operational Definition of Independent Variables 
Primary Independent Variable Operational Definition 
Patient Cohort Dichotomous 
0=AD cohort  
1=AD/SGA cohort 
Baseline Socio-Demographic Variable Operational Definition 
Age Continuous 









Urban Residence Dichotomous 
0=No (rural residence) 
1=Yes (urban residence) 
Baseline Clinical Variable Operational Definition 
CCI Continuous 
Weight index based on Dartmouth-Manitoba 
adaptation of CCI 
Post-Index Clinical Variable Operational Definition 
Tobacco Use and/or Dependence Dichotomous 
0=No (no post-index claim) 
1=Yes (at least one post-index claim) 
Antidepressant Persistence Continuous 






The patient cohort variable was dichotomized as the AD cohort and the AD/SGA cohort.  
The AD cohort comprised patients who used antidepressant therapy only, and the AD/SGA 
cohort represented patients who utilized both antidepressant and second-generation antipsychotic 
therapy. 
Age 
Patient age, measured in years and truncated to two digits without decimals, was defined 
based on the age at the index date.   
Gender 
Gender was dichotomized as male or female. 
Race/Ethnicity 
Race/ethnicity was categorized into four groups: Caucasians, African Americans, 
Hispanics, and Other.  Other included Asians and patients with Unknown race/ethnicity. 
Urban Residence 
Urban residence variables were dichotomized as either “no” (i.e., rural residence) or 
“yes” (i.e., urban residence). Urban and rural residences were identified by Texas Medicaid 
based on Medicaid Rural Service areas. 
Charlson Comorbidity Index (CCI) 
Comorbidities, also known as comorbid diseases or illnesses, play an important 
prognostic role in determining mortality.  In 1987, Charlson and associates
20
 developed the 




comorbidities.  The CCI is a weighted index that incorporates both the quantity (number) and 
quality (seriousness is ranked as 1, 2, 3, or 6) of comorbid disease, where patients with higher 
summated scores are considered to have higher risks of comorbid death.
20







) have been utilized in retrospective database 
analysis studies that assessed comorbidity data through ICD-9-CM codes.
21-25
  While the Deyo 
and Dartmouth-Manitoba are the most utilized adaptations, the Dartmouth-Manitoba method is 
considered to utilize a less strict interpretation of the CCI definitions.
22,25
  Therefore, the 
Dartmouth-Manitoba adaptation was utilized to determine the baseline comorbidity score (Table 




Table 2.6: Charlson Comorbidity Index (CCI) and Dartmouth-Manitoba Adaptation 
CCI Comorbid Condition CCI Weight Dartmouth-Manitoba ICD-9-CM codes 
Myocardial infarction 1 410.xx, 412* 
Congestive heart failure 1 402.01, 402.11, 402.91, 425.x, 428.x, 429.3, 
404.01, 404.03, 404.11, 404.13, 404.91, 404.93 
Peripheral vascular disease 1 440.x*, 441.x*, 442.x*, 443.1-443.9*, 447.1*, 
785.4*, 38.13-38.14(P)*, 38.16(P)*, 38.18(P)*, 
38.33-38.34(P)*, 38.36(P)* 38.38(P)*, 38.43-
38.44(P)*, 38.46(P)*, 38.48(P)*, 39.22-
39.26(P)* 
Cerebrovascular disease 1 362.34, 430-436, 437-437.1, 437.9, 438, 781.4, 
784.3, 997.0, 38.12(P), 38.42(P) 
Dementia 1 290.x*, 331-331.2* 
Chronic pulmonary disease 1 415.0*, 416.8-416.9*, 491.x-494*, 496* 
Connective tissue disease 1 710.x, 714.x 
Ulcer disease 1 531.xx-534.xx 
Mild liver disease 1 571.2*, 571.5-571.6*, 571.8-571.9* 
Diabetes 1 250.0x-250.3x* 
Diabetes with end organ 
damage 
2 250.4x-250.9x*† 
Hemiplegia 2 342.x, 344.x 
Moderate or severe renal 
disease 
2 585-586*, V42.0*, V45.1*, V56.x*, 39.27(P)*, 
39.42(P)*, 39.93-39.95(P)*, 54.98(P)* 
Any tumor 2 140.x-171.x*, 174.x-195.x*, 200.xx-208.x*, 




Moderate or severe liver 
disease 
3 572.2-572.4*, 456.0-456.2x*, 39.1(P)*, 
42.91(P)*† 
Metastatic solid tumor 6 196.x-199.x*† 
AIDS 6 042.x-044.x 
(P) follows all ICD-9-CM codes that describe procedures rather than diagnoses (Vol.III). 
*The codes with asterisks are included in the definition of a comorbidity if they are listed during 
either index or prior hospital discharges; other codes are included only if recorded prior to the 
index discharge. Each asterisk applies to all codes within the indicated range. 
†In the Dartmouth-Manitoba algorithm, these comorbidities take precedence over less severe 
comorbidities involving the same organ system. 
Adapted from: Needham DM, Scales DC, Laupacis A, Pronovost PJ. A systematic review of 
the Charlson comorbidity index using Canadian administrative databases: a perspective on risk 
adjustment in critical care research. J Crit Care. 2005; 20(1):12-19.  Romano PS, Roos LL, Jollis 
JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing 
perspectives. J Clin Epidemiol. 1993; 46(10):1075-1079; discussion 1081-1090.  D'Hoore W, 
Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index 





Tobacco Use and/or Dependence 
Post-index tobacco use and/or dependence was measured using the ICD-9-CM codes 
305.1, V15.82, 649.00-649.04, 989.84.
26-28
 Tobacco use and/or dependence was dichotomized as 
either “no” (where no claims for tobacco use and/or dependence exist during the 12-month post-
index period) or “yes” (where at least one claim for tobacco use and/or dependence was found 
during the 12-month post-index period). 
Antidepressant Persistence 
Antidepressant persistence was operationalized as the number of consecutive days of 







Statistical analyses were performed using PASW Statistics 18 (formally SPSS Statistics, 
Chicago IL), SAS for Windows, Version 9.3 (SAS Institute, Cary, NC), and StataSE 12.0 
(StataCorp, College Station, TX).  All statistical tests were two-tailed and utilized an a priori 
significance level of p<0.05.  Normal distributions and data abnormalities were determined using 
skewness, kurtosis, frequency, and normality tests.  
For Objectives 1-2, descriptive statistics, such as means, standard deviations (SD), and 
frequencies, were reported for all independent and dependent variables. Other statistical analyses 
included: Pearson’s chi-square test for dichotomous variables, independent samples t-tests for 
normally-distributed continuous variables, and Mann-Whitney U tests for non-parametric 
variables. 
For Objective 3, logistic regression was utilized to assess the medication adherence 
variables—MPR and PDC (dichotomized as meeting a threshold of ≥ 80% or not). MPR was 
defined as the sum of the days’ supply divided by the number of days in the post-index period. 
PDC represented the number of days with medication available divided by the number of days in 
the post-index period.   
For Objective 4, Cox proportional hazards regression was used to measure medication 
persistence defined as the time, in days, until medication nonpersistence occurred.  A gap of 
more than 45 days with no medication indicated nonpersistence.  Secondary analyses using 30-
day and 60-day gaps were also conducted.   
For Objectives 5, logistic regression was also utilized to assess the rates of suicide 
ideation and suicide attempts post-index.  
For Objective 6, generalized linear models associated with count data were used to 




hospitalization days, and outpatient/emergency department visits). Although the use of Poisson 
regression was originally planned, negative binomial regression was utilized instead due to over 
dispersed data (i.e., mean < variance). Overdispersion is supported by a significant Likelihood 
Ratio chi-square test of alpha=0. With count data with a high frequency of zeros, zero-inflated 
negative binomial regression is often utilized. Zero-inflated regression was utilized, specifically, 
when excessive zeros occurred and were generated from a process distinct from the count value 
zeros. A significant Vuong test further supports the need for a zero-inflated model. For count 
variables with a high frequency of zeros generated from the same process as the non-zeros, a 
hurdle model was utilized instead.
29
 
For Objective 7, generalized linear models with a gamma distribution and log-link 
function were utilized to estimate health care costs (i.e., psychotic depression-related medication 
costs, psychotic depression-related medical costs, psychotic depression-related total costs, all-
cause medication costs, all-cause medical costs, and all-cause total costs). A two-part model 
(using a logit model and a generalized linear model with a gamma distribution and log-link 
function) was used for dependent variables with high frequency of $0 costs.  
For the descriptive objective (Objective 2), cumulative incidence was calculated as a 
simple ratio of the total number of new cases of disease during 1-year of follow-up divided by 
the total number of patients susceptible to disease (i.e., dyslipidemia, diabetes mellitus, and 
extrapyramidal symptoms) at the index date.  For the statistical comparison objective (Objective 
8), Cox proportional hazards regression was used to measure the time to disease progression, in 
days, between cohorts.  
Table 2.7 provides a summary of the study objectives, hypotheses, variables, measures, 




the appropriate statistical technique based on the variables of interest (e.g., dichotomous, ordinal, 





Table 2.7: Summary of Study Objectives, Hypotheses, Variables, Measures, and Statistical Analyses 







Objective 1: To describe and compare the 
baseline socio-demographic and clinical 
characteristics of Texas Medicaid patients 
with MD-Psy who utilize either 
antidepressant monotherapy (AD cohort) or 
combination therapy with an antidepressant 





Age Continuous Patient Cohort Dichotomous Descriptive Statistics & 
Independent Samples T-
Test 
Race/Ethnicity Categorical Descriptive Statistics & 
Pearson’s  
Chi-Square (χ2) 
Gender Dichotomous Descriptive Statistics & 
Pearson’s  
Chi-Square (χ2) 
Urban Residence Dichotomous Descriptive Statistics & 
Pearson’s  
Chi-Square (χ2) 
CCI Continuous Descriptive Statistics & 
Mann-Whitney U 
Objective 2: To describe and compare the 
post-index clinical characteristics of the AD 
and AD/SGA cohorts. 
Tobacco Use and/or 
Dependence 
Dichotomous Patient Cohort 
 
 






Continuous Descriptive Statistics & 
Independent Samples T-
Test 
Cumulative Incidence of 
Dyslipidemia 
Continuous Descriptive Statistics & 
Pearson’s  
Chi-Square (χ2) 
Cumulative Incidence of 
Diabetes Mellitus 
 
Continuous Descriptive Statistics & 
Pearson’s  
Chi-Square (χ2) 
Cumulative Incidence of 
Extrapyramidal 
Symptoms 












Table 2.7: Summary of Study Objectives, Hypotheses, Variables, Measures, and Statistical Analyses (continued) 
 







Objective 3: To determine if medication adherence rates (medication possession ratio – MPR and proportion of days covered – PDC) differ between patients in the 
AD and AD/SGA cohorts, while controlling for covariates.   
H03A: The likelihood of being adherent as 
measured by MPR ≥ 80% to antidepressant 
therapy does not differ between the AD and 
AD/SGA cohorts, while controlling for 
covariates. 
 
Medication Adherence  
(MPR) 






H03B: The likelihood of being adherent as 
measured by PDC ≥ 80% to antidepressant 
therapy does not differ between the AD and 
AD/SGA cohorts, while controlling for 
covariates. 
 
Medication Adherence  
(PDC) 





Objective 4: To determine if the risk of medication nonpersistence differs between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
H04A: The time, in days, to antidepressant 
medication nonpersistence (using a 45-day 
gap of no medication) does not differ 
between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Medication Persistence  
(Survival Time) 





Cox Proportional Hazards 
Regression 
H04B: The time, in days, to antidepressant 
medication nonpersistence (using a 30-day 
gap of no medication) does not differ 
between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Medication Persistence  
(Survival Time) 





Cox Proportional Hazards 
Regression 
H04C: The time, in days, to antidepressant 
medication nonpersistence (using a 60-day 
gap of no medication) does not differ 
between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Medication Persistence  
(Survival Time) 











Table 2.7: Summary of Study Objectives, Hypotheses, Variables, Measures, and Statistical Analyses (continued) 
 







Objective 5: To determine if rates of post-index suicide ideation and suicide attempts differ between patients in the AD and AD/SGA cohorts, while controlling for 
covariates. 
H05A: The likelihood of having post-index 
suicide ideation does not differ between the 
AD and AD/SGA cohorts, while controlling 
for covariates. 
 





H05B: The likelihood of having a post-index 
suicide attempt does not differ between the 
AD and AD/SGA cohorts, while controlling 
for covariates. 
 





Objective 6: To identify if post-index health care utilization rates (psychotic depression-related hospitalizations, length of psychotic depression-related 
hospitalization stay, psychotic depression-related outpatient/emergency department visits, all-cause hospitalizations, length of all-cause hospitalization stay, all-
cause outpatient/emergency department visits) differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
H06A: The number of post-index psychotic 
depression-related hospitalizations does not 
differ between the AD and AD/SGA cohorts, 
while controlling for covariates. 
 
Number of Psychotic 
Depression-Related 
Hospitalizations 







H06B: The number of post-index psychotic 
depression-related hospitalization days (sum 
of hospital stays, in days) does not differ 
between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Number of Psychotic 
Depression-Related 
Hospitalization Days 







H06C: The number of post-index psychotic 
depression-related outpatient/emergency 
department visits does not differ between the 
AD and AD/SGA cohorts, while controlling 
for covariates. 
 
















Table 2.7: Summary of Study Objectives, Hypotheses, Variables, Measures, and Statistical Analyses (continued) 
 







H06D: The number of post-index all-cause 
hospitalizations does not differ between the 
AD and AD/SGA cohorts, while controlling 
for covariates. 
 
Number of All-Cause 
Hospitalization Days 








H06E: The number of post-index all-cause 
hospitalization days (sum of hospital stays, in 
days) does not differ between the AD and 
AD/SGA cohorts, while controlling for 
covariates. 
 
Number of All-Cause 
Hospitalizations Days 








H06F: The number of post-index all-cause 
outpatient/emergency department visits does 
not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. 
 
Number of All-Cause 
Emergency Department 
Visits 







Objective 7: To determine if post-index adjusted health care costs (psychotic depression-related medication, psychotic depression-related medical, psychotic 
depression-related total, all-cause medication, all-cause medical, and all-cause total costs) differ between patients in the AD and AD/SGA cohorts, while controlling 
for covariates. 
H07A: The post-index psychotic depression-
related medication costs do not differ 
between the AD and AD/SGA cohorts, while 









GLM with gamma 
distribution and log-link 
function 
H07B: The post-index psychotic depression-
related medical costs do not differ between 
the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Psychotic Depression-
Related Medical Costs 




GLM with gamma 
distribution and log-link 
function 
H07C: The post-index psychotic depression-
related total costs (psychotic depression-
related prescription and psychotic 
depression-related medical costs) do not 
differ between the AD and AD/SGA cohorts, 
while controlling for covariates. 
Psychotic Depression-
Related Costs 




GLM with gamma 





Table 2.7: Summary of Study Objectives, Hypotheses, Variables, Measures, and Statistical Analyses (continued) 
 







H07D: The post-index all-cause medication 
costs do not differ between the AD and 









GLM with gamma 
distribution and log-link 
function 
H07E: The post-index all-cause medical costs 
do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. 
 




GLM with gamma 
distribution and log-link 
function 
H07F: The post-index all-cause total costs do 
not differ between the AD and AD/SGA 









GLM with gamma 
distribution and log-link 
function 
Objective 8: To determine if the risks of medication therapy (incident dyslipidemia, incident diabetes mellitus, and incident extrapyramidal symptoms) differ 
between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
H08A: The progression to the first diagnosis 
of dyslipidemia (after a 45-day post-index 
period) does not differ between the AD and 








Cox Proportional Hazards 
Regression 
H08B: The progression to the first diagnosis 
of diabetes mellitus (after a 45-day post-
index period) does not differ between the AD 










Cox Proportional Hazards 
Regression 
H08C: The progression to the first diagnosis 
of extrapyramidal symptoms post-index does 
not differ between the AD and AD/SGA 








Cox Proportional Hazards 
Regression 
AD = antidepressant monotherapy; SGA = second-generation antipsychotic therapy; CCI = Charlson comorbidity index; MPR = medication possession ratio; 
PDC = proportion of days covered; GLM = generalized linear model 
aDescriptive statistics only and not a dependent variable.  
bCovariates include: age, race/ethnicity, gender, urban residence, CCI, tobacco use and/or dependence.  




I.  Statistical Test Assumptions and Sample Size Calculations 
 Statistical test assumptions were checked prior to conducting statistical test analyses.  
Sample size calculations were also conducted for each statistical test to determine the minimum 
number of patients needed in order to maintain power of 0.80 and an alpha of 0.05 for all 
statistical analyses. 
 
II.  General Linear Models 
 General linear models represent a class of statistical methods that maintain two very 
important characteristics: linearity and additivity.  Firstly, linear relationships between variables 
are assumed, where relationships are represented by a straight line.  Secondly, the effects of 
variables are additive in relation to each other, where for example, the effect of a third variable 
will add to the predictability of the first and second variables within a prediction equation.  
General linear model techniques involve bivariate forms (e.g., Pearson’s product-moment 
correlation) and simple multiple forms (e.g., multiple linear regression, logistic regression, or 
survival analysis).
30
   
 
III.  Multiple Linear Regression 
 Multiple linear regression is a highly utilized general linear model that assesses or 
predicts the relationship between a dependent variable and at least two independent variables.  
Multiple regression utilizes the following equation: Y’ = β0 + β 1X1 + β 2X2 + … + kXk, where Y’ 
represents the predictor dependent variable score, β0 is the intercept, X1 through Xk are the 
independent variables, and k is the total number of independent variables assessed in the model. 








Before multiple linear regression can be utilized the following assumptions were tested 
and met: 1) normal distribution of residuals across the predicted dependent variable scores; 2) 
linearity between residuals and predicted dependent variable scores; 3) homoscedasticity or the 
constant variance of the residuals across the predicted dependent variable scores; 4) 
independence of errors of prediction; and 5) the observations are sampled independently (e.g., as 
a simple random sample from a large population).
30,31
 
Based on G*Power (Version 3.1.7) software, an estimated total sample size of 395 
patients was needed to conduct a multiple regression analysis (power=0.80; two-tailed α=0.05; 




 and total number of predictors=8).
33,34
    
 
IV.  Logistic Regression  
 In order to assess Objectives 3 and 5, logistic regression was utilized to predict the 
dependent variables (or discrete outcomes) from a set of independent variables.  Logistic 
regression utilizes the following equation:  ln (odds of Y=1) = β0 + β 1X1 + β 2X2 + … + kXk, 
where Y=1 refers to having the outcome of interest (such as being adherent to medications) and 
the odds of Y=1 is equal to the (probability of Y=1) / (1–(probability of Y=1)).  Prior to utilizing 
logistic regression, the following statistical test assumptions were tested and met: 1) 
independence of observations; 2) linear relationship between the independent variables and the 
logit transformed dependent variable (e.g., assumption met by failing to reject the null hypothesis 
for the Hosmer and Lemeshow goodness-of-fit test); 3) independence of errors of prediction; and 






 Using G*Power (Version 3.1.7) software, a minimum total sample size of 4842 patients 
was calculated based on the following: power=0.80; two-tailed α=0.05; a conservative estimate 
of the probability of an event, Pr(Y=1|X=1)H0=0.05, based on the literature (range: 9.4% to 
21.8%);
35,36
 a range of odds ratios (OR=1.5 to 5.0); and a binomial independent variable 
distribution with 50% on AD/SGA therapy.
33,34
  Table 2.8 provides the range of estimated 
sample sizes needed to conduct a logistic regression analysis. 
 
Table 2.8: Estimated Sample Sizes for Logistic Regression 
Odds Ratio 1.5 2.5 5.0 
R-squared
a
 0.1 0.1 0.1 
Total Sample Size 3766 615 166 
    
Odds Ratio 1.5 5.0 5.0 
R-squared
a
 0.2 0.2 0.2 
Total Sample Size 4237 692 187 
    
Odds Ratio 1.5 5.0 5.0 
R-squared
a
 0.3 0.3 0.3 
Total Sample Size 4842 791 213 
Probability (Y=1|X=1)H0=0.05; two-tailed α=0.05; power=0.80; binomial distribution with 50% 
patients on AD/SGA therapy.
 
a










V.  Cox Proportional Hazards Regression 
 In order to assess Objectives 4 and 8, survival analysis, specifically the Cox proportional 
hazards regression method, was employed.  Survival analysis is a type of statistical technique 
that measures the time until a certain event, such as medication nonpersistence or the 
development of medication-related adverse events (e.g., dyslipidemia, diabetes mellitus, and 
extrapyramidal symptoms).  In Cox proportional hazards regression, the dependent variable is 




Cox proportional hazards regression utilizes the following equation:  log[λ(t|X)/λ0(t)] = 
Φ1X1 + Φ2X2 + … ΦkXk, where λ(t) represents the hazard function for survival time T, λ0(t) is the 
baseline hazard, and X represent the independent variables.
37
  When using regression with 
survival analysis, the assumptions similar to multiple linear regression are not required; however, 
meeting the assumptions of multivariate normality, linearity, and homoscedasticity may increase 
the power of the analysis.  In order to utilize survival analysis methods, the following 
assumptions were tested and met: 1) lack of systematic error between censored and remaining 
cases; 2) lack of change in survival conditions over time; and 3) the shape of the survival 
function is constant across cases and groups over time.
30
      
 Using StataSE 12.0 software, a minimum total sample size of 3411 patients was 
calculated based on the following: power=0.80; two-tailed α=0.05; a log Hazard ratio range of 
B=1.5-2.0; and an estimated range of the probability of an event based on the literature, 
Pr(Y=1|X=1)H0=0.08 to 0.50.
38
 Table 2.9 provides the range of estimated sample sizes needed to 






Table 2.9: Estimated Sample Sizes for Cox Proportional Hazards Regression 
B (log Hazard ratio)
a
 1.5 1.5 1.5 1.5 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.1 0.1 0.1 0.1 
Total Sample Size 2653 2122 708 425 
     
B (log Hazard ratio)
a
 1.5 1.5 1.5 1.5 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.2 0.2 0.2 0.2 
Total Sample Size 2984 2388 796 478 
     
B (log Hazard ratio)
a
 1.5 1.5 1.5 1.5 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.3 0.3 0.3 0.3 
Total Sample Size 3411 2729 910 546 
     
B (log Hazard ratio)
a
 2.0 2.0 2.0 2.0 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.1 0.1 0.1 0.1 
Total Sample Size 908 727 243 146 
     
B (log Hazard ratio)
a
 2.0 2.0 2.0 2.0 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.2 0.2 0.2 0.2 
Total Sample Size 1022 817 273 164 
     
B (log Hazard ratio)
a
 2.0 2.0 2.0 2.0 
P (Overall Event Rate)
b
 0.08 0.10 0.3 0.5 
R-squared
c
 0.3 0.3 0.3 0.3 
Total Sample Size 1167 934 312 187 
Probability (Y=1|X=1)H0=0.08-0.50; two-tailed α=0.05; power=0.80; binomial distribution with 
50% patients on AD/SGA therapy
  
a
Regression coefficient or the predicted change in log(base e) hazards as X1 changes by one unit, 
holding constant all other independent variables. 
b
Represents the proportion of patients in which 
the events occur during a 12-week follow-up period (based on the literature). 
c
Represents the 







VI.  Cumulative Incidence 
 Incidence is measured in cohort studies, where the basic equation used to measure 
incidence is a ratio of the total number of events that occurred in a specific population over a 
defined time period (numerator) by the total number of people in the population at risk during 
that same time period (denominator).  Incidence can be measured based on either (1) incidence 
based on persons at risk or (2) incidence based on person-time units at risk, where the units of 
measurement in the denominator determine which type of incidence measurement is utilized.  
When persons in the population provide different follow-up periods, incidence based on person-
time units at risk should be utilized.  However, when the follow-up period is complete or the 
same for each person, incidence based on individuals at risk is employed, where the cumulative 
incidence (also known as the incidence proportion) is calculated.
39
   
For Objective 2, cumulative incidence was calculated as the number of new cases of 
disease (i.e., dyslipidemia, diabetes mellitus, and extrapyramidal symptoms) that occurred during 
the one-yr follow-up period divided by the total number of susceptible cases without the disease 
at the index date during the one-yr follow-up period.  Before utilizing cumulative incidence in 
survival analysis, the assumptions associated with Cox proportional hazards regression (listed 







VII.  Generalized Linear Models 
Generalized linear models (GLMs) also represent a sizeable class of statistical models 
that utilize a theoretical framework, allowing for simplified implementation and flexibility 
during data analysis.
40
  GLMs have three components: a random component, a linear predictor, 
and a linearizing link function.
31,41
   
The random component of a GLM specifies the conditional distribution of the dependent 
variable (Yi) based on the values of the independent variables in the model.
31
 The distribution of 
Yi may consist of a normal distribution or other distributions in the exponential family such as 
Gaussian, inverse-Gaussian, Poisson, negative binomial, gamma, or beta distributions.
31,40
  For 
example, Gaussian distributions are variant distributions of the standard bell curve, where a 
normal curve represents one type of a Gaussian distribution.  Count data generally follow 
Poisson distributions, and as the samples grow, the distributions will approximate a normal 
distribution.  Gamma distributions are continuous positive distributions, where the variance of 
the dependent variable increases as its mean increases.
31
     
The second component of a GLM is the linear predictor, which represents the linear 
function of regressors, as described in the equation: ηi = α + β1Xi1 + β2Xi2 + … + βkXik.  
Regressors (Xij) are pre-specified functions of independent variables that may be, for example, 
quantitative, transformed, dummy-coded, or even represented as interactions.
31
 
The third component of a GLM is the linearizing link function, g(·), which allows 
transformation of the expected dependent variable, μi ≡ E(Yi), to the following linear predictor:  
g(μi) = ηi = α + β1Xi1 + β2Xi2 + … + βkXik.  The linearizing link function is smooth and invertible 
in nature allowing for the linear transformation of a non-linear dependent variable (or nonlinear 




(α + β1Xi1 + 




distribution of the dependent variable.
31
  Table 2.10 displays examples of exponential families 
and their canonical link functions and the dependent variable range of responses.  
 
Table 2.10: Exponential Families and Corresponding Canonical Links, Response Ranges, 
and Conditional Variance Functions 
Family Canonical Link Range of Yi V(Yi|ηi) 
Gaussian Identity (-∞, +∞) Φ 
Binomial Logit (0,1,…,ni) / (ni) μi(1–μi) / ni 
Poisson Log 0, 1, 2, … μi 
Gamma Inverse (0, ∞) Φ μ
2
i 
Inverse-Gamma Inverse-square (0, ∞) Φ μ
3
i 
Adapted from: Generalized Linear Models. In Fox J., Applied Regression Analysis and 
Generalized Linear Models. 2
nd




Key assumptions that were tested and met prior to utilizing GLMs included: 1) 
independence of observations; 2) correct model specification in relation to the link and variance 
functions; 3) correct measurement scale for the independent variables; and 4) lack of influence of 




Generalized Linear Model with Negative Binomial and Gamma Distributions  
 In order to assess Objectives 6 and 7, GLMs were utilized.  Specifically, generalized 
linear models (negative binomial regression, zero-inflated negative binomial regression, and 
negative binomial-logit hurdle model regression) were employed for Objective 6 since the 
dependent variables were overdispersed count variables with or without excess zeros. A GLM 




 Using G*Power (Version 3.1.7) software, a minimum total sample size of 102 patients 




10% difference in health care utilization),
45
 a mean exposure of 365 days, a binomial 
independent variable distribution with 50% on AD/SGA therapy, and a baseline health care 
utilization rate (i.e., suicide attempts and hospitalizations) range of 10% to 25% based on the 
literature.
33,34,46,47
  Table 2.11 provides the range of estimated sample sizes needed to conduct 
negative binomial regression based on a Poisson-distributed GLM. 
 
 
Table 2.11: Estimated Sample Sizes for Poisson-Distributed GLM  
Base Rate 0.10 0.15 0.20 0.25 
R-squared
a
 0.1 0.1 0.1 0.1 
Total Sample Size 80 53 51 32 
     
Base Rate 0.10 0.15 0.20 0.25 
R-squared
a
 0.2 0.2 0.2 0.2 
Total Sample Size 89 60 45 36 
     
Base Rate 0.10 0.15 0.20 0.25 
R-squared
a
 0.3 0.3 0.3 0.3 
Total Sample Size 102 68 51 41 














 reported that appropriately specified GLMs may more closely 
model the error structure of cost data compared to traditional models of ordinary least squares 
regression that utilize log-transformed costs.  Although there is a dearth of literature pertaining to 
power analyses for GLMs with a gamma distribution and log-link function, Jin and Zhao
49
 
support that the sample size needed for a gamma distribution will not be greater than the sample 
size required for a normal distribution at the same power level.  Therefore, G*Power (Version 
3.1.7) software was used to calculate the minimum size needed when employing a GLM with a 
gamma distribution and log-link function.  A sample size based on multiple linear regression was 
calculated, and an estimated total sample size of 395 patients was needed (power=0.80; two-




 and total number of predictors=8).
33,34
    
Based on the estimated sample sizes for each statistical analysis (i.e., multiple linear 
regression, logistic regression, Cox proportional hazards regression, and negative binomial and 
gamma-distributed GLMs), the minimum overall sample size of 4842 patients was required for 
the present study.  
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Chapter 3:  Results 
CHAPTER OVERVIEW 
 This chapter provides a description of the study results. Details regarding the patient 
selection process, patient socio-demographics, and patient clinical characteristics are presented. 
The study objectives, hypotheses, and statistical analysis results are also provided. 
 
EXTRACTION OF ELIGIBLE PATIENTS 
 From September 2007 through December 2012, a total of 28,049 patients had at least one 
diagnosis for severe major depressive disorder with psychotic features. Of those patients, 7,148 
(25.5%) had no prescription claims for an antidepressant medication. Therefore, the remaining 
20,901 patients were assessed for the study inclusion and exclusion criteria in order to determine 
the final sample.  
 The final sample size included 926 patients (3.3%) and two study cohorts. Of the final 
sample, there were 510 patients in the antidepressant monotherapy (AD) cohort and 416 patients 
in the antidepressant plus second-generation antipsychotic (AD/SGA) cohort. The study 
inclusion and exclusion criteria, as well as the resulting sample sizes, are provided in Table 3.1. 
During the post-index period, SSRI therapy accounted for almost half of the antidepressant 
prescription claims (46.0%). For the AD/SGA cohort, the top three utilized SGA medications 
were risperidone (29.0%), quetiapine (27.4%), and aripiprazole (22.3%). The antidepressant and 





Table 3.1: Patient Selection in Texas Medicaid Database 
Study Criteria Subjects Excluded Subjects Remaining 
N % N % 
Initial Sample 28,049 100.0 




7,148 25.5 20,901 74.5 
Did not have the 6-month pre-index and 
12-month post-index periods of 
continuous enrollment 
14,172 50.5 6,729 24.0 
No diagnosis for psychotic depression 
during pre-index or post-index periods 
2,667 9.5 4,062 14.5 
Had a claim for electroconvulsive 
therapy
 
during pre-index or post-index 
periods 
8 0.0 4,054 14.5 
Had at least one diagnosis for 
confounding disease state(s): 
     Bipolar disorder
b
 
     Schizophrenia 
     Mental retardation 
     Other cerebral degenerations  
     Dementia 
     Pervasive development disorder 
     Parkinson’s disease 















Did not have at least two post-index 
antidepressant medication claims 
321 1.1 1,706 6.1 
Had a claim for clozapine
 
during pre-
index or post-index periods 
0 0.0 1,706 6.1 
Had a claim for an FGA
 
during pre-
index or post-index periods
 
164 0.6 1,542 5.5 
Had a claim for an SGA during pre-
index period 
175 0.6 1,367 4.9 
Did not have at least two post-index 
SGA medication claims 
153 0.5 1,214 4.3 
Did not have overlap of ≥30-day if on 
antidepressant and SGA therapy 
25 0.1 1,189 4.2 
Did not start first SGA on index date 
 




FGA = first-generation antipsychotic; SGA = second-generation antipsychotic 
a
During period of September 1, 2007 to December 31, 2012 
b
Also includes manic depression and cyclothymic disorder 
c




Table 3.2: Antidepressant Medication Prescription Claims by Medication Class 





     Citalopram 
     Escitalopram 
     Fluoxetine 
     Fluvoxamine 
     Paroxetine 















SSRI & Partial Agonist 







     Desvenlafaxine 
     Duloxetine 





























     Amitriptyline 
     Amoxapine 
     Doxepin 
     Imipramine 















SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake 
inhibitor; TCA= tricyclic antidepressant 
a






Table 3.3: Second-Generation Antipsychotic Prescription Claims by Medication 
Second-Generation Antipsychotic
a

































AD = antidepressant; SGA = second-generation antipsychotic 
a
Represents oral and injectable medications 
b
Includes olanzapine and fluoxetine combination product (Symbyax) 
c
Includes one medical claim for Geodon® injection 
d








Baseline socio-demographic and clinical characteristics were calculated for the final 
study sample. Results are presented in Table 3.4. 
 
BASELINE SOCIO-DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF FINAL SAMPLE 
 Of the final sample, the majority of patients were aged 35 years or older (64.0%). 
Females (66.8%) represented the majority of patients based on gender, and most patients were of 
either Caucasian (25.2%), African American (34.9%), or Hispanic (36.7%) race/ethnicity. Urban 
dwellers comprised 79.5% of the final sample, and over two-thirds (68.9%) had no comorbidities 





Table 3.4: Baseline Summary Statistics for Final Sample 
Socio-Demographics  N % 
Age groups (years)   
18-24 156 16.8 
25-34 177 19.1 
35-44 144 15.6 
45-54 309 33.4 
55-63 140 15.1 
Total 926 100.0 
Gender   
Female 619 66.8 
Male 307 33.2 
Total 926 100.0 
Race/Ethnicity   
Caucasian 233 25.2 
African American 323 34.9 




Total 926 100.0 
Urban Residence   
Yes 736 79.5 
No 190 20.5 
Total 926 100.0 
Clinical Characteristic N % 
Charlson Comorbidity Index (CCI)   
0 638 68.9 
1 143 15.4 
2 75 8.1 
3-4 47 5.1 
>4 23 2.5 
Total 926 100.0 
a






I.  Objective 1: Description and Comparison of Baseline Characteristics 
 The purpose of Objective 1 was to describe and compare the baseline socio-demographic 
and clinical characteristics of Texas Medicaid patients with MD-Psy who utilized either 
antidepressant monotherapy (AD cohort) or combination therapy with an antidepressant and a 
second-generation antipsychotic (AD/SGA cohort). Table 3.5 provides the comparison of 
baseline socio-demographic and clinical characteristics between the AD and AD/SGA cohorts.  
On average, compared to the AD/SGA cohort, the AD cohort was significantly younger 
(p=0.001) and had more comorbidities based on the Charlson Comorbidity Index score 
(p<0.001).  There was a significant difference in relation to race/ethnicity (p<0.001), where the 
AD cohort had larger proportions of Caucasians and Hispanics, compared to the AD/SGA 
cohort.  Finally, the AD/SGA cohort had significantly less females (p<0.001) and rural dwellers 














39.2 (±13.3) 42.0 (±13.0) 0.001* 
Gender (%)
b 
   <0.001* 
     Female 72.2 60.3  
     Male 27.8 39.7  
Race/Ethnicity (%)
b 
  <0.001* 
     Caucasian 30.0 19.2  
     African American 28.0 43.3  
     Hispanic 39.2 33.7  
     Other
c 
2.7 3.8  
Urban Residence (%)
b 
  <0.001* 
     No 25.7 14.2  




     Median 










AD = antidepressant; SGA = second-generation antipsychotic 
a













II.  Objective 2: Description and Comparison of Post-Index Clinical Characteristics 
The purpose of Objective 2 was to describe and compare the post-index clinical 
characteristics of the AD and AD/SGA cohorts. Table 3.6 and 3.7 provide descriptions and 
comparisons of the post-index clinical characteristics between cohorts.  
Overall, the cumulative incidences of dyslipidemia were 20.5% and 17.0% for the AD 
cohort and the AD/SGA cohort, respectively. Compared to dyslipidemia, the cumulative 
incidences of diabetes mellitus were lower for both cohorts (6.8% for the AD cohort versus 6.3% 
for the AD/SGA cohort).  The cumulative incidences were even lower for extrapyramidal 
symptoms at 1.6% (AD cohort) and 1.0% (AD/SGA cohort). There were no significant 
differences between the number of new cases of dyslipidemia, diabetes mellitus, or 
extrapyramidal symptoms between cohorts. 
There was no significant difference between the two cohorts regarding tobacco use or 
dependence post-index (p=0.074). On average, compared to the AD cohort, the antidepressant 
persistence rate using a 45-day permissible gap was significantly longer for the AD/SGA cohort 
by approximately 34 days (p<0.001). The combination cohort’s SGA persistence rate using a 45-
day permissible gap had a mean (±SD) of 178.6 (±127.9) days, where almost half of the 





Table 3.6: Description of Post-Index Characteristics by Cohort 




N % N % 
Dyslipidemia      
Yes 79 20.5 55 17.0 








Diabetes Mellitus     
Yes    27 6.8 22 6.3 








Extrapyramidal Symptoms     
Yes  8 1.6 4 1.0 








Tobacco Use/Dependence     
Yes 111 21.8 71 17.1 
No 399 78.2 345 82.9 
Total 510 100.0 416 100.0 
AD Persistence (days)
b 
    
0-30  117 22.9 66 15.9 
31-90  106 20.8 75 18.0 
91-150 88 17.3 57 13.7 
>150 199 39.0 218 52.4 
Total 510 100.0 416 100.0 
SGA Persistence (days)
c 
    
0-30  -- -- 71 17.1 
31-90  -- -- 80 19.2 
91-150 -- -- 60 14.4 
>150 -- -- 205 49.3 
Total N/A N/A 416 100.0 
AD = antidepressant; SGA = second-generation antipsychotic  
a
Represents the number of patients susceptible to the disease at index 
b
Persistence calculated using a 45-day permissible gap 
c



















20.5 17.0 0.230 
Diabetes Mellitus Incidence (%)
a,b 
     
 




1.6 1.0 0.412 
Tobacco Use/Dependence (%)
b
 21.8 17.1 0.074 
AD Persistence (45-day gap)
c
 
   Mode 
   Median 














SGA Persistence (45-day gap)
e
 
   Mode 
   Median 










AD = antidepressant; SGA = second-generation antipsychotic 
a





Independent samples t-test 
d
Significant difference between cohorts at p<0.001 
e







III.  Objective 3: Antidepressant Adherence Based on MPR and PDC 
 The purpose of Objective 3 was to determine if the rates of antidepressant 
medication adherence (medication possession ratio – MPR and proportion of days covered – 
PDC) differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
Therefore, two logistic regression analyses were employed with the dependent variables being 
MPR (not adherent was MPR < 80%; adherent was MPR ≥ 80%) and PDC (not adherent was 
PDC < 80%; adherent was PDC ≥ 80%). The primary independent variable being assessed was 
the study cohort (AD versus AD/SGA). The study covariates utilized in both models included: 
age, gender, race/ethnicity, urban residence, Charlson Comorbidity Index score, and tobacco use 
and/or dependence. Multicollinearity, or high correlations among independent variables, was 
assessed using multiple linear regression analyses. Collinearity statistics showed that tolerance 
values ranged from 0.565 to 0.960 and variance inflation factor values (calculated as the inverse 
of tolerance) ranged from 1.042 to 1.771. Since the values for tolerance and variance inflation 
factor for each independent variable were above 0.1 and below 10, respectively, multicollinearity 
was not a statistical issue of concern. Table 3.8 provides descriptions and comparisons of the 





Table 3.8: Description and Comparison of Antidepressant Adherence Measures (MPR and 




























AD = antidepressant; SGA = second-generation antipsychotic; MPR = medication possession 
ratio; PDC = proportion of days covered 
a
Pearson’s chi-square  
*Significant at p<0.05 
 
  
Of the final sample, 355 patients (38.3%) were adherent to their antidepressant 
medication therapy based on MPR. A Hosmer and Lemeshow Goodness of Fit test yielded a 
non-significant p-value indicating good model fit with the data (χ
2
=8.591; df=8; p=0.378). Table 
3.9 displays the results of the logistic regression analysis assessing the likelihood of 
antidepressant adherence based on MPR. A chi-square test comparing the full model (i.e., model 
includes all covariates) to the constant model (i.e., model contains no covariates) was significant 
(χ
2
=80.774; df=9; p<0.001), indicating that at least one covariate was related to the outcome.  
Compared to patients on antidepressant therapy only, the odds of being adherent to 
antidepressant medication therapy was 42.0% significantly higher for patients utilizing both an 
antidepressant and second-generation antipsychotic therapy (OR=1.420; 95% CI=1.062-1.898; 
p=0.018), while controlling for other variables in the model. Age was also a significant positive 
predictor, where the odds of being adherent increased significantly by 4.4% as age increased by 
one year (OR=1.044; 95% CI=1.031-1.056; p<0.001). Compared to Caucasian patients, African 
Americans (OR=0.649; 95% CI=0.448-0.938; p=0.021) had a significantly lower likelihood of 




of being adherent based on MPR were significantly lower by about 33.1% for tobacco 
users/dependents (OR=0.669; 95% CI=0.467-0.959; p=0.029). However, gender, being of 
Hispanic ethnicity, being of other race, urban residence, and Charlson Comorbidity Index score 
were not significantly related to adherence based on MPR.  
   Of the final sample, 306 patients (33.0%) were adherent to their antidepressant 
medication therapy based on PDC. A Hosmer and Lemeshow Goodness of Fit test yielded a non-
significant p-value indicating good model fit with the data (χ
2
=6.287; df=8; p=0.615). Table 3.10 
displays the results of the logistic regression analysis assessing the likelihood of antidepressant 
adherence based on PDC. A chi-square test comparing the full model (i.e., model includes all 
covariates) to the constant model (i.e., model contains no covariates) was significant (χ
2
=74.295; 
df=9; p<0.001), indicating that at least one covariate was related to the outcome. For PDC, the 
results were very similar to MPR. Compared to patients on antidepressant therapy only, the odds 
of being adherent to antidepressant medication therapy based on PDC was 52.3% significantly 
higher for patients utilizing both an antidepressant and second-generation antipsychotic therapy 
(OR=1.523; 95% CI=1.129-2.053; p=0.006), while controlling for other variables in the model. 
Age (OR=1.039; 95% CI=1.027-1.052; p<0.001) was also a significant positive predictor of 
adherence to antidepressant therapy. Compared to Caucasians, African Americans (OR=0.612; 
95% CI=0.419-0.894; p=0.011) had a significantly lower likelihood of antidepressant adherence. 
Compared to non-tobacco users/dependents, the odds of being adherent based on PDC were 
significantly lower by over 36.4% for tobacco users/dependents (OR=0.636; 95% CI=0.437-
0.927; p=0.019). Gender, being of Hispanic ethnicity, being of other race, urban residence, and 





H03A: The likelihood of being adherent as measured by MPR ≥ 80% to antidepressant therapy 
does not differ between the AD and AD/SGA cohorts, while controlling for covariates. 
[Rejected] 
 
H03B: The likelihood of being adherent as measured by PDC ≥ 80% to antidepressant therapy 






Table 3.9: Logistic Regression Analysis Comparing the Likelihood of Antidepressant 









AD/SGA 1.420 1.062 1.898 5.596 0.018* 
Covariates 
Age 1.044 1.031 1.056 51.360 <0.001* 
Female 0.922 0.684 1.242 0.285 0.594 
African American 0.649 0.448 0.938 5.290 0.021* 
Hispanic 0.800 0.548 1.168 1.336 0.248 
Other
a
 1.363 0.607 3.060 0.564 0.453 
Urban Residence 0.758 0.528 1.089 2.249 0.134 
Charlson Comorbidity Index
 
0.940 0.841 1.051 1.183 0.277 
Tobacco Use/Dependence 0.669 0.467 0.959 4.788 0.029* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 




Table 3.10: Logistic Regression Analysis Comparing the Likelihood of Antidepressant 









AD/SGA 1.523 1.129 2.053 7.606 0.006* 
Covariates 
Age 1.039 1.027 1.052 39.506 <0.001* 
Female 0.827 0.610 1.121 1.494 0.222 
African American 0.612 0.419 0.894 6.462 0.011* 
Hispanic 0.744 0.505 1.096 2.242 0.134 
Other
a
 1.232 0.552 2.748 0.259 0.611 
Urban Residence 0.738 0.509 1.069 2.580 0.108 
Charlson Comorbidity Index
 
0.919 0.817 1.034 1.957 0.162 
Tobacco Use/Dependence 0.636 0.437 0.927 5.546 0.019* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 






IV.  Objective 4: Antidepressant Nonpersistence 
 The purpose of Objective 4 was to determine if the risk of antidepressant medication 
nonpersistence differs between patients in the AD and AD/SGA cohorts, while controlling for 
covariates. Therefore, three Cox proportional hazards regression models were employed with the 
continuous dependent variables being persistence using a 45-day permissible gap (primary 
analysis), persistence using a 30-day permissible gap (secondary analysis), and persistence using 
a 60-day permissible gap (secondary analysis). The primary independent variable was the study 
cohort (AD vs. AD/SGA), and the covariates were age, gender, race/ethnicity, urban residence, 
Charlson Comorbidity Index score, and tobacco use and/or dependence.  Patients were censored 
if they continued antidepressant medication use through the last day of the post-index period 
(i.e., day 365). 
 Prior to utilizing statistical analyses, multicollinearity was assessed and found to 
be absent based on the tolerance and variance inflation factor scores. The proportionality of 
hazards assumption for Cox proportional hazards regression requires that each case (and thus 
each treatment cohort) has the same shape in relation to survival function over time. Essentially, 
there can be no interactions between treatment cohorts (or other covariates) and time. 
Proportionality of hazards can be tested by adding all time-dependent interactions to the original 
model. If any interactions are significant then the assumption has been violated.
1
  No significant 
interactions were found. Therefore, the proportionality of hazards assumptions were met for 
persistence with a 45-day gap (Wald χ
2
=7.114, df=9, p=0.625), persistence with a 30-day gap 
(Wald χ
2
= 7.606, df=9, p=0.574), and persistence with a 60-day gap (Wald χ
2
= 13.130, df=9, 
p=0.157). Table 3.11 provides descriptions and comparisons of the antidepressant persistence 











AD Persistence (45-day gap) 
   Mode 
   Median 














AD Persistence (30-day gap) 
   Mode 
   Median 














AD Persistence (60-day gap) 
   Mode 
   Median 














AD = antidepressant; SGA = second-generation antipsychotic 
a
Independent samples t-test 
*Significant at p<0.05 
 
 
Using persistence with a 45-day gap, the mean survival time (±SD) prior to 
antidepressant medication nonpersistence was 172.3 days (±130.4). For the AD cohort, the mean 
survival time (±SD) was 156.8 (±127.1), and for the AD/SGA cohort, the mean survival time 
(±SD) was 191.3 (±132.1). Table 3.12 provides the results for the Cox proportional hazards 
regression model using persistence with a 45-day permissible gap, where medication 
nonpersistence was established when a gap period >45 days between any two consecutive 
medication fills occurred.  The global null hypothesis test was significant (χ
2
=69.965; df=9; 
p<0.001), indicating the rejection of the null hypothesis that all coefficients are equal to zero.  
The primary variable of interest was significant, where the hazard of antidepressant 
nonpersistence for the AD/SGA cohort was about 23.2% significantly lower than the hazard for 
those in the AD cohort (HR=0.768; 95% CI=0.659-0.896; p=0.001), while controlling for other 




decreased by approximately 1.8% (HR=0.982; 95% CI=0.976-0.988; p<0.001). Compared to 
Caucasian patients, the hazards of medication nonpersistence was significantly higher by about 
45.5% for African Americans (HR=1.455; 95% CI=1.192-1.776; p<0.001) and 30.1% for 
Hispanics (HR=1.301; 95% CI=1.061-1.594; p=0.011). Compared to non-tobacco 
users/dependents, the hazard of antidepressant nonpersistence was significantly higher by 24.9% 
in tobacco users/dependents, while controlling for the other covariates in the model (HR=1.249; 
95% CI=1.040-1.501; p=0.017). The remaining covariates were not significantly related to the 
dependent variable.  
 
H04A: The time, in days, to antidepressant medication nonpersistence (using a 45-day gap of no 







Table 3.12: Cox Proportional Hazards Regression Model Comparing Survival Time 
(Persistence Using a 45-Day Gap) Prior to Antidepressant Medication 
Nonpersistence Among Cohorts (N=926) 
 Hazard 
Ratio 






AD/SGA 0.768 0.659 0.896 11.283 0.001* 
Covariates 
Age 0.982 0.976 0.988 36.684 <0.001* 
Female 1.025 0.876 1.200 0.097 0.755 
African American 1.455 1.192 1.776 13.613 <0.001* 
Hispanic 1.301 1.061 1.594 6.408 0.011* 
Other
a
 1.204 0.783 1.852 0.713 0.398 
Urban Residence 1.133 0.934 1.375 1.610 0.205 
Charlson Comorbidity Index
 
1.010 0.956 1.067 0.124 0.725 
Tobacco Use/Dependence 1.249 1.040 1.501 5.678 0.017* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 






Cox Proportional Hazards regression secondary analyses were employed using 
persistence with a 30-day permissible gap and persistence with a 60-day permissible gap.  
Results of the analyses are provided in Tables 3.13 and 3.14. Similarly to the regression model 
using persistence with a 45-day gap, both secondary models were significant in relation to 
cohort, age, African American race, and Hispanic ethnicity (p<0.05). Persistence with a 30-day 
gap matched the results of the first model, where tobacco use and/or dependence was related to 
significantly worse hazards of medication nonpersistence (HR=1.270; 95% CI=1.058-1.524; 
p=0.010). Interestingly, using persistence with a 60-day gap, urban dwellers had a significantly 
higher hazard of medication nonpersistence by approximately 22.7%, compared to rural dwellers 
(HR=1.227; 95% CI=1.004-1.499; p=0.046). 
 
H04B: The time, in days, to antidepressant medication nonpersistence (using a 30-day gap of no 
medication) does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. [Rejected] 
 
H04C: The time, in days, to antidepressant medication nonpersistence (using a 60-day gap of no 








Table 3.13: Secondary Analysis—Cox Proportional Hazards Regression Model  Comparing 
Survival Time (Persistence Using a 30-Day Gap) Prior to Antidepressant 
Medication Nonpersistence Among Cohorts (N=926) 
 Hazard 
Ratio 






AD/SGA 0.782 0.670 0.913 9.748 0.002* 
Covariates 
Age 0.984 0.978 0.989 30.578 <0.001* 
Female 1.052 0.899 1.231 0.402 0.526 
African American 1.502 1.231 1.832 16.102 <0.001* 
Hispanic 1.307 1.066 1.602 6.641 0.010* 
Other
a
 1.244 0.808 1.914 0.983 0.321 
Urban Residence 1.157 0.953 1.404 2.159 0.142 
Charlson Comorbidity Index
 
1.018 0.962 1.077 0.377 0.539 
Tobacco Use/Dependence 1.270 1.058 1.524 6.575 0.010* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 




Table 3.14: Secondary Analysis—Cox Proportional Hazards Regression Model Comparing 
Survival Time (Persistence Using a 60-Day Gap) Prior to Antidepressant 
Medication Nonpersistence Among Cohorts (N=926) 
 Hazard 
Ratio 






AD/SGA 0.716 0.611 0.840 16.937 <0.001* 
Covariates 
Age 0.979 0.974 0.985 46.090 <0.001* 
Female 1.002 0.852 1.178 0.000 0.983 
African American 1.506 1.226 1.851 15.220 <0.001* 
Hispanic 1.312 1.064 1.618 6.451 0.011* 
Other
a
 1.235 0.794 1.920 0.878 0.349 
Urban Residence 1.227 1.004 1.499 3.995 0.046* 
Charlson Comorbidity Index
 
1.023 0.968 1.083 0.653 0.419 
Tobacco Use/Dependence 1.183 0.977 1.431 2.967 0.085 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 





V.  Objective 5: Suicide Ideation and Suicide Attempts 
 The purpose of Objective 5 was to determine if the rates of post-index suicide ideation 
and suicide attempts differ between patients in the AD and AD/SGA cohorts, while controlling 
for covariates. Due to the small sample sizes (i.e., 38 patients with suicide ideation and 9 patients 
with at least one suicide attempt), the dependent variables were aggregated. Therefore, one 
logistic regression analysis was employed, and the newly aggregated dependent variable—post-
index suicide ideation and/or suicide attempt (1=yes; 0=no)—was tested. The primary 
independent variable being assessed was the study cohort (AD vs. AD/SGA). The study 
covariates utilized in both models included: age, gender, race/ethnicity, urban residence, 
Charlson Comorbidity Index score, and antidepressant persistence based on a 45-day permissible 
gap. Collinearity statistics showed that tolerance values ranged from 0.562 to 0.953 and variance 
inflation factor values (calculated as the inverse of tolerance) ranged from 1.050 to 1.780. 
Therefore, multicollinearity was not a statistical issue of concern. Table 3.15 provides 
descriptions and comparisons of the post-index suicide ideation and attempt rates between 
cohorts. 
 Approximately, 4.4% of the final sample had suicide ideation and/or a suicide attempt 
post-index (32 patients had suicide ideation only, 3 had attempted suicide, and 6 had both suicide 
ideation and at least one suicide attempt). A Hosmer and Lemeshow Goodness of Fit test yielded 
a non-significant p-value indicating good model fit with the data (χ
2
=3.939; df=8; p=0.863). 
Table 3.16 displays the results of the logistic regression analysis assessing the likelihood of 
having suicide ideation and/or a suicide attempt. A chi-square test comparing the full model (i.e., 
model includes all covariates) to the constant model (i.e., model contains no covariates) was 
significant (χ
2




outcome. The odds of having suicide ideation and/or a suicide attempt post-index was not 
significantly different between cohorts (OR=0.661; 95% CI=0.316-1.386; p=0.273), while 
controlling for other variables in the model. Compared to Caucasian patients, the likelihood of 
having suicide ideation and/or an attempt post-index was significantly lower by approximately 
63.8% in African American patients (OR=0.362; 95% CI=0.137-0.957; p=0.040). Tobacco 
users/dependents were four times more likely to have post-index suicide ideation and/or a suicide 
attempt compared to non-users/dependents (OR=4.096; 95% CI=2.062-8.137; p<0.001). As 
patients persisted one day longer on their antidepressant therapy, the odds of having suicide 
ideation and/or a suicide attempt significantly decreased by 0.4% (OR=0.996; 95% CI=0.993-
0.999; p=0.022). However, the other covariates (age, gender, being of Hispanic ethnicity, being 
of other race, urban residence, and Charlson Comorbidity Index score) were not significantly 
related to having suicide ideation and/or a suicide attempt post-index.    
 
H05A: The likelihood of having post-index suicide ideation and/or a suicide attempt does not 







Table 3.15: Description and Comparison of Post-Index Suicide Ideation and Suicide 




























Suicide Ideation and/or Attempt (%)
a
 








AD = antidepressant; SGA = second-generation antipsychotic 
a
Pearson’s chi-square 




Table 3.16: Logistic Regression Analysis Comparing the Likelihood of Having Post-Index 









AD/SGA 0.661 0.316 1.386 1.199 0.273 
Covariates 
Age 0.985 0.959 1.011 1.264 0.261 
Female 1.395 0.648 3.004 0.724 0.395 
African American 0.362 0.137 0.957 4.199 0.040* 
Hispanic 1.144 0.505 2.590 0.105 0.746 
Other
a
 0.884 0.103 7.584 0.013 0.911 
Urban Residence 0.981 0.420 2.292 0.002 0.965 
Charlson Comorbidity Index
 
1.187 0.971 1.452 2.800 0.094 
Tobacco Use/Dependence 4.096 2.062 8.137 16.207 <0.001* 
Antidepressant Persistence
b 
0.996 0.993 0.999 5.215 0.022* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 





VI.  Objective 6: Rates of Health Care Utilization 
The purpose of Objective 6 was to identify if post-index health care utilization rates 
(psychotic depression-related hospitalizations, length of psychotic depression-related 
hospitalization stay, psychotic depression-related outpatient/emergency department visits, all-
cause hospitalizations, length of all-cause hospitalization stay, all-cause outpatient/emergency 
department visits) differ between patients in the AD and AD/SGA cohorts, while controlling for 
covariates. Approximately, 4.3% had at least one psychotic depression-related hospitalization 
post-index (36 patients had one hospitalization and 4 had two hospitalizations). Of these patients, 
the mean (±SD) length of stay for a psychotic depression-related hospitalization was 7.3 (±3.8) 
days. Due to the small sample sizes, the hypotheses testing psychotic depression-related 
hospitalizations and associated lengths of stay could not be tested. 
Prior to running the statistical models, normality was checked using the Kolmogorov-
Smirnov test. The tests indicated non-normality as the assumption of normality was rejected 
based on significant results (p<0.001). All models had a significant Likelihood Ratio chi-square 
test of alpha=0 (p<0.001), which indicated overdispersion (i.e., mean < variance) and that the 
data were better estimated using negative binomial regression models versus Poisson regression 
models.  A significant Vuong test found that all-cause hospitalizations were better estimated 
using a zero-inflated negative binomial regression model rather than an ordinary negative 
binomial regression model (p=0.004). Therefore, four generalized linear regression models were 
employed (two negative binomial regression analyses, one negative binomial-logit hurdle 
regression analysis, and one zero-inflated negative binomial regression analysis). The dependent 
variables were psychotic depression-related outpatient/emergency department visits, all-cause 




outpatient/emergency department visits. The primary independent variable was the study cohort 
(AD vs. AD/SGA), and the study covariates were age, gender, race/ethnicity, urban residence, 
Charlson Comorbidity Index score, tobacco use and/or dependence, and antidepressant 
persistence based on a 45-day permissible gap. Table 3.17 provides descriptions and 






Table 3.17: Description and Comparison of Post-Index Health Care Utilization Rates 
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AD = antidepressant; SGA = second-generation antipsychotic 
a
Mann-Whitney U 







The mean (±SD) psychotic depression-related outpatient/emergency department visits, 
all-cause hospitalizations, all-cause hospitalizations days, and all-cause outpatient/emergency 
department visits were 5.1 (±7.2) visits, 0.3 (±0.8) hospitalizations, 2.1 (±6.2) days, and 22.0 
(±18.2) visits, respectively. Tables 3.18-3.21 display the results of the generalized linear 
regression models using negative binomial regression, zero-inflated negative binomial 
regression, and negative binomial-logit hurdle regression.  For each model, the Likelihood Ratio 
chi-square test was significant (p<0.001), indicating the rejection of the null hypothesis that all 
coefficients are equal to zero. 
For total psychotic depression-related outpatient/emergency department visits, the 
AD/SGA cohort had significantly more visits (by approximately 60.0%) than the AD cohort 
(IRR=1.600; 95% CI=1.377-1.859; p<0.001), while controlling for other variables in the model. 
All covariates (except age, being African American, and tobacco use and/or dependence) 
remained significant predictors at p<0.05. Regarding total all-cause hospitalizations, although a 
univariate analysis found a significantly lower number of total all-cause hospitalizations for the 
combination cohort, multivariate analyses using zero-inflated negative binomial regression 
showed no significant difference between cohorts with race/ethnicity, Charlson Comorbidity 
Index, and antidepressant persistence being the only significant predictors of total all-cause 
hospitalizations (p<0.05). For patients with summated hospital lengths of stay greater than zero 
days, the AD/SGA cohort had significantly longer stays by approximately 42.3% than the AD 
cohort (IRR=1.423; 95% CI=1.072-1.888; p=0.015), while controlling for other variables in the 
model. Also, race/ethnicity, Charlson Comorbidity Index score, and antidepressant persistence 
remained significant predictors at p<0.05. However, the likelihood of having an all-cause 




to the AD cohort (OR=0.693; 95% CI=0.488-0.983; p=0.040).  In other words, patients in the 
AD/SGA cohort were significantly less likely to have an all-cause hospitalization, but when 
these patients did have at least one, their hospitalization lengths of stay were significantly longer 
compared to the AD cohort. Finally, there was no significant difference between cohorts 
regarding total all-cause outpatient/emergency department visits; however, age, being of African 
American race, Charlson Comorbidity Index score, tobacco use and/or dependence, and 
antidepressant persistence were significant predictors (p<0.05). 
 
H06A: The number of post-index psychotic depression-related hospitalizations does not differ 
between the AD and AD/SGA cohorts, while controlling for covariates.  
[Unable to Test] 
 
H06B: The number of post-index psychotic depression-related hospitalization days (sum of 
hospital says, in days) does not differ between the AD and AD/SGA cohorts, while controlling 
for covariates. [Unable to Test] 
 
H06C: The number of post-index psychotic depression-related outpatient/emergency department 
visits does not differ between the AD and AD/SGA cohorts, while controlling for covariates. 
[Rejected] 
 
H06D: The number of post-index all-cause hospitalizations does not differ between the AD and 





H06E: The number of post-index all-cause hospitalization days (sum of hospital stays in days) 
does not differ between the AD and AD/SGA cohorts, while controlling for covariates. 
[Rejected] 
H06F: The number of post-index all-cause outpatient/emergency department visits does not differ 




Table 3.18: Negative Binomial Regression Analysis Comparing Psychotic Depression 
Outpatient/Emergency Department Visits Among Cohorts (N=926) 






AD/SGA 1.600 1.377     1.859 6.13 <0.001* 
Covariates 
Age 1.003 0.997     1.010 1.13 0.260 
Female 0.726 0.621    0.847 -4.05 <0.001* 
African American 1.104 0.908     1.343 0.99 0.321 
Hispanic 1.274 1.043      1.556 2.37 0.018* 
Other
a
 1.698 1.114     2.589 2.46 0.014* 
Urban Residence 0.723 0.597 0.874 -3.35 <0.001* 
Charlson Comorbidity Index
 
0.851 0.800   0.905 -5.14 <0.001* 
Tobacco Use/Dependence 0.962 0.797    1.162 -0.40 0.690 
Antidepressant Persistence
b 
1.002 1.001 1.003 7.09 <0.001* 
IRR = incidence rate ratio; AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown;  
b
Persistence based on a 45-day permissible gap;  







Table 3.19: Zero-Inflated Negative Binomial Regression Analysis Comparing All-Cause 
Hospitalization Among Cohorts (N=926) 







AD/SGA 1.376 0.933     2.030 1.61 0.107 
Covariates 
Age 1.007 0.994     1.019 1.00 0.316 
Female 1.361  0.946     0 .957 1.66 0.097 
African American 0.430 0.272     0.679 -3.61 <0.001* 
Hispanic 0.599 0.397    0.903 -2.45 0.014* 
Other
a
 0.127 0.023    0.693 -2.38 0.017* 
Urban Residence 0.847 0.562     1.278 -0.79 0.430 
Charlson Comorbidity Index
 
1.206 1.088     1.337 3.57 <0.001* 
Tobacco Use/Dependence 1.225 0.841     1.783 1.06 0.291 
Antidepressant Persistence
b 
  0.997 0.996    0.999 -3.73 <0.001* 
Inflate 
Cohort 
AD/SGA 2.5981 0.953 4.244 3.09 0.002* 
Covariates 
Age 0.0727 0.021 0.124 2.77 0.006* 
Female 0.7076 -0.892 2.307 0.87 0.386 
African American -0.9280 -2.923 1.067 -0.91 0.362 
Hispanic -1.7406 -3.630 0.149 -1.81 0.071 
Other
a
 -1.6571 -6.917 3.603 -0.62 0.537 
Urban Residence 0.7145 -1.188 2.617 0.74 0.462 
Charlson Comorbidity Index
 
-2.0498 -3.663 -0.437 -2.49 0.013* 
Tobacco Use/Dependence -1.7927 -3.503 -0.082 -2.05 0.040* 
Antidepressant Persistence
b 
-0.0059 -0.012 0.000 -1.94 0.052 
IRR = incidence rate ratio; AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown;  
b
Persistence based on a 45-day permissible gap;  





Table 3.20: Negative Binomial-Logit Hurdle Model Regression Analysis Comparing All-
Cause Hospitalization Days Among Cohorts (N=926) 













 0.976 1.003 -1.51 0.131 
Female 1.351
c
 0.935 1.951 1.60 0.109 
African American 0.471
c
 0.303 0.733 -3.33 0.001* 
Hispanic 0.951
c





 0.051 1.054 -1.89 0.058 
Urban Residence 0.642
c





 1.259 1.601 5.72 <0.001* 
Tobacco Use/Dependence 1.473
c





 0.997 1.000 -1.83 0.067 








 1.001    1.021 2.07    0.039* 
Female 0.769
d
 0.576     1.027 -1.78    0.075 
African American 0.707
d
 0.500    0.998 -1.97    0.049* 
Hispanic 0.736
d





 0.036    0.725 -2.38    0.017* 
Urban Residence 0.932
d





 1.022    1.207 2.47    0.013* 
Tobacco Use/Dependence 1.196
d





 0.998   1.000 -1.48    0.138 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown;  
b
Persistence based on a 45-day permissible gap;  
c
Represents an odds ratio 
d
Represents an incidence rate ratio 







Table 3.21: Negative Binomial Regression Analysis Comparing All-Cause 
Outpatient/Emergency Department Visits Among Cohorts (N=926) 






AD/SGA 1.005 0.914    1.106 0.11 0.912 
Covariates 
Age 1.004 1.000    1.007 1.98 0.048* 
Female 0.988 0.896    1.089 -0.25 0.803 
African American 0.806 0.714      0.910 -3.49 <0.001* 
Hispanic 1.058 0.935     1.198 0.89 0.373 
Other
a
 0.920 0.702    1.204 -0.61 0.542 
Urban Residence 1.016 0.901    1.146 0.26 0.794 
Charlson Comorbidity Index
 
1.173 1.128    1.220 8.01 <0.001* 
Tobacco Use/Dependence 1.285 1.145    1.442 4.26 <0.001* 
Antidepressant Persistence
b 
1.001 1.001    1.001 5.59 <0.001* 
IRR = incidence rate ratio; AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown;  
b
Persistence based on a 45-day permissible gap;  





VII.  Objective 7: Costs of Health Care Utilization 
 The purpose of Objective 7 was to determine if post-index adjusted health care costs 
(psychotic depression-related medication, psychotic depression-related medical, psychotic 
depression-related total, all-cause medication, all-cause medical, and all-cause total costs) differ 
between patients in the AD and AD/SGA cohorts, while controlling for covariates. Due to the 
distribution of the dependent variables, six generalized linear regression models with gamma 
distributions and log-link functions were employed with the dependent variables being psychotic 
depression-related medication costs, psychotic depression-related medical costs, psychotic 
depression-related total costs, all-cause medication costs, all-cause medical costs, and all-cause 
total costs. The primary independent variable assessed was the study cohort (AD vs. AD/SGA). 
The study covariates utilized in the models included: age, gender, race/ethnicity, urban residence, 
Charlson Comorbidity Index score, and antidepressant persistence based on a 45-day permissible 
gap. For psychotic depression-related medical costs, a two-part model for continuous outcomes 
(a logit model and a generalized linear model with a gamma distribution and log-link function) 
was utilized due to the large frequency of $0 dollars.   
Prior to running the generalized linear models with gamma distributions and log-link 
functions, normality was checked using the Kolmogorov-Smirnov test. The tests indicated non-
normality, where the assumption of normality was rejected based on significant results 
(p<0.001). For each model, a Likelihood Ratio chi-square test comparing the full models (i.e., 
model includes all covariates) to the constant model (i.e., model contains no covariates) was 
significant (p<0.001), indicating that at least one covariate was related to the outcome. Table 
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AD = antidepressant; SGA = second-generation antipsychotic 
a
Generalized linear model univariate analysis with gamma distribution and log-link function 







For psychotic depression-related medication costs, the mean (±SD) total adjusted costs 
were $1,717.53 (±2,532.07). Table 3.23 displays the results of the generalized linear regression 
analysis. The AD/SGA cohort psychotic depression-related medication costs were almost six 
times significantly higher than the AD cohort [Exp(B)=5.982; 95% CI=5.221-6.854; p<0.001], 
while controlling for other variables in the model. Age, place of residence, and antidepressant 
persistence were also significant predictors of psychotic depression-related medication costs 
(p<0.05).  
For psychotic depression-related medical costs, the mean (±SD) adjusted costs were 
$954.39 (±2,666.17), where 15.6% of the final sample had $0 accrued costs. Table 3.24 displays 
the results of the two-part model regression analysis using a logit model and a generalized linear 
regression model. Results show that the AD/SGA cohort had over a two times significantly 
higher likelihood of having psychotic depression-related medical costs that were greater than $0, 
compared to the AD cohort (OR=2.691; 95% CI=1.755-4.127; p<0.001). Of those patients with 
psychotic depression-related medical costs greater than $0, costs were 51.0% higher for the 
AD/SGA cohort versus the AD cohort [Exp(B)=1.510; 95% CI=1.235-1.845; p<0.001]. Gender, 
being of Hispanic ethnicity, being of other race, and antidepressant persistence were significant 
predictors of psychotic depression-related medical costs greater than $0 (p<0.05). 
For the psychotic depression-related total costs, the mean (±SD) total adjusted costs were 
$2671.91 (±3,923.37). Table 3.25 displays the results of the generalized linear regression 
analysis. Results showed that the AD/SGA cohort had over three times significantly higher costs 
than the AD cohort [Exp(B)=3.413; 95% CI=2.938-3.965; p<0.001], while controlling for other 
variables in the model. Gender, being of other race, and antidepressant persistence remained 




For all-cause medication costs, the mean (±SD) total adjusted costs were $3,514.74 
(±5,731.71). Table 3.26 displays the results of the generalized linear regression analysis. All-
cause medication costs were significantly higher by 79.1% for the AD/SGA cohort, compared to 
the AD cohort [Exp(B)=1.791; 95% CI=1.558-2.060; p<0.001], while controlling for other 
variables in the model. Age, gender, being African American, being of other race, Charlson 
Comorbidity Index score, and antidepressant persistence were significant predictors of all-cause 
medication costs (p<0.05).  
For all-cause medical costs, the mean (±SD) total adjusted costs were $17,761.92 
(±36,304.30). Table 3.27 displays the results of the generalized linear regression analysis. There 
was no significant difference between cohorts; however, all independent variables (except being 
of other race and antidepressant persistence) remained significant predictors at p<0.05.  
Finally for all-cause total adjusted costs, the mean (±SD) total adjusted costs were 
$21,276.65 (±37,190.22). Table 3.28 displays the results of the generalized linear regression 
analysis. The significance results for all-cause total costs were similar to the results for all-cause 
medical costs.   
 
H07A: The post-index psychotic depression-related medication costs do not differ between the 
AD and AD/SGA cohorts, while controlling for covariates. [Rejected] 
 
H07B: The post-index psychotic depression-related medical costs do not differ between the AD 





H07C: The post-index psychotic depression-related total costs do not differ between the AD and 
AD/SGA cohorts, while controlling for covariates. [Rejected] 
 
H07D: The post-index all-cause medication costs do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. [Rejected] 
 
H07E: The post-index all-cause medical costs do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. [Not Rejected] 
 
H07F: The post-index all-cause total costs do not differ between the AD and AD/SGA cohorts, 








Table 3.23: Generalized Linear Model Regression Analysis Comparing Psychotic                   
Depression-Related Medication Costs Among Cohorts (N=926) 






AD/SGA 5.982 5.221 6.854 664.219 <0.001* 
Covariates 
Age 1.006 1.001 1.012 4.797 0.029* 
Female 1.031 0.895 1.187 0.179 0.672 
African American 0.850 0.712 1.016 3.188 0.074 
Hispanic 1.069 0.891 1.284 0.516 0.472 
Other
a
 1.107 0.747 1.641 0.257 0.612 
Urban Residence 0.804 0.674 0.959 5.913 0.015* 
Charlson Comorbidity Index 
 
0.965 0.920 1.013 2.071 0.150 
Tobacco Use/Dependence 0.946 0.799 1.119 0.419 0.517 
Antidepressant Persistence
b
 1.004 1.004 1.005 240.148 <0.001* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 







Table 3.24: Two-Part Model Regression Analysis Comparing Psychotic Depression-Related 
Medical Costs Among Cohorts (N=926) 







AD/SGA 2.691 1.755 4.127 20.594 <0.001* 
Covariates 
Age 0.998 0.983 1.014 0.055 0.815 
Female 0.987 0.656 1.486 0.004 0.950 
African American 1.308 0.795 2.152 1.117 0.291 
Hispanic 1.153 0.707 1.879 0.325 0.569 
Other
a
 1.686 0.463 6.133 0.628 0.428 
Urban Residence 0.840 0.515 1.371 0.486 0.486 
Charlson Comorbidity Index
 
0.748 0.664 0.843 22.888 <0.001* 
Tobacco Use/Dependence 1.432 0.873 2.348 2.022 0.155 
Antidepressant Persistence
b




AD/SGA 1.510 1.235 1.845 16.173 <0.001* 
Covariates 
Age 0.995 0.987 1.003 1.671 0.196 
Female 0.620 0.503 0.763 20.269 <0.001* 
African American 0.939 0.718 1.228 .213 0.644 
Hispanic 1.458 1.111 1.914 7.392 0.007* 
Other
a
 2.941 1.651 5.238 13.417 <0.001* 
Urban Residence 1.134 0.870 1.478 .869 0.351 
Charlson Comorbidity Index
 
1.051 0.960 1.151 1.145 0.285 
Tobacco Use/Dependence 1.244 0.971 1.594 2.993 0.084 
Antidepressant Persistence
b
 1.002 1.001 1.002 15.771 <0.001* 
OR = odds ratio; AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 
c
Gamma distribution and log-link function 





Table 3.25: Generalized Linear Model Regression Analysis Comparing Psychotic 
Depression-Related Total Costs Among Cohorts (N=926) 






AD/SGA 3.413 2.938 3.965 257.679 <0.001* 
Covariates 
Age 1.000 0.994 1.006 0.000 0.991 
Female 0.827 0.709 0.965 5.807 0.016* 
African American 0.865 0.711 1.051 2.123 0.145 
Hispanic 1.196 0.980 1.461 3.099 0.078 
Other
a
 1.710 1.105 2.645 5.810 0.016* 
Urban Residence 0.924 0.762 1.121 0.639 0.424 
Charlson Comorbidity Index
 
0.969 0.916 1.025 1.218 0.270 
Tobacco Use/Dependence 1.126 0.936 1.353 1.584 0.208 
Antidepressant Persistence
b
 1.003 1.003 1.004 117.537 <0.001* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 




Table 3.26: Generalized Linear Model Regression Analysis Comparing All-Cause 
Medication Costs Among Cohorts (N=926) 






AD/SGA 1.791 1.558 2.060 67.125 <0.001* 
Covariates 
Age 1.015 1.010 1.021 32.000 <0.001* 
Female 0.780 0.677 0.900 11.628 0.001* 
African American 0.814 0.682 0.972 5.174 0.023* 
Hispanic 0.872 0.724 1.050 2.096 0.148 
Other
a
 2.297 1.534 3.439 16.310 <0.001* 
Urban Residence 1.083 0.909 1.291 0.805 0.370 
Charlson Comorbidity Index
 
1.222 1.155 1.293 48.330 <0.001* 
Tobacco Use/Dependence 0.999 0.842 1.185 0.000 0.987 
Antidepressant Persistence
b
 1.002 1.002 1.003 89.090 <0.001* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 




Table 3.27: Generalized Linear Model Regression Analysis Comparing All-Cause Medical 
Costs Among Cohorts (N=926) 






AD/SGA 0.964 0.810 1.146 0.173 0.677 
Covariates 
Age 1.011 1.005 1.018 11.167 0.001* 
Female 1.397 1.172 1.666 13.923 <0.001* 
African American 0.718 0.575 0.895 8.654 0.003* 
Hispanic 0.752 0.602 0.939 6.312 0.012* 
Other
a
 0.755 0.467 1.220 1.321 0.250 
Urban Residence 1.291 1.040 1.601 5.385 0.020* 
Charlson Comorbidity Index
 
1.342 1.248 1.444 62.557 <0.001* 
Tobacco Use/Dependence 1.907 1.553 2.341 38.021 <0.001* 
Antidepressant Persistence
b
 1.000 0.999 1.001 0.136 0.713 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 




Table 3.28: Generalized Linear Model Regression Analysis Comparing All-Cause Total 
Costs Among Cohorts (N=926) 






AD/SGA 1.081 0.936 1.248 1.125 0.289 
Covariates 
Age 1.011 1.005 1.016 15.506 <0.001* 
Female 1.255 1.085 1.452 9.325 0.002* 
African American 0.730 0.608 0.877 11.322 0.001* 
Hispanic 0.772 0.641 0.929 7.473 0.006* 
Other
a
 0.884 0.592 1.318 0.367 0.544 
Urban Residence 1.248 1.043 1.492 5.876 0.015* 
Charlson Comorbidity Index
 
1.314 1.238 1.396 79.664 <0.001* 
Tobacco Use/Dependence 1.760 1.483 2.089 41.961 <0.001* 
Antidepressant Persistence
b
 1.000 1.000 1.001 2.119 0.146 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 
b
Persistence based on a 45-day permissible gap 




VIII.  Objective 8: Dyslipidemia and Diabetes Mellitus Risks of Medication Therapy 
 The purpose of Objective 8 was to determine if the risks of medication therapy (incident 
dyslipidemia, incident diabetes mellitus, and incident extrapyramidal symptoms) differ between 
patients in the AD and AD/SGA cohorts, while controlling for covariates. Since a total of 12 
patients were diagnosed with extrapyramidal symptoms post-index, only two Cox proportional 
hazards regression models were employed with the continuous dependent variables being 
progression time to the first diagnosis of dyslipidemia and progression time to the first diagnosis 
of diabetes mellitus. The primary independent variable was the study cohort (AD vs. AD/SGA), 
and the study covariates were age, gender, race/ethnicity, urban residence, Charlson Comorbidity 
Index score, tobacco use and/or dependence, and antidepressant persistence using a 45-day gap. 
For the dyslipidemia analysis, patients were censored if they did not have a diagnosis for 
dyslipidemia through day 365 of the post-index period. For the diabetes mellitus analysis, 
patients were censored if they did not have a diagnosis for diabetes mellitus through day 365 of 
the post-index period.  
Prior to utilizing statistical analyses, multicollinearity was assessed using collinearity 
statistics and was found to be absent based on the tolerance and variance inflation factor scores. 
The proportionality of hazards assumption was met for the dyslipidemia analysis (Wald 
χ
2
=12.314, df=10, p=0.265). However, the proportionality of hazards assumption was not met for 
the diabetes mellitus analysis (Wald χ
2
=18.682, df=10, p=0.045), where a significant gender-
time interaction was identified (p=0.008). Since treatment cohorts were established at index and 
suppressing this interaction would estimate an average effect over the observed range of time for 
the data,
2
 the regression model without the interaction could be retained. Nevertheless, a 




changes in the cohort variable occurred. Descriptions and comparisons of the rates of incident 
dyslipidemia, diabetes mellitus, and extrapyramidal symptoms are provided in Tables 3.6 and 
3.7.  
 For the 134 patients who had at least one diagnosis for dyslipidemia, the mean time 
(±SD) to dyslipidemia progression was 181.9 days (±96.4). For the AD cohort, the mean time 
(±SD) to dyslipidemia progression was 171.9 (±93.5), and for the AD/SGA cohort, the mean 
time (±SD) was 196.1 (±99.5). Table 3.29 provides the results for the Cox proportional hazards 
regression model comparing time to progression for dyslipidemia between cohorts.  The global 
null hypothesis test was significant (χ
2
=52.832; df=10; p<0.001), indicating the rejection of the 
null hypothesis that all coefficients are equal to zero. Results showed that there was no 
significant difference in time to progression (survival time) among cohorts, while controlling for 
other covariates in the model. However, as age increased by one year, the hazard of progression 
to dyslipidemia significantly increased by approximately 4.1% (HR=1.041; 95% CI=1.025-
1.057; p<0.001). Compared to non-tobacco users/dependents, the hazards of medication 
nonpersistence was significantly higher by 66.8% for tobacco users/dependents (HR=1.668; 95% 
CI=1.137-2.446; p=0.009). The remaining covariates were not significantly related to the 
dependent variable. 
For the 49 patients who had at least one diagnosis for diabetes mellitus, the mean time 
(±SD) to diabetes mellitus was 169.5 days (±92.6). For the AD cohort, the mean time (±SD) to 
diabetes mellitus progression was 151.1 (±79.2), and for the AD/SGA cohort, the mean time 
(±SD) was 192.0 (±104.3). Table 3.30 provides the results for the Cox proportional hazards 
regression model comparing time to progression for diabetes mellitus between cohorts. The 
global null hypothesis test was significant (χ
2




of the null hypothesis that all coefficients are equal to zero. Similarly to dyslipidemia, results 
showed that there was no significant difference in time to progression to diabetes mellitus 
(survival time) among cohorts, while controlling for other covariates in the model. Also, as age 
increased by one year, the hazard of progression to diabetes mellitus significantly increased by 
about 3.5% (HR=1.035; 95% CI=1.009-1.061; p=0.007). Interestingly, the hazards of 
progression to diabetes mellitus were significantly higher—more than twice as high—in 
Hispanic patients compared to Caucasian patients (HR=2.261; 95% CI=1.018-5.023; p=0.045). 
Lastly, as antidepressant persistence increased by one day, the hazards of the progression to 
diabetes mellitus significantly increase by 0.3% (HR=1.003; 95% CI=1.001-1.005; p=0.008). 
The remaining covariates were not significantly related to the dependent variable.  A sensitivity 
analysis using the covariates listed above, as well as the gender-time interaction, found no 
significant difference between cohorts (HR=0.815; 95% CI=0.449-1.477; p=0.500). 
 
H08A: The progression to the first diagnosis of dyslipidemia (after a 45-day post-index period) 
does not differ between the AD and AD/SGA cohorts, while controlling for covariates.  
[Not Rejected] 
 
H08B: The progression to the first diagnosis of diabetes mellitus (after a 45-day post-index 
period) does not differ between the AD and AD/SGA cohorts, while controlling for covariates. 
[Not Rejected] 
 
H08C: The progression to the first diagnosis of extrapyramidal symptoms post-index does not 




Table 3.29: Cox Proportional Hazards Regression Model Comparing Dyslipidemia Time to 
Progression Among Cohorts (N=709) 
 Hazard 
Ratio 






AD/SGA 0.750 0.523 1.076 2.435 0.119 
Covariates 
Age 1.041 1.025 1.057 27.191 <0.001* 
Female 1.030 0.710 1.495 0.025 0.875 
African American 0.791 0.499 1.254 0.993 0.319 
Hispanic 1.222 0.784 1.906 0.785 0.376 
Other
a
 1.384 0.574 3.338 0.522 0.470 
Urban Residence 1.310 0.817 2.101 1.255 0.263 
Charlson Comorbidity Index
 
1.026 0.887 1.187 0.123 0.725 
Tobacco Use/Dependence 1.668 1.137 2.446 6.839 0.009* 
Persistence (45-day gap) 1.000 0.999 1.002 0.083 0.773 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 




Table 3.30: Cox Proportional Hazards Regression Model Comparing Diabetes Mellitus 
Time to Progression Among Cohorts (N=750) 
 Hazard 
Ratio 






AD/SGA 0.822 0.453 1.490 0.419 0.517 
Covariates 
Age 1.035 1.009 1.061 7.304 0.007* 
Female 1.417 0.745 2.693 1.129 0.288 
African American 1.320 0.582 2.997 0.442 0.506 
Hispanic 2.261 1.018 5.023 4.012 0.045* 
Other
a
 1.989 0.424 9.327 0.761 0.383 
Urban Residence 0.963 0.446 2.082 0.009 0.924 
Charlson Comorbidity Index
 
1.232 0.992 1.529 3.577 0.059 
Tobacco Use/Dependence 1.417 0.730 2.750 1.059 0.303 
Persistence (45-day gap) 1.003 1.001 1.005 7.054 0.008* 
AD = antidepressant; SGA = second-generation antipsychotic 
a
Other includes: Asian, Unknown 





Table 3.31 displays the results of the hypotheses testing for the study. 
Table 3.31: Results of Hypotheses Testing 
Objectives/Hypotheses 
 
Statistical Analysis Result 
Objective 1: To describe and compare the baseline socio-demographic and clinical 
characteristics of Texas Medicaid patients with MD-Psy who utilize either 
antidepressant monotherapy (AD cohort) or combination therapy with an 
antidepressant and a second-generation antipsychotic (AD/SGA cohort). 
 
Descriptive Statistics No Hypothesis 
Objective 2: To describe and compare the post-index clinical characteristics of the 
AD and AD/SGA cohorts. 
 
Descriptive Statistics No Hypothesis 
Objective 3: To determine if the rates of medication adherence (medication possession ratio – MPR and proportion of days covered – 
PDC) differ between patients in the AD and AD/SGA cohorts, while controlling for covariates.   
 
H03A: The likelihood of being adherent as measured by MPR ≥ 80% to antidepressant 
therapy does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 
Logistic Regression Rejected 
H03B: The likelihood of being adherent as measured by PDC ≥ 80% to antidepressant 
therapy does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 
Logistic Regression Rejected 
Objective 4: To determine if the risk of medication nonpersistence differs between patients in the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
H04A: The time, in days, to antidepressant medication nonpersistence (using a 45-day 
gap of no medication) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 










Statistical Analysis Result 
H04B: The time, in days, to antidepressant medication nonpersistence (using a 30-day 
gap of no medication) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Cox Proportional Hazards 
Regression 
Rejected 
H04C: The time, in days, to antidepressant medication nonpersistence (using a 60-day 
gap of no medication) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Cox Proportional Hazards 
Regression 
Rejected 
Objective 5: To determine if the rate of post-index suicide ideation and suicide attempts differ between patients in the AD and 
AD/SGA cohorts, while controlling for covariates. 
 
H05A: The likelihood of having post-index suicide ideation and/or suicide attempt 
does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates. 
 
Logistic Regression Not Rejected 
Objective 6: To identify if post-index health care utilization rates (psychotic depression-related hospitalizations, length of psychotic 
depression-related hospitalization stay, psychotic depression-related outpatient/emergency department visits, all-cause 
hospitalizations, length of all-cause hospitalization stay, all-cause outpatient/emergency department visits) differ between patients in 
the AD and AD/SGA cohorts, while controlling for covariates. 
 
H06A: The number of post-index psychotic depression-related hospitalizations does 
not differ between the AD and AD/SGA cohorts, while controlling for covariates. 
 
Descriptive Statistics Unable to Test 
H06B: The number of post-index psychotic depression-related hospitalization days 
(sum of hospital says, in days) does not differ between the AD and AD/SGA cohorts, 
while controlling for covariates. 
 










Statistical Analysis Result 
H06C: The number of post-index psychotic depression-related outpatient/emergency 
department visits does not differ between the AD and AD/SGA cohorts, while 





H06D: The number of post-index all-cause hospitalizations does not differ between 





H06E: The number of post-index all-cause hospitalization days (sum of hospital stays, 






H06F: The number of post-index all-cause outpatient/emergency department visits 






Objective 7: To determine if post-index adjusted health care costs (psychotic depression-related and all-cause medication, medical, 
and total costs) differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 
H07A: The post-index psychotic depression-related medication costs do not differ 
between the AD and AD/SGA cohorts, while controlling for covariates. 
GLM with gamma 
distribution and log-link 
function 
Rejected 
H07B: The post-index psychotic depression-related medical costs do not differ 
between the AD and AD/SGA cohorts, while controlling for covariates. 
GLM with gamma 
distribution and log-link 
function 
Rejected 
H07C: The post-index psychotic depression-related total costs (psychotic depression-
related prescription and psychotic depression-related medical costs) do not differ 
between the AD and AD/SGA cohorts, while controlling for covariates. 
 
GLM with gamma 











Statistical Analysis Result 
H07D: The post-index all-cause medication costs do not differ between the AD and 
AD/SGA cohorts, while controlling for covariates. 
 
GLM with gamma 
distribution and log-link 
function 
Rejected 
H07E: The post-index all-cause medical costs do not differ between the AD and 
AD/SGA cohorts, while controlling for covariates. 
GLM with gamma 
distribution and log-link 
function 
Not Rejected 
H07F: The post-index all-cause total costs do not differ between the AD and AD/SGA 
cohorts, while controlling for covariates. 
 
GLM with gamma 




Objective 8: To determine if the risks of medication therapy (incident dyslipidemia, incident diabetes mellitus, and incident 
extrapyramidal symptoms) differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
 
H08A: The progression to the first diagnosis of dyslipidemia (after a 45-day post-
index period) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates. 
 
Cox Proportional Hazards 
Regression 
Not Rejected 
H08B: The progression to the first diagnosis of diabetes mellitus (after a 45-day post-
index period) does not differ between the AD and AD/SGA cohorts, while 
controlling for covariates.  
 
Cox Proportional Hazards 
Regression 
Not Rejected 
H08C: The progression to the first diagnosis of extrapyramidal symptoms post-index 
does not differ between the AD and AD/SGA cohorts, while controlling for 
covariates.  
 
Descriptive Statistics Unable to Test 
AD = antidepressant; SGA = second-generation antipsychotic; MPR= medication possession ratio; PDC = proportion of days 
covered; GLM = generalized linear model 
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Chapter 4:  Discussion and Conclusion 
CHAPTER OVERVIEW 
This chapter provides a comprehensive discussion of the study results. The 
chapter begins by reintroducing the study purpose and objectives. It then provides 
detailed explanations and comparisons between related studies found in the literature. 
The chapter closes with an explanation of the study limitations, recommendations for 
future research, final conclusions, and implications. 
 
REVIEW OF STUDY PURPOSE 
The purpose of the present study was to assess the medication therapy of patients 
with unipolar psychotic depression in relation to medication adherence, medication 
persistence, suicide ideation and attempts, health care utilization, health care costs, and 
medication safety using Texas Medicaid data from September 2007 to December 2012.  
The present study aimed to enhance the understanding of this severe subtype of major 
depressive disorder and provide information to fill the gaps in knowledge that clinicians 
and decision-makers may use when considering treatment options for unipolar psychotic 
depression.  To our knowledge, the present study is the first retrospective analysis 
utilizing a large database claims dataset to primarily assess unipolar major depressive 





 The present study assessed eight objectives and eighteen hypotheses. For each 
objective, the results are evaluated and discussed, as well as compared and contrasted 
with related studies. 
 
I.  Objectives 1 and 2 
 The aim of Objective 1 was to describe and compare the baseline socio-
demographic and clinical characteristics of patients with psychotic depression who utilize 
either antidepressant monotherapy (AD cohort) or combination therapy with an 
antidepressant plus a second-generation antipsychotic (AD/SGA cohort). The aim of 
Objective 2 was to assess post-index tobacco use and/or dependence among cohorts.  
 There still remains a lack of consensus among international guidelines in regards 
to the treatment of psychotic depression. In European countries, antidepressant 
monotherapy remains first-line therapy; while in the US, either combination therapy with 
an antidepressant plus an antipsychotic agent or electroconvulsive therapy is considered 
the best therapy.
1
 Surprisingly, in the present study, more than half of the patients in our 
final sample utilized antidepressant monotherapy (AD cohort = 510 patients) versus 
combination therapy (AD/SGA cohort = 416 patients). This deviation from first-line 
recommendations could be explained by a number of reasons that the present study was 
unable to measure; however, it is important to acknowledge that it is recommended that 
providers weigh the risks and benefits of treatment when prescribing therapy. Present 
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comorbidities (e.g., diabetes mellitus and dyslipidemia) and the known adverse events of 
antipsychotics (e.g., increased risk of elevated blood glucose, lipids, and weight gain) 
could potentially influence prescribing habits favoring antidepressant monotherapy. This 
may be the case in the present study as the AD cohort had a slightly but significantly 
higher mean Charlson Comorbidity Index score, compared to the AD/SGA cohort (0.8 
versus 0.5, p<0.001). 
 The overall age and percent of females in the present study is consistent with the 
literature focusing on first-admission or first-episode patients with psychotic depression.
2-
4
 However, in contrast to previous studies on psychotic depression, the majority of 
patients were of Caucasian race (studies ranged from 60.7% to 85.2%).
2,3,5-7
 In the 
present study, the percent of Caucasians was much smaller at 25.2% as the majority of 
the final sample was of either African American race (34.9%) or Hispanic ethnicity 
(36.7%). (Caucasians represent approximately 19% of the total population of non-elderly 
Texas Medicaid patients.)
8
 Since all of the patients in the present study were publically 
insured through the Texas Medicaid program (an indication of low socio-economic 
status), our sample may be different from much of the existing literature, where less than 
one-quarter of psychotically depressed patients either utilized public insurance or 
comprised the bottom socio-economic status quartile.
3,5
 Due to these differences, the 
present study provides a unique addition to the present literature on psychotic depression, 
as there is a dearth of information regarding minority and indigent populations. 
 The present study also contributes by increasing the knowledge related to tobacco 
use and/or dependence and place of residence (urban versus rural) in psychotic 
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depression. While the percent of tobacco users and/or dependents was similar to the 
percent of lifetime smokers in a previous study on psychotic depression,
3
 the present 
study offered more insight into the relationship between tobacco use and/or dependence 
and adherence, persistence, suicidality, heath care utilization, expenditures, and 
medication safety. Correspondingly, the analysis of urban versus rural residence has not 
been previously assessed in other psychotic depression studies, where the exploration of 
rural versus urban living could be of merit to payers, such as Texas Medicaid. 
 
II.  Objectives 2 through 4 
 The aim of Objective 2 was to describe the post-index AD persistence and SGA 
persistence using 45-day permissible gaps among cohorts. The aim of Objective 3 was to 
determine if the rates of antidepressant medication adherence (medication possession 
ratio – MPR and proportion of days covered – PDC) differ between patients in the AD 
and AD/SGA cohorts, while controlling for covariates. The aim of Objective 4 was to 
determine if the risk of antidepressant medication nonpersistence differs between patients 
in the AD and AD/SGA cohorts, while controlling for covariates. 
 The present study reflects a novel approach to evaluating medication adherence in 
patients diagnosed with major depressive disorder with psychotic features. To date, this is 
the first known study analyzing treatment adherence in psychotically depressed patients 
using MPR and PDC. Overall, 38.3% and 33.0% of patients were adherent to their 
antidepressant medications based on MPR ≥ 80% and PDC ≥ 80%, respectively. In the 
literature, only one study was remotely similar in analyzing medication usage as a 
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percentage of time as calculated based on responses from face-to-face patient interviews.  
The results were similar to the present study, where the authors reported 39.1% and 
31.4% of patients utilized their antidepressant medications “75% to 100%” of the time 
from discharge to six months and from six months to 24 months, respectively. Univariate 
analysis found that younger age was associated with a lower likelihood of regular 
medication use at 75% to 100% of the time, compared to older age.
2
 Similarly, in the 
present study, increasing age was associated with higher likelihoods of antidepressant 
adherence for both MPR and PDC. Utilizing combination therapy, being Caucasian 
versus African American, and the absence of tobacco use and/or dependence were also 
associated with higher likelihoods of antidepressant adherence for MPR and PDC. 
 The present study is also innovative in its approach by analyzing medication 
persistence in relation to both second-generation antipsychotic medications and 
antidepressant medications. While there are no studies in the literature that assess 
medication persistence in psychotic depression, this analysis can be compared to the 
current recommendations for medication treatment continuation in psychotic depression. 
Although four to nine months of antipsychotic use has been advocated; currently, 
there is little consensus in how long a patient with psychotic depression should be treated 
with an antipsychotic medication.
9
  The Texas Medication Algorithm Project
10
 
recommends continuing an antipsychotic medication for one to two months during the 
continuation phase, where a psychotically depressed patient has achieved a clinical 
response but is not yet in remission.  Wijkstra and associates
11
 found that, after seven 
weeks of acute treatment, continued treatment with a second-generation antipsychotic 
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was effective and well-tolerated at the four month follow-up period in patients with 
psychotic depression.  Antipsychotic-related recommendations and previous results in the 
literature are comparable to the results of the present study, where the mean use of 
second-generation antipsychotics was approximately 179 days (or almost six months) 
before a gap in therapy occurred.  
In relation to antidepressant treatment, the recommendation for antidepressant 
treatment has ranged from six to nine months after the acute phase to at least one year 
after remission has been achieved.
10,12
 Overall, patients in the present study persisted on 
their antidepressant medications for approximately 172 days (or about six months) before 
the occurrence of a gap in therapy—less than the recommended treatment time for 
psychotic depression. The risk of antidepressant nonpersistence was significantly higher 
in antidepressant monotherapy users, younger patients, minorities (African Americans 
and Hispanics), and those with tobacco use and/or dependence. The study results may be 
a consequence of many unmeasured factors, such as receiving second-line medication 
therapy, socio-demographic disadvantages, and having less investment in their overall 
health. 
 
III.  Objective 5 
 The aim of Objective 5 was to determine if the rates of post-index suicide ideation 
and suicide attempts differ between patients in the AD and AD/SGA cohorts, while 
controlling for covariates. Overall, the rates of suicide ideation and suicide attempts were 
low for both the 6-month pre-index period (suicide ideation = 4.1%; suicide attempts = 
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 assessing patients with psychotic depression report a lifetime 
history of suicide ideation and suicide attempts as high as 55.8% and 36.7%, respectively. 
A nine-month long hospital study in Milan reported a low rate of previous suicide 
attempts at 7.1% (n=4 of 18) in their sample of patients with psychotic depression, where 
the mean number of previous attempts was 0.39 (±0.85).
14
 Compared to the above 
studies, the lower rates of suicide ideation and suicide attempts are reasonable in the 
present study due to the shorter pre-index period and the inability to obtain lifetime 
histories through patient interviews. In addition, the use of claims data to detect suicide 
ideation may underestimate its true rate, as it may be underreported. While completed 
suicide was not assessed in the present study, a nationwide Danish study found that 2.3% 
of patients with psychotic depression completed suicide over a nineteen-year period.
15
 
Future studies should explore the role of psychotic depression in completed suicides. 
Comparatively, studies by Gaudiano and associates
6,16
 reported higher rates of 
current suicide ideation (16.7%; n=10 of 60) and recent suicide attempts (10.0%; n=6 of 
60) in patients with psychotic depression, and Schaffer and associates
13
 estimated active 
suicidal ideation and current suicide attempts at 16.9% (n=31 of 183) and 20.8% (n=38 of 
183), respectively, in the STOP-PD study. A Nigerian study
17
 also found high rates of 
current suicide ideation (58.1%; n=75 of 129) and suicide attempts (17.8%; n=23 of 129) 
in patients with psychotic depression in sub-Saharan Africa. A four-year long cohort 
study found a very high first-hospital admission rate for suicide attempts at 36.8% (n=32 
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of 87). Dissimilar rates of suicidality between the present study and results found in the 
literature are most likely attributed to differences in study designs such as: comparing 
psychotic depressed patients versus non-psychotic depressed patients, the use of 
prospective versus retrospective designs, and the use of longer study periods. Conversely 
from other studies, Johnson and associates
5
 reported zero new suicide attempts in their 
psychotic depressed group (N=92) one year after initial patient interviews.  
In the present study, tobacco use and/or dependence and lower antidepressant 
medication persistence were significantly associated with a higher likelihood of 
suicidality (i.e., suicide ideation and attempts). These are reasonable findings as this may 
reflect suicidal patients’ decreased propensity to take a more active role in their overall 
health due to their more detrimental mental health state.  Only two psychotic depression-
related studies have evaluated factors associated with suicidality.
13,15
 Schaffer and 
associates
13
 reported that male gender, Hispanic ethnicity, and higher depression scores 
were associated with severe intensity of current suicidality in patients with psychotic 
depression (p<0.05). The other study was a large nationwide, register-based study in 
Denmark found that older age, male gender, and previous self-harm were significant risk 
factors for completed suicide in patients with psychotic depression (p<0.05); however, 
receiving a disability pension was protective against suicide (p<0.05).
15
 Comparatively, 
the lack of the present study’s ability to differentiate the differences in suicidality 
intensity between patients (e.g., lower versus more severe suicidality), smaller sample 
size, and potential underreporting in claims data may explain the differences in results 
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between studies in relation to independent predictors of suicide ideation and suicide 
attempts. 
 
IV.  Objective 6 
 The aim of Objective 6 was to identify if post-index psychotic depression-related 
and all-cause health care utilization rates (i.e., hospitalizations, lengths of stay, and 
outpatient/emergency room visits) differ between patients in the AD and AD/SGA 
cohorts, while controlling for covariates. For psychotic depression-related 
hospitalizations, approximately 3.9% and 0.4% had one hospitalization or two 
hospitalizations, respectively. For patients with at least one hospitalization, the mean 
(±SD) length of psychotic depression-related hospitalization stay was 7.3 (±3.8) days, 
where the overall mean (±SD) length of stay was 0.3 (±1.7) days. Approximately, 83.9% 
of the sample had at least one post-index outpatient/emergency department visit. About 
22.1% of the sample had at least one all-cause hospitalization, and the corresponding 
mean (±SD) length of stay was 2.1 (±6.2) days. Almost the entire study sample (99.6%) 
had at least one all-cause outpatient/emergency department visit during the post-index 
period.  
Primarily, previous studies involving MD-psy compared rates of health care 
utilization (e.g., hospitalization, length of stay, outpatient treatment, and emergency 
department visits) between psychotically depressed and non-psychotically depressed 
patients found higher rates of hospitalization and longer lengths of stay associated with 
patients with psychotic depression.
5,6,14,18-20





 found that 15.0% (n=15 of 60) and 26.5% (n=17 of 60) of their sample of 
psychotically depressed patients had one or two previous psychiatric-related 
hospitalizations in their lifetime, respectively. Johnson and associates
5
 conducted a large 
epidemiological study and reported a similar finding of 22.8% (n=26 of 114) for having 
at least one lifetime psychiatric hospitalization, and Forty and associates
20
 reported an 
even higher rate of psychiatric hospital admission in 60.9% (n=39 of 64) of their 
psychotically depressed patients in their community-based study of 585 patients with 
major depressive disorder. Buoli and associates reported a mean (±SD) of 3.5 (±3.9) 
previous hospitalizations in their sample of 36 patients with psychotic depression. The 
rates of and average number of hospitalizations in previous studies are higher due to the 
present study’s inability to conduct patient interviews and determine lifetime rates of 
hospitalization. Conversely, no patients reported new psychiatric hospitalizations at one 
year follow-up in the study by Johnson and associates,
5
 where the low rate of re-
hospitalization could be attributed to the smaller sample size compared to the present 
study (92 versus 926 patients).  
Inpatient studies involving patients with psychotic depression estimated mean 
(±SD) lengths of psychiatric hospitalization stay that ranged from 19.0 (±10.2) days to 
31.9 (±17.2) days.
14,18,19
 Crebbin and associates
4
 counted a total of 10,025 inpatient days 
over a thirteen year period for 81 patients with first-episode psychotic depression, where 
the mean length of stay was 95 days. Longer lengths of stay in previous studies could be 
attributed to differences in inpatient treatment practices across European countries and 





 assessed psychiatric-related emergency department and 
outpatient visits in patients with psychotic depression and found that 15.1% had at least 
one emotional or drug-related emergency department visit, and 16.7%, 24.1% and 30.6% 
sought psychiatric outpatient treatment with an MD, psychiatrist, or both, respectively. 
Compared to the present study, the lower rates of outpatient and emergency department 
visits could be attributed to the lower sample size (n=114) and differences in socio-
demographics (where 60.7% of the sample was of Caucasian race and only 20.7% of the 
sample was in the bottom quartile for socioeconomic status).  
Only one study
5
 focusing on psychotic depression estimated rates for all-cause 
hospitalizations (23.7%) and all-cause outpatient treatment (72.3%), and these results 
were similar to the findings of the present study. Also, two studies
21,22
 that assessed 
adjunctive treatment with second-generation antipsychotics in patients with major 
depressive disorder (but not psychotic depression specifically) reported similar rates of 
all-cause hospitalization in patients taking combination therapy with aripiprazole (13.7% 
to 15.1%), olanzapine (22.7% to 23.3%), and quetiapine (23.1% to 27.7%). While the 
present study did not assess differences in rates within cohorts, the overall all-cause 
utilization rate was similar.  
Finally, the present study adds to the literature by identifying significant factors 
associated with health care utilization (hospitalizations, length of stay, and 
outpatient/emergency department visits) in patients with major depression with psychotic 
features. Interestingly, those with tobacco use and/or dependence had significantly more 
all-cause outpatient/emergency department visits, compared to non-tobacco users 
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(p<0.05). This finding may support the need for more research concerning the role of 
tobacco use and smoking in health care utilization in patients with mental health 
disorders. 
  
V.  Objective 7 
 The aim of Objective 7 was to determine if post-index psychotic depression-
related and all-cause adjusted health care costs (i.e., medication, medical, and total costs) 
differ between patients in the AD and AD/SGA cohorts, while controlling for covariates. 
Overall, the mean (±SD) costs for psychotic depression-related medication, medical and 
total costs were $1,717.53 (±2,532.07), $954.39 (±2,666.17), $2671.91 (±3,923.37), 
respectively. Significant predictors of higher total psychotic depression-related costs 
included: treatment cohort (AD/SGA), being male, not being African American, and 
increasing antidepressant persistence. In addition, the mean (±SD) costs for all-cause 
medication, medical and total costs were $3514.74 (±5,731.71), $17,761.92 (±36,304.30), 
$21,276.65 (±37,190.22), respectively. Significant predictors of higher total all-cause 
costs did not include treatment cohort, but did include: higher age, being female, being of 
Caucasian race, urban residence, higher Charlson Comorbidity Index score, and tobacco 
use and/or dependence. 
 Major depression studies
5,6
 have determined that the societal costs associated with 
psychotic depression were significantly higher than the costs associated with depression 
without psychotic features (p<0.05). Psychotically depressed patients had higher rates of 
non-employment and receiving public assistance, welfare, and disability, compared to 
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patients with non-psychotic major depression (p<0.05). Interestingly, Leadholm and 
associates
15
 found that receiving a disability pension was a significant protective factor 
against suicides in psychotic depressed patients. This is especially important since suicide 




While the present study did not focus on costs to society, direct costs to Texas 
Medicaid were evaluated. Only one psychotic depression-related study
4
 estimated direct 
costs associated with psychotic depression. This study found that total psychiatric 
inpatient costs in Northern England were similar between patients with first-episode 
psychotic depression and patients with first-episode schizophrenia (£2.6 million versus 
£2.8 million, respectively) over a thirteen-year period. Two major depression cost 
studies
21,22
 (which included patients with psychotic depression but did not evaluate 
psychotic depression separately) estimated the all-cause total medical costs associated 
with adjunctive treatment with aripiprazole, olanzapine, and quetiapine. Depending on 
the second-generation antipsychotic utilized, Halpern and associates
21
 estimated all-cause 
medical costs to range from $10,664 to $16,556 over a 12-month period, where Nadkarni 
and associates
22
 calculated all-cause medical costs to be in the range of $8,669 to 
$12,889. These reported costs are much lower than the mean all-cause medical cost of the 
present study, further emphasizing the detrimental role of psychotic depression (a more 
severe variant of major depressive disorder) in relation to health care expenditures. While 
previous psychotic depression studies did not assess predictors of health care costs, the 
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present study sheds some light on independent factors that may be important in MD-psy 
and should be further evaluated in future studies. 
 
VI.  Objectives 2 and 8 
 The aim of Objective 2 was to describe and compare the post-index cumulative 
incidence rates of dyslipidemia, diabetes mellitus, and extrapyramidal symptoms among 
cohorts. The aim of Objective 8 was to determine if the risks of medication therapy 
(incident dyslipidemia, incident diabetes mellitus, and incident extrapyramidal 
symptoms) differ between patients in the AD and AD/SGA cohorts, while controlling for 
covariates.  
The overall cumulative incidence of dyslipidemia was 18.9% (n=134 of 709), 
where the rates for the AD cohort and AD/SGA cohort were 20.5% and 17.0%, 
respectively. A chi-square test (comparing incidence rates) and a Cox proportional 
hazards regression model (measuring survival time until the onset of dyslipidemia) found 
no significant differences between the two cohorts. While the majority studies in 
psychotic depression measured weight gain as the only metabolic adverse event,
11,23-27
 a 
few studies assessed dyslipidemia in relation to changes in cholesterol, triglycerides, and 
lipids during pharmacological treatment.
7,26,28
 Konstantinidis and associates
28
 reported 
lower incidence rates of hyperlipidemia and hypercholesterolemia (both 4.0%), compared 
to the present study; however, their sample size was much smaller (n=25) and follow-up 
occurred after six weeks of combination therapy with citalopram and quetiapine. While 
Meyers and associates
7
 of the STOP-PD study did not report new cases of dyslipidemia 
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after twelve weeks of use of olanzapine or olanzapine plus sertraline, the authors noted 
significant increases in triglycerides and cholesterol levels over time in both young and 
old patient groups. Correspondingly, age was found to be a significant predictor in the 
present study, where older age was associated with significantly higher hazards of 
progression to dyslipidemia. Deligiannidis and associates
26
 also utilized data from the 
STOP-PD study and found that females had significantly higher total cholesterol and 
LDL levels, compared to males (p<0.05); however, no significant differences between 
treatments were observed. 
The overall cumulative incidence of diabetes mellitus was 6.5% (n=49 of 750), 
where the rates for the AD cohort and the AD/SGA cohort were 6.8% and 6.3%, 
respectively. A chi-square test (comparing incidence rates) and a Cox proportional 
hazards regression model (measuring survival time until the onset of diabetes mellitus) 
found no significant differences between the two cohorts. While the majority studies in 





 of the STOP-PD study assessed changes in blood glucose levels 
after treatment with olanzapine or olanzapine plus sertraline and reported significantly 
higher levels of blood glucose in young patients at twelve weeks and/or study termination 
compared to baseline. While the effect of age was not assessed in the same way as the 
study above, age remained a significant positive predictor of progression to diabetes 
mellitus in the present study. Also, Deligiannidis and associates
26
 also analyzed data from 
the STOP-PD study and found that younger patients had significantly lower levels of 
blood glucose, on average over the course of their visits, compared to older patients 
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(p<0.05). This result parallels the present study, where increasing age is associated with 
higher hazards of the onset of diabetes mellitus. 
The overall cumulative incidence of extrapyramidal symptoms was 1.3% (n=12 of 
915), where the rates for the AD cohort and the AD/SGA cohort were 1.6% and 1.0%, 
respectively. A chi-square test comparing incidence rates of extrapyramidal symptoms 
found no significant difference between the two cohorts. Previous studies assessing the 
use of antidepressants and second-generation antipsychotics in psychotic depression 
reported much higher incidence rates of extrapyramidal symptoms (e.g., tremor, rigidity, 
akathisia, and tardive dyskinesia).
7,27-30
  An eight-week open-label, naturalistic study 
reported an overall incidence rate of mild tremors in 3.9% (n=2 or 51) of patients who 
utilized combination therapy with an SGA (risperidone, olanzapine, or quetiapine) and an 
antidepressant (citalopram or venlafaxine).  Also at the end of this study, one patient was 
switched from risperidone to quetiapine due to the onset of akathisia.
27
  Meyers and 
associates
7
 calculated incidence rates of 7.7% (n=20 of 259) and 8.5% (n=22 of 259) for 
akathisia and tardive dyskinesia, respectively, after twelve weeks of treatment with 
olanzapine and sertraline or olanzapine alone. A six-week study using combination 
therapy with quetiapine and citalopram reported a lower incidence rate for tremors at 
4.0% (n=1 or 25),
28
 and a five-week study utilizing combination therapy with citalopram 
and amisulpride led to tremors in 9.1% of patients (n=1 of 11).
29
  Comparatively, Mulsant 
and associates
30
  reported even higher rates of akathisia (25.0%) and tardive dyskinesia 
(18.8%) in their antidepressant cohort (nortriptyline); however, this study utilized a small 
sample (n=16) of older patients that were 50 years of age or older. Differences between 
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the present study’s extrapyramidal symptom incidence rates and the existing literature are 
primarily associated with differences in study designs: prospective versus retrospective 
analyses, the use of placebos and randomization, and the use of clinical patient 
interviews.  Also, very importantly, the use of Texas Medicaid retrospective claims data 
might not capture all cases of extrapyramidal symptoms that occurred during the study 
period; therefore, the incidence of extrapyramidal symptoms may be underreported. 
 
STUDY LIMITATIONS AND FUTURE RESEARCH 
 To our knowledge, the present study is the first to analyze psychotic depression in 
relation to medication adherence, persistence, suicidality, health care utilization, health 
care costs, and medication safety among two different cohorts (antidepressant 
monotherapy versus combination therapy) of Texas Medicaid patients. While it utilizes 
several novel methodological approaches for the study of psychotic depression (i.e., 
MPR, PDC, persistence, place of residence, Charlson Comorbidity Index, and tobacco 
use and/or dependence), there are several limitations that must be addressed prior to 
interpreting the study results.  
In general, the use of administrative claims data is associated with some 
limitations in itself. Firstly, the data only represent prescription claims—they are not 
necessarily indicative of actual prescription usage. However, this limitation was partially 
reduced by including only the patients that had at least two prescription claims—a proxy 
for medication usage. Secondly, claims data does not always allow researchers to 
ascertain the reasons why medications were prescribed (e.g., metformin prescribed for 
 
 176 
diabetes versus weight loss). Thirdly, certain outcomes, such as tobacco use and/or 
dependence, suicidality, and medication adverse events are likely to be underreported in 
large claims databases. Fourthly, fraudulent claims and human error with miscoding 
could have occurred in these datasets. Fifthly, due to the limited patient database, the 
final sample size was smaller than anticipated, which may have led to decreased power 
especially when analyzing suicides attempts, suicide ideation, and medication adverse 
events. Finally, the study’s generalizability is limited to populations similar to the 
original dataset – in this case, Texas Medicaid patients (e.g., indigent samples with high 
rates of African Americans and Hispanics) who were first-time users of antidepressant 
therapy for psychotic depression. 
Selection bias was a substantial limitation in this study, where unmeasured patient 
factors might have unknowingly influenced the study outcomes. Because randomization 
was not utilized in this study, an equal distribution of all patient-related factors could not 
be assumed among cohorts. First of all, mental health scores and relapse rates were not 
available through Texas Medicaid claims data, and as a result, the authors were not able 
to assess whether one cohort was more likely to consist of patients with a higher degree 
of depression or psychosis severity over the other. The practice of utilizing antidepressant 
monotherapy first for the “healthier” patients cannot be ruled out, especially in light of 
certain international guideline practices where monotherapy is acknowledged as an 
option;
31
 therefore, the bias of comparing unequal cohorts could be likely in this study. 
Secondly, since variables describing physician prescribing behavior were not available, 
the effect of guideline adoption rates on study outcomes could not be assessed. It is 
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possible that the lack of guideline adoption could have contributed to the larger sample of 
antidepressant monotherapy users in this study,
32
 especially since the American 
Psychiatric Association
33
 and Harvard South Shore Program
34
 guidelines were not 
available throughout the full study period. However, it is important to keep in mind that 
at least one major set of recommendations on psychotic depression, the Texas Medication 
Algorithm Project guidelines which advocate the use of combination therapy, was 
available since 1999.
10
  Thirdly, patients with successful suicides were not captured in 
this study; therefore, the authors were unable to determine whether monotherapy or 
combination therapy was more efficacious in terms of decreasing the number of 
completed suicides in psychotic depression.  Fourthly, it is widely accepted that a high 
rate of patients (36.6-59.0%) with major depressive disorder smoke, and many of these 
patients self-medicate with tobacco in order to relieve the psychological and physical 
symptoms of depression.
35
  Potentially, self-medication with tobacco could be an 
unmeasured confounder on study outcomes, and the possibility of decreased rates of 
antidepressant utilization, adherence, and persistence may unknowingly result. Finally, 
the study included patients with only one diagnosis for major depressive disorder with 
psychotic features. Future studies may decide to include patients with at least two 
diagnoses codes in order to exclude patients whose providers are ruling out psychotic 
depression. Overall, selection bias is problematic in this study as outcomes may be 




Other study limitations were associated with the inability to analyze the effect of: 
1) individual second-generation antipsychotic agents, 2) individual antidepressant 
treatment, 3) smoking and medication dosages, 4) cognitive behavioral therapies, 5) 
electroconvulsive therapy, and 6) prescribing behaviors. Nevertheless, these limitations 
offer opportunities for future research in psychotic depression.  
In the present study, aripiprazole, risperidone, and quetiapine were the top three 
second-generation antipsychotics utilized. Future studies could analyze differences 
between these second-generation antipsychotics (in addition to olanzapine) to determine 
which medication is associated with better health outcomes. Similarly, comparisons 
between tricyclic antidepressants (the most recommended antidepressants in treatment 
guidelines) and selective serotonin reuptake inhibitors (the most commonly used 
antidepressants in the present study) could be assessed. Other therapies such as cognitive 
behavioral and electroconvulsive therapy are utilized in the treatment of psychotic 
depression and ought to be studied further.  Moreover, clinician behavior in relation to 
why one therapy is prescribed over another (i.e., antidepressant monotherapy versus 
combination therapy) and treatment guideline adherence could be examined in future 
studies. Finally, future studies which have access to more complete patient data could 
replicate the methodology of the present study with the addition of more clinical data, 
such as patient histories, relapses, depression scores, and psychosis scores. Further 
assessment of important factors on study outcomes (e.g., tobacco use and/or dependence) 




CONCLUSIONS AND IMPLICATIONS 
 In summary, the primary purpose of the present study was to analyze health-
related outcomes of adherence, persistence, suicidality, health care utilization, health care 
costs, and medication safety associated with the treatment of psychotic depression. The 
results indicate that AD/SGA therapy users fared significantly better than AD 
monotherapy users in relation to antidepressant medication adherence based on MPR and 
PDC. Also, combination therapy users had significantly better antidepressant persistence 
rates based on a 45-day permissible gap and secondary analyses using 30-day and 60-day 
gaps. Alternatively, AD monotherapy users had a significantly lower rate of psychotic 
depression-related outpatient/emergency department visits, as well as significantly lower 
psychotic depression-related costs for medication, medical, and total costs and all-cause 
medication costs.  
 The implications of the study results are generally positive. First of all, the present 
study adds to the existing literature on psychotic depression and has filled a gap in 
knowledge related to medication adherence, persistence, health care utilization and costs 
for Texas Medicaid patients with psychotic depression. Secondly, the study results might 
have an impact on treatment decisions, especially for Texas Medicaid beneficiaries and 
the clinicians serving Texas Medicaid patients. While this study does not have the ability 
to interpret which therapy is more efficacious over the other, the results support that 
increased medication utilization leads to increased rates of medical care and costs. Texas 
Medicaid decision makers may need to conduct more studies on psychotic depression in 
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order to further delineate when one therapy may be appropriate over the other in terms of 
treatment efficacy and decreasing health care waste. Research assessing treatment non-
adherence in patients and treatment guideline non-adherence in clinicians could also be 
further investigated by Texas Medicaid decision makers. Overall, the authors support the 
need for research and interventions in order to reduce costs and improve outcomes in 
patients with psychotic depression.  This study aimed to provide real-world estimates of 
psychotic depression-related outcomes, and the authors hope the study findings provide a 
positive step forward in understanding appropriate treatment for major depressive 
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